Burden of childhood asthma in Portugal by Manuel José Ferreira de Magalhães
 				
  
 
BURDEN OF CHILDHOOD 
ASTHMA IN PORTUGAL 
 
 
 
MANUEL JOSÉ FERREIRA DE MAGALHÃES 
TESE DE DOUTORAMENTO APRESENTADA 
À FACULDADE DE MEDICINA DA UNIVERSIDADE DO PORTO EM  
INVESTIGAÇÃO CLÍNICA E EM SERVIÇOS DE SAÚDE 
 
Porto | 2017 
 
 III 
 
BURDEN OF CHILDHOOD ASTHMA 
IN PORTUGAL 
 
 
 
MANUEL JOSÉ FERREIRA DE MAGALHÃES 
 
 
TESE DE DOUTORAMENTO  
EM INVESTIGAÇÃO CLÍNICA E EM SERVIÇOS DE SAÚDE 
 
 
APRESENTADA À FACULDADE DE MEDICINA  
DA UNIVERSIDADE DO PORTO 
 
 
2017  
IV | Burden of childhood asthma in Portugal 
  
 V 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Art.º 48º, § 3º - “A Faculdade não responde pelas doutrinas expendidas na 
dissertação.” (Regulamento da Faculdade de Medicina da Universidade do Porto 
– Decreto-Lei nº 19337 de 29 de Janeiro de 1931) 
  
VI | Burden of childhood asthma in Portugal 
  
 VII 
 
Júri da Prova de Doutoramento 
 
Doutor Altamiro Manuel Rodrigues da Costa Pereira (Presidente) 
Professor Catedrático da Faculdade de Medicina da Universidade do Porto 
 
Doutor Luís Miguel Borrego 
Professor Auxiliar Convidado da Faculdade de Ciências Médicas da Universidade Nova de 
Lisboa 
 
Doutor Ricardo Ribeiro Marques Cunha Fernandes 
Professor Auxiliar Convidado da Faculdade de Medicina da Universidade de Lisboa 
 
Doutor Alberto António Moreira Caldas Afonso 
Professor Catedrático Convidado do Instituto de Ciências Biomédicas Abel Salazar da 
Universidade do Porto 
 
Doutor José Luís Delgado 
Professor Associado da Faculdade de Medicina da Universidade do Porto 
 
Doutor João Almeida Lopes da Fonseca (Orientador) 
Professor Auxiliar da Faculdade de Medicina da Universidade do Porto 
  
VIII | Burden of childhood asthma in Portugal 
  
 IX 
Corpo Catedrático da Faculdade de Medicina do Porto 
Professores Catedráticos Efetivos 
Doutor Manuel Alberto Coimbra Sobrinho Simões 
Doutora Maria Amélia Duarte Ferreira 
Doutor José Agostinho Marques Lopes 
Doutor Patrício Manuel Vieira Araújo Soares Silva 
Doutor Alberto Manuel Barros da Silva 
Doutor José Manuel Lopes Teixeira Amarante 
Doutor José Henrique Dias Pinto de Barros 
Doutora Maria Fátima Machado Henriques Carneiro 
Doutora Isabel Maria Amorim Pereira Ramos 
Doutora Deolinda Maria Valente Alves Lima Teixeira 
Doutora Maria Dulce Cordeiro Madeira 
Doutor Altamiro Manuel Rodrigues Costa Pereira 
Doutor Rui Manuel Almeida Mota Cardoso 
Doutor José Carlos Neves da Cunha Areias 
Doutor Manuel Jesus Falcão Pestana Vasconcelos 
Doutor João Francisco Montenegro Andrade Lima Bernardes 
Doutora Maria Leonor Martins Soares David 
Doutor Rui Manuel Lopes Nunes 
Doutor José Eduardo Torres Eckenroth Guimarães 
Doutor Francisco Fernando Rocha Gonçalves 
Doutor José Manuel Pereira Dias de Castro Lopes 
Doutor António Albino Coelho Marques Abrantes Teixeira 
Doutor Joaquim Adelino Correia Ferreira Leite Moreira 
Doutora Raquel Ângela Silva Soares Lino  
X | Burden of childhood asthma in Portugal 
 
Professores Jubilados ou Aposentados 
Doutor Alexandre Alberto Guerra Sousa Pinto 
Doutor Álvaro Jerónimo Leal Machado de Aguiar 
Doutor António Augusto Lopes Vaz 
Doutor António Carlos Freitas Ribeiro Saraiva 
Doutor António Carvalho Almeida Coimbra 
Doutor António Fernandes Oliveira Barbosa Ribeiro Braga 
Doutor António José Pacheco Palha 
Doutor António Manuel Sampaio de Araújo Teixeira 
Doutor Belmiro dos Santos Patrício 
Doutor Cândido Alves Hipólito Reis 
Doutor Carlos Rodrigo Magalhães Ramalhão 
Doutor Cassiano Pena de Abreu e Lima 
Doutor Daniel Filipe Lima Moura 
Doutor Daniel Santos Pinto Serrão 
Doutor Eduardo Jorge Cunha Rodrigues Pereira 
Doutor Fernando Tavarela Veloso 
Doutor Francisco de Sousa Lé 
Doutor Henrique José Ferreira Gonçalves Lecour de Menezes 
Doutor Jorge Manuel Mergulhão Castro Tavares 
Doutor José Carvalho de Oliveira 
Doutor José Fernando Barros Castro Correia 
Doutor José Luís Medina Vieira 
Doutor José Manuel Costa Mesquita Guimarães 
Doutor Levi Eugénio Ribeiro Guerra 
Doutor Luís Alberto Martins Gomes de Almeida 
Doutor Manuel António Caldeira Pais Clemente 
Doutor Manuel Augusto Cardoso de Oliveira 
Doutor Manuel Machado Rodrigues Gomes 
Doutor Manuel Maria Paula Barbosa 
Doutora Maria da Conceição Fernandes Marques Magalhães 
Doutora Maria Isabel Amorim de Azevedo 
Doutor Mário José Cerqueira Gomes Braga 
Doutor Serafim Correia Pinto Guimarães 
Doutor Valdemar Miguel Botelho dos Santos Cardoso 
Doutor Walter Friedrich Alfred Osswald  
 XI 
Ao abrigo do Art.º 8º do Decreto-Lei n.º 388/70, fazem parte desta dissertação as seguintes 
publicações:  
 
1. Ferreira-Magalhães M, Sá-Sousa A, Morais-Almeida M, Pité H, Azevedo LF, Azevedo I, 
Bugalho-Almeida A, Fonseca JA. Asthma-like symptoms, diagnostic tests, and asthma 
medication use in children and adolescents: a population-based nationwide survey. J 
Asthma 2016; 53:269-276. 
[Full-paper; Fator de impacto 1,85 do Journal Citation Reports®, ISI Web of Knowledge; Percentil 75 de 
‘Respiratory System’(revista n.º39/58)] 
 
2. Ferreira-Magalhães M, Sá-Sousa A, Morais-Almeida M, Azevedo LF, Azevedo I, Pereira AM, 
Fonseca JA. High prevalence of hospitalisation for asthma in a population-based paediatric 
sample. Arch Dis Child 2015; 100:507–508. 
[Original research letter; Fator de impacto 3,23 do Journal Citation Reports®, ISI Web of Knowledge; 
Percentil 15 de ‘Pediatrics’(revista n.º13/120)] 
 
3. Ferreira-Magalhães M, Pereira AM, Sá-Sousa A, Morais-Almeida M, Azevedo I, Azevedo 
LF, Fonseca JA. Asthma control in children is associated with nasal symptoms, obesity and 
health insurance: a nationwide survey. Pediatr Allergy Immunol 2015; 26(5):466-473. 
[Full-paper; Fator de impacto 3,95 do Journal Citation Reports®, ISI Web of Knowledge; Percentil 5 de 
‘Pediatrics’(revista n.º5/120)] 
 
4. Ferreira-Magalhães M, Amaral R, Pereira AM, Sá-Sousa A, Azevedo I, Azevedo LF, Fonseca 
JA. Cost of asthma in children: a nationwide, population-based, cost-of-ilness study. 
[Full-paper; Submetido] 
 
 
No âmbito deste projeto de doutoramento: 
- participei na análise dos dados pediátricos do Estudo INAsma; 
- participei na definição dos objetivos do projeto CASCA e na sua concretização 
através de apoio em todas as fases do trabalho de campo; 
- na definição de hipóteses e análise estatística dos dados de todos os artigos; 
- fui responsável pela redação da versão inicial de todos os artigos incluídos nesta 
dissertação. 
 
XII | Burden of childhood asthma in Portugal 
A investigação subjacente a esta dissertação foi realizada no Departamento de Ciências 
da Informação e da Decisão em Saúde (CIDES) e no Centro de Investigação em 
Tecnologias e Serviços de Saúde (CINTESIS) da Faculdade de Medicina da Universidade do 
Porto, sob orientação do Professor Doutor João de Almeida Lopes da Fonseca (Faculdade 
de Medicina da Universidade do Porto) e co-orientação da Professora Doutora Maria Inês 
Águeda Azevedo (Faculdade de Medicina da Universidade do Porto).  
 
O estudo INAsma (Inquérito Nacional da Asma) foi apoiado e pela Sociedade Portuguesa 
de Alergologia e Imunologia Clínica, Sociedade Portuguesa de Pneumologia e Fundação 
Ciência e Tecnologia – Harvard Medical School Portugal (HMSPIDSIM/SIM/0018/2009). 
 
A recolha de dados do estudo CED2013 foi realizada com o apoio de Guimarães, Capital 
Europeia da Cultura 2013 e da Tempo Livre - Centro Comunitário de Desporto e Tempos 
Livres. 
 
O projeto CASCA (Custo da Asma da Criança em Portugal) foi financiado por Fundação 
Calouste Gulbenkian através do Bolsa de Investigação em Saúde 2012 [P-125964]. 
 
  
 XIII 
Abreviaturas 
ACSS – Portuguese Health Services Central Administration 
ADSE - Instituto de Proteção e Assistência na Doença 
aOR – adjusted odds ratio 
BMI - body mass index 
CASCA – Cost of childhood asthma in Portugal 
DALY – disability-adjusted life years 
ETS – environmental tobacco smoke 
FeNO – exhaled nitric oxide 
GARD – Global Alliance against Chronic Respiratory Diseases 
GBD – Global Burden of Disease Study 
GINA – Global Initiative for Asthma 
HRQoL – health-related quality of life 
ICS – inhaled steroids 
INE – Instituto Nacional de Estatística 
ISAAC - International Study of Asthma and Allergies in Childhood 
JCR – Journal Citation Reports 
LABA – long acting b2-agonists 
LTRA – leukotriene receptor antagonists 
NCA – not-controlled asthma 
OR – odds ratio 
PFT – pulmonary function tests 
QoL – quality of life 
SABA – short acting b2-agonists 
SD – standard deviation 
WCA – well-controlled asthma 
WHO – World Health Organisation 
WoS – Web of Science 
95%CI – 95% confidence interval 
 
  
XIV | Burden of childhood asthma in Portugal 
  
 XV 
Agradecimentos 
Ao Prof. Doutor João Fonseca, orientador de Doutoramento e mentor científico desde o 
primeiro ano da licenciatura em Medicina. Um agradecimento especial e um abraço 
sentido. Pelo espírito crítico, clareza, integridade e retidão que sempre me transmitiu e que 
me fizeram crescer enquanto investigador, médico e homem. 
À Prof. Doutora Inês Azevedo, co-orientadora do doutoramento e orientadora de internato 
de formação específica em Pediatria Médica. Um agradecimento por me ter 
acompanhado de forma transversal na minha atividade científica e clínica. Um 
agradecimento por me ter acolhido prontamente e por ter acreditado em todos os passos 
do meu percurso. Pela amizade, confiança e companheirismo. 
Ao Prof. Doutor Altamira Costa Pereira, diretor do Programa Doutoral em Investigação 
Clínica e em Serviços de Saúde. Um agradecimento pela oportunidade criada para 
desenvolver todos os meus trabalhos conducentes ao grau de Doutor. 
Ao Prof. Doutor Caldas Afonso, ex-Diretor de Serviço de Pediatria do Centro Hospitalar de 
São João. Um agradecimento pela confiança depositada em mim e por todas as 
oportunidades criadas. Tudo isso me fez acreditar que era possível levar a cabo o internato 
de formação específica e o programa doutoral em simultâneo. 
Ao Prof. Luís Filipe Azevedo, pelo apoio metodológico cuidado e sempre pertinente. 
À Ana Sá e Sousa e à Rita Amaral, não só pela ajuda preciosa em diversas fases desta tese, 
mas também pela companhia e pelos sorrisos enquanto tudo isto ganhava forma. 
Ao Joaquim Guimarães, por todo o dinamismo que imprimiu na recolha de dados no 
estudo CED2013. 
A todos os co-autores dos artigos desta tese, pela ajuda fundamental em cada momento 
de discussão e disseminação de resultados. 
A todos os meus colegas do Serviço de Pediatria do Centro Hospitalar de São João. Um 
agradecimento por terem partilhado comigo este período e, acima de tudo, pela 
motivação extra que me deram para alcançar todas estas metas.  
XVI | Burden of childhood asthma in Portugal 
À Liane, amiga incondicional. Um agradecimento sentido pelo apoio e ajuda em todos os 
momentos, especialmente nos mais difíceis. Pelo percurso profissional e pessoal de longos 
anos que demonstram que a amizade torna tudo mais fácil. 
Ao Luís, amigo incondicional. Um agradecimento sentido pelos conselhos e por toda a 
amizade. Desde as boleias para as aulas de Introdução à Medicina, até aos dias de hoje. 
  
E à família. 
Maria Antónia e Pedro. Pela união e valor de família que temos, e por todo o apoio que 
me dão e nunca me negam. 
A ti, mamã. Pelo acompanhamento incondicional em toda a minha formação, como 
criança e homem, e por toda a força e perseverança que me passaste para toda a minha 
vida. 
A ti, papá. Pelos ensinamentos valiosos. Não esquecerei o valor do trabalho e da 
honestidade que tão bem me transmitiste, através dos teus atos e do teu percurso de vida 
impressionante. 
A ti, Eva. Por tudo, e por nada. Pelas palavras que sempre me dirás. Porque nenhuma 
palavra pode exprimir tamanho agradecimento e afeto. À nossa família. 
A ti, Manelinho. Por encheres o meu coração, e fazeres com que tudo valha a pena, com 
apenas um olhar e um sorriso. 
 
Index |1 
INDEX 
 
ABSTRACT ................................................................................................................................ 5 
RESUMO ................................................................................................................................... 9 
1. INTRODUCTION ................................................................................................................ 13 
1.1 From pathophysiology to clinical presentation ..................................................... 13 
1.2 Burden of asthma ..................................................................................................... 15 
1.3 Epidemiology of childhood asthma ....................................................................... 18 
1.4 Diagnostic tests and medication use in childhood asthma ................................ 21 
1.5 Healthcare services use in childhood asthma ...................................................... 23 
1.6 Asthma control in children ....................................................................................... 26 
1.7 Quality of life in childhood asthma ......................................................................... 28 
1.8 Cost of asthma .......................................................................................................... 29 
2. AIMS .................................................................................................................................. 31 
3. PhD STUDIES ..................................................................................................................... 33 
4. PAPERS ............................................................................................................................. 35 
4.1 Paper 1 - Prevalence of childhood asthma, diagnostic tests and meds .......... 37 
4.2 Paper 2 - Lifetime hospitalisations because of asthma in children ..................... 59 
4.3 Paper 3 - Control of asthma in children ................................................................. 69 
4.4 Paper 4 - Cost of childhood asthma ...................................................................... 91 
5. DISCUSSION .................................................................................................................... 121 
5.1 Major findings .......................................................................................................... 122 
5.2 Strengths and limitations ........................................................................................ 123 
5.3 Epidemiology of childhood asthma ..................................................................... 126 
5.4 Diagnostic tests and medication use in childhood asthma .............................. 129 
5.5 Healthcare services use in childhood asthma .................................................... 130 
2 | Burden of childhood asthma in Portugal 
5.6 Asthma control in children ..................................................................................... 132 
5.7 Cost of childhood asthma ..................................................................................... 135 
5.8 Future directions ...................................................................................................... 138 
6. CONCLUSION ................................................................................................................ 141 
7. REFERENCES ................................................................................................................... 145 
8. APPENDICES ................................................................................................................... 155 
8.1 PhD Tasks .................................................................................................................. 157 
8.2 PhD Outputs ............................................................................................................ 163 
8.3 Awards / Distinctions .............................................................................................. 167 
8.4 Published papers .................................................................................................... 169 
 
  
Index |3 
4 | Burden of childhood asthma in Portugal 
  
 Abstract | 5 
ABSTRACT 
Background and aims 
Asthma is one of the most common chronic diseases in childhood. However, there is a 
paucity of data on its burden, especially on healthcare services use, level of asthma control 
and associated costs. Population-based studies and comprehensive analysis are important 
to assess the whole spectrum of the childhood asthma burden. 
The main aim of this research project was to study the burden of asthma in Portuguese 
children. In order to capture the whole burden of disease, five specific aims were defined: 
1) estimate the prevalence of childhood asthma and asthma-like symptoms; 2) assess the 
proportion of diagnostic tests and medication use in asthma; 3) estimate the proportion of 
asthma-related healthcare services use; 4) analyse the proportion of controlled asthma and 
its determinants; 5) determine the cost of illness of asthma and the cost variations with the 
level of asthma control. 
Methods 
Data from two primary studies were collected and analysed. 
Study 1: the ‘Portuguese National Asthma Survey’ (INAsma), a nationwide, cross-sectional, 
population-based telephone survey developed in 2010; pediatric-specific data from first 
and second phases of INAsma study were analysed. From the 6,003 interviews of Portuguese 
of all ages, 716 children (0- to 17-years old) were included in the first phase of INAsma, and 
98 in the second phase. 
Study 2: the ‘Asthma in school-aged children: the Guimarães study’ (CED2013), a cross-
sectional, school-based survey conducted in 2013, used to empower the results of the aim 
5) of this research project. From the 2,550 responders between 5 and 12 years old, 110 were 
included in the cost-of-illness study. 
‘Lifetime asthma’ was defined as a positive answer to “Have you ever had asthma?”. 
‘Current asthma’ was defined as ‘lifetime asthma’ and (1) wheezing, (2) waking with 
breathlessness, or (3) asthma attack in the previous 12 months, and/or (4) taking asthma 
medication at the time of the interview. Lifetime hospitalisation was defined as a positive 
answer to “Have you ever been hospitalised for asthma (inpatient admission >24 hours)?”; 
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only children aged 6- to 17-years old were analysed for lifetime hospitalisations. Asthma 
control definition was based on GINA criteria, grouping partially controlled and uncontrolled 
asthma as ‘not controlled asthma’ (NCA). We used multivariate logistic regression to study 
factors associated with NCA and with unscheduled medical visits for asthma. 
The Cost of Childhood Asthma in Portugal (CASCA Project) was a nationwide, population- 
and prevalence-based, cost-of-illness study with a societal perspective. Participants in this 
cost-of-illness study were derived from the INAsma study and CED2013 study.  Additional 
secondary data from several national databases were compiled to inform item values (in 
euros). Direct costs (healthcare services, diagnostic tests, medication and medical devices) 
were measured using a bottom-up approach (person-based) and indirect costs 
(absenteeism, transportation and subsidies) were quantified using the human capital 
method. 
Results 
1. Prevalence of childhood asthma and asthma-like symptoms 
The prevalence of asthma-like symptoms was 39.4% [95% confidence interval (95%CI), 35.7–
43.3]. The most common symptoms were waking with cough (30.9%) and wheezing (19.1%). 
The prevalence of lifetime asthma was 11.2 (95%CI, 9.1-13.7), and of current asthma was 
8.4% (95%CI, 6.6–10.7).  
2. Diagnostic tests and medication use in childhood asthma 
Among children with current asthma, 79.9% and 52.9% reported prior allergy testing and 
pulmonary function testing (PFT), respectively. Inhaled medication use in the previous 12 
months was reported by 67.6% (reliever inhalers, 40.1%; controller inhalers, 41.5%). Those who 
only used inhaled reliever medications experienced more asthma attacks [odds ratio (OR), 
2.69]. Significantly fewer children with current asthma living in rural areas than those living in 
urban areas had undergone PFT or used inhaled medication (OR: 0.06 for PFT, 0.20 for 
medication). 
3. Healthcare services use in childhood asthma 
In the previous year, 90% (95%CI 84-96%) of children with current asthma had healthcare 
visits because of asthma: 86% (95%CI 79-93%) had scheduled medical visits, 39% (95%CI 29-
 Abstract | 7 
48%) had emergency room visits and 25% (95%CI 16-33%) had at least one unscheduled 
medical visit to a doctor. The risk of unscheduled medical visits was higher in children with 
nasal symptoms (aOR 3.63) and in those without health insurance (aOR 2.79), and lower in 
adolescents (aOR 0.19). 
The prevalence of lifetime hospitalisations for asthma in all Portuguese children was 3.9% 
(95%CI, 2.6–5.7). In children with lifetime asthma, this prevalence was 29.7% (95%CI, 23.6–
36.7), and in those with current asthma was 36.5 (95%CI, 28.8-44.9). The presence of any 
asthma-like symptom in the previous 12 months increased the proportion of lifetime 
hospitalisations (OR 1.85; 95%CI, 1.16-2.95). Female children had more hospitalisations than 
males (OR 1.97; 95%CI, 1.22-3.18). 
4. Asthma control in children 
About half of the children had NCA (49%, 95%CI 39-59%). In the multivariate model, risk 
factors for NCA were: substantial nasal symptoms (aOR 6.80), overweight/obesity (aOR 3.44) 
and not having health insurance (aOR 3.78). All the children with NCA had nasal symptoms, 
and the lack of asthma control was also associated with the increasing number of nasal 
symptoms (p<0.001). 
5. Cost of childhood asthma 
The mean annualised costs per child was €929.35 (95%CI, 809.65–1,061.11) for total costs, 
€698.65 (95%CI, 600.88–798.27) for direct costs, and €230.70 (95%CI, 197.36–263.81) for 
indirect costs. The extrapolations for the Portuguese children amount to €161,410,007.61 
(95%CI, 140,620,769.55–184,293,968.55) for the total costs. Direct costs represent 75.2% and 
indirect costs 24.8% of the total costs. The costliest domain was the healthcare service use 
(51.1% of total costs), specifically the scheduled medical visits (20.7% of total costs) and 
those related to acute asthma care (30% of total costs): emergency department visits (11.7% 
of total costs), hospitalisations (10.8% of total costs) and non-scheduled medical visits (7.9% 
of total costs). Children with partly controlled asthma and uncontrolled asthma had higher 
mean costs per year (adjusted exponential model coefficients: 1.46 [95%CI, 1.12-1.90] and 
2.25 [95%CI, 1.56-3.24], respectively). 
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Conclusions 
The results of these studies allowed for a comprehensive estimation of the burden of 
childhood asthma in Portugal. 
Current asthma affects 8.4% (173,681) of Portuguese children. Only half of children with 
current asthma had ever undergone PFT and even less use controller inhalers. Those who 
only used reliever inhalers reported more asthma attacks. The results obtained may indicate 
substandard asthma care, mainly in rural areas. Poor control was observed in half of the 
Portuguese children with asthma. Nasal symptoms and obesity were found to be important 
determinants of asthma control and children without health insurance (private or state 
owned) are at greater risk of poor asthma outcomes; this association was not previously 
reported in a European country. Also, for the first time, it was described the proportion of 
asthmatic children hospitalised because of asthma, at least once in their life: more than one 
third of children with current asthma were hospitalised during their childhood. 
The high clinical and healthcare burden of childhood asthma in Portugal is reflected in its 
costs. The childhood asthma in Portugal costs more than 161 million euros per year, more 
than 900 € per child with current asthma. Direct costs were ¾ of total costs, mainly related 
to related to acute asthma care (non-scheduled visits, emergency and hospitalisations). The 
most important determinants for higher costs were the asthma attacks in the previous 12 
months (1.6-fold) and having uncontrolled asthma (2.3-fold). A better asthma control, and 
a reduction in the acute use of healthcare services, should be the major target for potential 
reduction of the clinical and economic burden of this disease. 
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RESUMO 
Introdução e objetivos 
A asma é uma das doenças crónicas mais comuns em idade pediátrica. No 
entanto, o conhecimento sobre seu impacto, especialmente no que diz respeito ao uso de 
serviços de saúde, ao nível de controlo da asma e aos custos associados é escasso. São 
necessários estudos de base populacional e abrangentes para avaliar todo o espectro do 
impacto da asma em idade pediátrica. 
O principal objetivo deste projeto de investigação foi estudar o impacto da asma 
em idade pediátrica, em Portugal. Para avaliar o impacto global desta doença foram 
delineados cinco objetivos específicos: 1) estimar a prevalência de asma e sintomas 
relacionados; 2) avaliar a proporção de testes de diagnóstico e medicação utilizados na 
asma; 3) estimar a proporção de utilização de serviços de saúde associados à asma; 4) 
analisar a proporção de asma controlada e seus determinantes; 5) determinar o custo da 
doença na asma e as variações dos custos com o nível de controlo. 
Métodos 
Foram recolhidos e analisados os dados de dois estudos. 
Estudo 1: "Inquérito Nacional sobre Asma" (INAsma), um estudo transversal de base 
populacional nacional desenvolvido em 2010, através da aplicação de entrevista 
telefónica assistida por computado; foram analisados os dados pediátricos da primeira e 
segunda fase do estudo INAsma. Das 6.003 entrevistas realizadas a Portugueses de todas 
as idades, foram incluídas 716 crianças (dos 0 aos 17 anos) na primeira fase e 98 crianças 
na segunda fase. 
Estudo 2: "Asma em crianças em idade escolar; estudo Vimaranense” (CED2013), um 
estudo transversal realizado nas escolas básicas do 1º ciclo de Guimarães, em 2013, 
utilizado para o objetivo 5). Dos 2.550 participantes entre os 5 e 12 anos de idade, foram 
incluídas 110 crianças para o estudo do custo de doença. 
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A ‘asma ao longo da vida’ foi definida como uma resposta positiva a "Alguma vez teve 
asma?". A ‘asma atual’ foi definida como ‘asma ao longo da vida’ e (1) sibilância/pieira, 
(2) acordar com falta de ar, ou (3) ataque de asma nos 12 meses anteriores, e/ou (4) estar 
sob medicação para a asma no momento da entrevista. A hospitalização ao longo da 
vida foi definida como uma resposta positiva à pergunta "Alguma vez já foi hospitalizado 
por asma (internamento > 24 horas)?". Foram analisados dados de hospitalizações ao longo 
da vida entre as idades de 6 a 17 anos. A definição de controlo da asma foi baseada nos 
critérios do GINA, agrupando a asma parcialmente controlada e mal controlada como 
"asma não controlada" (NCA). Para estudar os fatores associados à NCA e a visitas médicas 
não programadas por asma foi efetuado um modelo de regressão logística multivariada. 
O Projeto Custo da Asma na Criança em Portugal (Projeto CASCA) foi um estudo de custo 
de doença a nível nacional, de base populacional, baseado na prevalência da doença 
e na perspetiva da sociedade. Os participantes neste estudo de custo de doença foram 
obtidos a partir do estudo INAsma e estudo CED2013. Dados de bases nacionais foram 
utilizadas para recolha de valores monetários (em euros) dos diferentes domínios 
analisados. Os custos diretos (serviços de saúde, testes de diagnóstico, medicamentos e 
dispositivos médicos) foram medidos através de uma abordagem bottom-up (baseado no 
indivíduo) e os custos indiretos (absentismo, transporte e subsídios) foram quantificados 
utilizando o método de capital humano. 
Resultados 
1. Prevalência da asma pediátrica e sintomas relacionados com a asma 
A prevalência de sintomas associados à asma foi de 39,4% [intervalo de confiança de 95% 
(95%CI), 35,7-43,3]. Os sintomas mais comuns foram acordar com tosse (30,9%) e sibilância 
(19,1%). A prevalência de asma ao longo da vida foi de 11,2 (95%CI, 9,1-13,7), e da asma 
atual foi de 8,4% (95%CI, 6,6-10,7). 
2. Utilização de testes diagnóstico e medicação em crianças asmáticas 
Entre as crianças com asma atual, 79,9% e 52,9% reportaram história prévia de realização 
de teste de alergia e testes de função pulmonar (PFT), respetivamente. O uso de 
medicação inalada nos 12 meses anteriores foi de 67,6% (inaladores de alívio rápido, 40,1%; 
inaladores de controlo, 41,5%). Os que só usaram inaladores de alívio rápido tiveram mais 
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crises de asma [razão de odds (OR), 2,69]. As crianças com asma atual que habitavam em 
áreas rurais realizaram um numero significativamente menor de PFTs ou medicação 
inalada, quando comparados com as que viviam em áreas urbanas (OR: 0,06 para PFT, 
0,20 de medicação).  
3. Utilização de serviços de saúde por crianças asmáticas  
Nos 12 meses anteriores, 90% (IC 95% 84-96%) das crianças com asma atual realizaram 
consultas médicas devido à sua asma: 86% (95%CI 79-93%) tiveram consultas agendadas, 
39% (95%CI 29-48%) foram a um serviço de urgência e 25% (95%CI 16-33%) tiveram, pelo 
menos, uma consulta não programada. O risco de necessitarem de consultas médicas não 
programadas foi maior em crianças com sintomas nasais (aOR 3.63) e nas que não tinham 
seguro de saúde (aOR 2,79), tendo sido menor em adolescentes (aOR 0,19). 
A prevalência de hospitalizações alguma vez na vida devido a asma foi de 3,9% (95%CI, 
2,6-5,7). Em crianças com asma ao longo da vida essa prevalência foi de 29,7% (95%CI, 
23,6-36,7), e naquelas com asma atual foi de 36,5 (95%CI, 28,8-44,9). A presença de 
qualquer sintoma associado à asma nos 12 meses anteriores aumentou a proporção de 
hospitalizações alguma vez na vida (OR 1,85; 95%CI, 1,16-2,95). Crianças do sexo feminino 
tiveram mais internamentos do que as do sexo masculino (OR 1,97; 95%CI, 1,22-3,18). 
4. Controlo da asma em crianças  
Cerca de metade das crianças tinham NCA (49%, 95%CI 39-59%). No modelo multivariado, 
os fatores de risco para NCA foram: sintomas nasais substanciais (aOR 6.80), sobrepeso/ 
obesidade (aOR 3.44) e não ter seguro de saúde (aOR 3,78). Todas as crianças com NCA 
tinham pelo menos um sintoma nasal, e a falta de controlo da asma também foi associada 
com um maior número de sintomas nasais diferentes (p <0,001). 
5. Custo da asma em crianças  
A média dos custos totais anuais por criança foi de 929,35€ (95%CI, 809,65–1.061,11), dos 
quais 698,65€ (95%CI, 600,88–798,27) para custos diretos e 230.70€ (95%CI, 197,36–263,81) 
para os custos indiretos. O valor absoluto para as crianças portuguesas foi de 
161.410.007,61€ (95%CI, 140.620.769,55–184.293.968,55) para os custos totais. Os custos 
diretos representaram 75,2% e os custos indiretos 24,8% dos custos totais. O domínio com 
custos mais elevados foi a utilização de serviços de saúde (51,1% dos custos totais), 
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especificamente as consultas médicas agendadas (20,7% dos custos totais) e os cuidados 
agudos de asma (30% dos custos totais): idas ao serviço de urgência (11,7% dos custos 
totais), internamentos (10,8% dos custos totais) e consultas médicas não agendadas (7.9% 
dos custos totais). As crianças com asma não controlada e asma parcialmente controlada 
tiveram maiores custos médios por ano (coeficientes do modelo exponencial ajustado: 1,46 
[95%CI, 1,12-1,90] e 2,25 e [95%CI, 1,56-3,24], respetivamente). 
Conclusões 
Os resultados destes estudos permitiram a obtenção de estimativas abrangentes sobre o 
impacto da asma em idade pediátrica, em Portugal. 
A asma atual afeta 8,4% (173.681) das crianças portuguesas. Apenas metade das crianças 
com asma atual tinha realizado uma PFT alguma vez na vida e mais da metade não usava 
inaladores de controlo. As crianças que só usavam inaladores de alívio reportaram mais 
crises de asma. Os resultados obtidos podem indicar cuidados inadequados, 
principalmente em meios rurais. A falta de controlo foi observada em metade das crianças 
Portuguesas com asma. Os sintomas nasais e a obesidade foram identificados como 
determinantes importantes no controlo da asma. Além disso, as crianças sem seguro de 
saúde (privado ou estatal) estão em maior risco de pior controlo da asma; esta associação 
não tinha sido previamente documentada em nenhum país europeu. Também, pela 
primeira vez, foi descrita a proporção de crianças asmáticas que necessitaram de algum 
internamento por asma durante a sua vida: mais de um terço das crianças com asma atual 
foram internadas por asma durante a infância e adolescência. 
O elevado impacto clínico e no sistema de saúde da asma pediátrica é refletido nos custos 
associados. A asma pediátrica em Portugal custa mais de 161 milhões de euros por ano, 
correspondendo a mais de 900€ por criança com asma atual. Os custos diretos 
representaram ¾ do total dos custos, especialmente relacionados com a utilização serviços 
de saúde em contexto de exacerbações.  Os fatores mais importantes para a custos mais 
elevados são as crises de asma nos últimos 12 meses (1,6 vezes) e asma não controlada 
(2,3 vezes). Um melhor controlo da asma, assim como uma redução da utilização de 
serviços de saúde devido a exacerbações, devem ser os principais alvos para reduzir o 
impacto clínico e económico da asma pediátrica. 
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1. INTRODUCTION 
1.1 From pathophysiology to clinical presentation 
Asthma is a disease with variable presentation caused by a composite interaction of 
genetic and environmental factors, leading to multiple immunological and histological 
changes 1. The crosstalk between impaired innate immunity and environmental 
susceptibility is responsible for the epithelial cell damage and adaptive immune response 
that causes inflammation 2. The cellular and humoral changes lead to the classical bronchial 
hyper-reactivity with smooth muscle cells contraction, mucus overproduction, airway wall 
remodelling and airway narrowing 3. Impaired immunity in asthma is complex and may vary 
between patients, being typically classified as a TH2 disorder with eosinophilic inflammation 
or a TH17 disorder with neutrophilic inflammation. However, overlap between these immune 
disorders are often present, as well as changes in other immunologic pathways 1. 
Environmental triggers are also major players in asthma pathophysiology; viruses, exercise, 
cold, irritant or allergen exposure and other well-known factors interact to promote disease 
development, maintenance, and exacerbation. 
Because of this close interaction, several models of asthma definition and classification were 
successively proposed. These models tend to rely on biological markers or in functional 
parameters. As so, the definition of endotypes and phenotypes is a major advance in what 
concerns therapeutic targeting, diagnosis and severity classification 4,5. However, these 
models have several pitfalls and uncertainty is still present when diagnosing asthma in 
clinical and epidemiological grounds. 
The Global Initiative for Asthma (GINA) is a taskforce that intends to compile and 
disseminate scientific evidence on asthma, in order to create worldwide consensus in 
diagnosis and management of asthma 6. GINA defines asthma as “a heterogeneous 
disease, usually characterized by chronic airway inflammation; it is defined by the history of 
respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that 
vary over time and in intensity, together with variable expiratory airflow limitation”. 
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Defining asthma during childhood presents additional challenges. Asthma is one of the most 
common chronic diseases in childhood, but the lack of suitable objective measures for 
younger ages, or the difficulty of having accurate symptom description throughout 
childhood, are major limitations when diagnosing asthma in clinical practice and in surveys. 
Asthma symptoms usually begin during childhood and evolve differently as children grow 7. 
Viral infections and atopy play a major role in developing wheezing disorders and possible 
asthma development in latter childhood and adulthood 8,9. 
In preschool children, asthma diagnosis must be based on symptomatic patterns 6. In older 
children, diagnosis should be based on symptomatic patterns and in objective variable 
expiratory airflow limitation. The most common signs/symptoms observed in asthma are: 
- Wheeze - an expiratory continuous high-pitched sound with musical quality. Is the 
most distinctive asthma symptom and is generally present when the child is exposed 
to a trigger. However, since it is the result of intrathoracic airway narrowing and 
expiratory flow limitation, there are several mechanisms and reasons for a child to 
wheeze, from anatomical abnormalities of the airways to cystic fibrosis 10; 
- Recurrent or persistent non-productive cough – a physiological mechanism that is 
usually present in children with asthma. It is caused by the release of pro-
inflammatory mediators by airway mucosa, leading to activation of the afferent 
neurons of the cough reflex. Cough in asthma also typically appears during an 
episode of exacerbation, but it is commonly associated to an insidious and recurrent 
presentation, specifically, during exercise or at night 11; 
- Breathlessness and chest tightness – these are more specific symptoms that tend to 
appear mostly during moderate to severe exacerbations. These symptoms are the 
patient’s perception of the difficulty in breathing due to narrowing of the airways 
and turbulent airflow; 
- Activity limitation – a defence mechanism that is present when children with asthma 
have some degree of ventilation/oxygenation impairment. Younger children usually 
remain quiet and avoid playing; older children tend to avoid exercise and daily 
activities;  
- Asthma attacks – rapid worsening episodes that usually present with a constellation 
of symptoms and that require prompt reliever medication.  
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1.2 Burden of asthma 
The burden of asthma as long been an important field of research, aiming to improve 
asthma care management and outcomes. In 1993, Costa Pereira A. had already 
developed studies in the community aiming to understand the impact asthma, specifically, 
the prevalence of asthma and asthma-like symptoms, the use of healthcare services or the 
assessment of control of symptoms 12. At the present, asthma is recognized as one of the 
most common noncommunicable chronic diseases in the world 13. The Global Burden of 
Disease (GBD) study is a worldwide comprehensive cross-sectional study that aggregates 
data on mortality and morbidity from more than 300 diseases and injuries in 188 countries 14. 
The Institute for Health Metrics and Evaluation publishes GBD results periodically since 1990, 
observing trends in prevalence or risk factors across ages and among populations, aiming 
to inform decision-makers towards an improvement in health outcomes. According to the 
estimates from the GBD study 2015, approximately 358 million people of all ages have 
asthma worldwide 15. This study also pointed asthma as one of the leading disabling 
conditions (ranked 23rd), being responsible for more than 26 million disability-adjusted life 
years (DALYs)/year and more than 397,000 deaths/year in the world 16,17. In children, chronic 
respiratory diseases were the 4th noncommunicable group of diseases with the highest 
DALYs (>500 DALYs/100,000 inhabitants) and asthma was one of the diseases with the 
highest DALYs (ranked in the top 10 worldwide and in the top 5 in Portugal when compared 
with other single noncommunicable diseases) (Table 1) 18. Deaths because of asthma in 
children can be high in developing countries (Table 2), but in Portugal there were only 5 
deaths between the year 2000 and 2010 19. 
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Table 1 Disability-adjusted life years from asthma by age, and corresponding ranking when 
compared with other single noncommunicable diseases (data from Global Disease Burden Study; 
level 4 ranking) 16. 
Age 
(years) 
Global  Europe  Portugal 
DALYs* Rank#  DALYs* Rank#  DALYs* Rank# 
Under 5 257.54 5  116.39 11  177.25 4 
5-9 461.15 1  367.97 1  496.75 1 
10-14 383.37 2  369.49 4  477.60 2 
15-19 297.09 8  319.22 7  451.26 5 
*Disability-adjusted Life Years per 100,000 inhabitants; # Ranking when compared with other 
single noncommunicable diseases 
 
 
 
Table 2 Deaths from asthma by age, and corresponding ranking when compared with other single 
noncommunicable diseases (data from Global Disease Burden Study; level 4 ranking) 17. 
Age 
(years) 
Global  Europe  Portugal 
Deaths* Rank#  Deaths* Rank#  Deaths* Rank# 
Under 5 9,483.23 16  57.82 27  0.24 29 
5-9 2,751.77 12  29.10 19  0.09 33 
10-14 3,638.71 10  43.81 15  0.18 27 
15-19 3,970.09 11  59.65 24  0.33 32 
*Number of deaths per year; #Ranking when compared with other single noncommunicable 
diseases 
 
The World Health Organization (WHO) Global Alliance against Chronic Respiratory Diseases 
(GARD) framework identified the worldwide needs in chronic respiratory diseases (specially 
asthma) data and action plans, including the ones of developed countries 20. Specifically, 
the GARD advocates that population-based studies are required for the assessment of 
disease epidemiologic estimates and burden, and that it should be implemented in different 
countries and settings. Innes Asher and Neil Pearce have recently stated the importance of 
continuously monitoring childhood asthma prevalence and burden in order to reduce the 
impact of this disease, with a particular focus on the need for economic studies on asthma 
21. 
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Taking into account these needs on the research field of asthma burden, it is also crucial to 
aggregate comprehensive, precise, generalizable and quality data to inform health policy-
makers. Indeed, in the era of widespread information, it is important that health policies can 
be perfectly fitted to the needs of the populations. Healthcare services resources and 
interventions should be allocated adequately, after assessing several disease estimates. 
These types of estimates are part of a burden of disease study and are important to measure 
population health outcomes. A stepwise approach of the burden of childhood asthma 
should go from prevalence estimates, to diagnostic tests, medication, healthcare services 
use, level of asthma control and economic impact. 
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1.3 Epidemiology of childhood asthma 
The clinical presentation of asthma is characterized by a great symptomatic heterogeneity. 
In order to identify the broad clinical spectrum of the disease, composite measures for 
asthma definition are increasingly necessary, aiming to obtain more accurate 
epidemiological prevalence estimates 22. Epidemiological studies with simple and direct 
questionnaires are essential to obtain good quality data. Prevalence surveys are the first 
step for a full assessment of a disease burden and their main goals are: to know the number 
of affected patients in a population; to compare the prevalence of disease in different 
populations; to examine trends in disease prevalence or severity over time; and to assess 
the need for health resources allocation. 
The results of the 25-year International Study of Asthma and Allergies in Childhood (ISAAC) 
have changed the global knowledge about the prevalence of asthma and related 
symptoms, with the implementation of straightforward methodologies and simple ready to 
use tools in high, medium and lower income countries 23. A total of 306 centres in 105 
countries were included during the 3 phases of ISAAC and children between 6-7 years old 
and 13-14 years old were selected. The ISAAC survey included 5 Portuguese cities: Porto, 
Lisboa, Coimbra, Portimão and Funchal. However, as most other studies on the prevalence 
of asthma or asthma-like symptoms in childhood, it was limited to specific ages and settings. 
Also, most of the studies that used the ISAAC questionnaire were mainly based on wheeze 
24, with little or no focus on other asthma-like symptoms, an approach that has been recently 
questioned 22. 
Prevalence of asthma-like symptoms 
According to ISAAC, the prevalence of asthma symptoms in children may reach higher than 
35% in some settings, and the global burden is still increasing 25. The global prevalence of 
current (i.e., reported in the previous 12 months) wheeze in the 6- to 7-year-old group varied 
from 37.6% in Costa Rica to 2.4% in India, and in the 13- to 14-year-old group from 32.6% in 
New Zealand to 0.8% in China. In Western Europe, prevalence of current wheeze and cough 
was, respectively, 9.7% and 20.7% in the 6- to 7-year-old group, and 15.2% and 29.3% in the 
13- to 14-year-old group.  
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Wheeze is the most studied asthma-like symptom in children. A great variability can be 
observed in the prevalence of current wheeze depending on the countries, settings and 
pediatric age groups (from 1% to 38% in ISAAC) 25. A recent Portuguese nationwide study 
on pre-schoolers estimated a current wheeze prevalence of 24.5% 26. There are no other 
nationwide Portuguese studies in older children, however Phase III ISAAC estimates for 
current wheeze was 12.9% in the 6- to 7-year-old group, and 10.4% in the 13- to 14-year-old 
group, in 2002 27. 
Nocturnal cough is a well-known frequent asthma-like symptom; however, it is difficult to find 
data on this symptom, specifically on the proportion of nocturnal cough in asthmatic 
children. Mvula et al.  found that 27.3% of children aged 5 to 18 years had cough at night, 
apart from cold or chest infection, but nothing was said about the proportion of asthmatic 
children that had cough 28. Also, the prevalence of asthma attacks is seldom reported. The 
United States National Center for Health Statistics reported a 5.4% prevalence of asthma 
attacks in the previous 12 months among children aged 0 to 17 years 29. 
Knowing these pitfalls in data of childhood asthma burden, a comprehensive nationwide 
Portuguese study on the prevalence of different asthma-like symptoms across all pediatric 
ages stands out as a decisive step for understanding the patterns of asthma-like symptoms 
in Portuguese children, specifically in those with asthma. 
Asthma Prevalence 
Epidemiologic definition of asthma is not consensual, leading to hardly comparable data in 
reported prevalence estimates that greatly depend on the definition used 22,30. First, asthma 
estimates depend on the time of diagnosis or the occurrence of asthma-like symptoms 
included in the definition: 1) it can be based on a known diagnosis of asthma ever in life 
(‘ever had asthma’ or ‘lifetime asthma’ or ‘doctor diagnose asthma’); 2) it can be based 
on active asthma (‘current asthma’, usually with the presence of one or more asthma 
symptoms in the previous 12 months). Second, asthma estimates can vary greatly with the 
type and number of asthma-like symptoms included in the definition. In fact, despite asthma 
being considered a heterogeneous disease with multiple presenting symptoms, 
epidemiological childhood asthma definitions and clinical asthma phenotypes are 
excessively based on wheezing 31,32. Skytt et al. 33, with data from the Copenhagen 
Prospective Study on Asthma in Childhood, addressed the lack of validity of wheezing for 
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asthma diagnosis in children aged 0 to 3 years. They argued for a global description of 
asthma symptoms to reduce the risk of misclassification of asthma in children. Wheezing-
based asthma definitions are also limited by differences in the concept and perception of 
wheeze 34. Fernandes et al. reported a lack of perception of the term “wheezing” among 
Portuguese parents and health professionals 35. 
The ISAAC used two asthma prevalence approaches: 1) a doctor diagnosis of asthma ever 
in the lifetime (“ever had asthma”); and 2) “ever had asthma” plus “current wheeze”. The 
estimates of the first definition were the most disseminated. In Western Europe, the ISAAC 
estimates for the 6- to 7-year-old group were 9.1% for “ever had asthma” and 4.5% for “ever 
had asthma plus current wheeze”; for the 13- to 14-year-old group, the estimates were 16.3% 
for “ever had asthma” and 7.7% for “ever had asthma plus current wheeze”. In Portugal, the 
prevalence of “ever had asthma” was 9.8% in the 6- to 7-year-old group and 13.2% in the 
13- to 14-year-old group 27. Many other studies have been conducted in Portugal, mainly 
school-based or primary care-based, in selected regions and selected pediatric ages, 
leading to different prevalence estimates 36–42. The Portuguese Study of Allergic Diseases in 
Childhood (PAC), preformed in Madeira, Cape Verde and Macau, showed a prevalence 
around 10% in children between 6-10 years old in Madeira 38. In pre-schoolers, two recent 
Portuguese studies had also reported estimates of physician asthma diagnosis of 4.6% 26,43. 
These studies brought important data, however, neither the ISAAC nor the other studies 
estimated the prevalence of asthma across all pediatric ages (<18 years old) or among a 
representative nationwide sample in Portugal 37–39,42. In fact, few studies worldwide have 
estimated the nationwide prevalence of asthma in children. Schmitz et al. 44 reported a 4.7% 
prevalence of a doctor-diagnosed lifetime asthma in the German population of 0- to 17-
year-old using data from the 2003-2006 German Health Interview and Examination Survey 
for Children and Adolescents (KiGGS). Data from the 2010 United States National Health 
Interview Survey for children under the age of 18 years reported an estimated doctor-
diagnosed lifetime asthma prevalence of 13.6% and current asthma prevalence of 9.5% 
45,46. 
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1.4 Diagnostic tests and medication use in childhood asthma 
Diagnostic tests use in childhood asthma 
Asthma diagnosis and management is much based on symptoms 6. However, diagnostic 
tests are also important for diagnosis and assessment of disease. Pulmonary function tests 
(PFT), especially spirometry with bronchodilation test, are recommended for every child with 
asthma suspicion above 5 years of age 6. Also, allergy tests, namely skin prick tests or serum 
specific immunoglobulin E to aeroallergens, are important for the assessment of atopic 
status and optimization of asthma management. Airway inflammation assessment, with 
exhaled nitric oxide (FeNO) testing, is a recent tool that became clinically feasible in the last 
years and may be useful in clinical practice 47. Moreover, other blood workouts or chest x-
rays are often performed in asthmatic patients, depending on the occasion and setting 48. 
Blood workout can be performed to assess atopic status, but it can be also used, more 
widely, in acute severe exacerbations (i.e. blood gases). Chest x-rays are rarely useful and 
should not be used routinely; however, it should be reserved for children with other clinical 
features that may point to other diagnoses and for severe presentations.  
Despite GINA recommendations for diagnostic test use in children with asthma, there is a 
paucity of data regarding the real-life use of diagnostic tests in asthma. Data from the USA 
showed that only 21% of the family physicians/pediatricians used spirometry for all guideline-
recommended clinical situations 49. In Portugal, and to the best of our knowledge, there 
were no published data about the proportion of diagnostic test use in childhood asthma. 
Medication use in childhood asthma 
Pharmacological treatment is an important part of asthma management and should be 
adjusted in a continuous control-based cycle 6. There are 3 main categories of asthma-
specific medications: 1) controller medications; 2) reliever medications; 3) add-on therapies 
for severe asthma. GINA advocates a stepwise approach to the treatment of asthma in 
children. At Step 1, the initial option can be short-acting b2-agonist (SABA) relievers for 
symptom relief (especially for children under 6 years of age), or low-dose inhaled 
corticosteroids (ICS); at Step 2, treatment with low-dose ICS or leukotriene receptor 
antagonists (LTRA), with as-needed SABA, is preferred; at steps 3–4, different options can be 
made, such as doubling the dose of ICS, adding ICS and LTRA, or initiating the association 
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ICS and long-acting b2-agonist (LABA); at step 5, add-on treatment for severe asthma 
should be considered. 
In the USA, a study based on a prescription database estimated that more than 60% of 
asthmatic children between 6 and 18 years of age were prescribed with, at least, one drug; 
SABA was the most frequent medication (52.7% in non-severe asthma and 91.9% in severe 
asthma), followed by oral steroids (23.0% in non-severe asthma and 63.6% in severe asthma) 
or ICS (15.3% in non-severe asthma and 79.8% in severe asthma), LTRA (16.6% in non-severe 
asthma and 48.7% in severe asthma), and association ICS/LABA (10.1% in non-severe 
asthma and 21.8% in severe asthma) 50. In Europe, Dahlen et al reported that 82% of 
asthmatic Swedish adolescents used asthma medicines in the previous 12 months 51. 
To understand the burden of childhood asthma in Portugal, data on use of asthma 
medication should be collected at community level and within all pediatric ages. 
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1.5 Healthcare services use in childhood asthma 
One of the major aims of a disease burden study is to inform and help policymakers, 
especially in the field of healthcare services management. Knowing the patterns of use of 
different healthcare services is crucial to advocate future action plans, in order to improve 
management and control of the disease. In childhood asthma, data on healthcare services 
use is scarce. In a recent state of art manuscript on disease burden of childhood asthma 
written by the ISAAC main authors, they didn’t present data or comment anything about 
healthcare services use in asthmatic children 21; however, they stated that 
emergency/unplanned medical visits, hospital admissions and medication (controller and 
reliever), are important components of costs in childhood asthma. 
It is known that a higher use of healthcare visits and/or asthma medication is associated 
with worse asthma control in children 52–54. Also, literature on asthma disease burden in all 
ages showed that asthma has a higher burden in pediatric ages and that hospitalisations 
and medications are the most import drivers of direct costs 55. 
Hospitalisations, emergency and medical visits in childhood asthma 
Physician medical visits are pivotal in asthma management. Ideally, asthmatic children 
should be managed with regular scheduled medical visits, with no need for unscheduled 
medical visits, emergency department admissions or hospitalisations.  
Data on medical visits on childhood asthma are infrequently reported in the literature, 
difficult to find and have high variability in ages and settings covered by the different studies. 
There are data on asthma hospitalisation rates in specific years and populations, mainly 
based in hospital admission databases 19,56,57. In the USA, asthma was responsible for 2.3% of 
overall hospitalisations in children in the first decade of this century and, in 2009, the rate of 
hospitalisations for childhood asthma was 18.4 per 10,000 person-years 56. In Portugal, the 
most recent study on asthma hospitalizations, with national data from Health Services 
Central Administration (ACSS) from 2000-2010, showed a mean global, all-age, rate of 
annual hospitalisations of 28.1 per 100,000 inhabitants, and 66.6 per 100,000 inhabitants in 
those aged 0 to 18 years 19. However, there is a lack of knowledge about the prevalence of 
hospitalisations for asthma among the overall pediatric population and, specifically, among 
those with a known asthma diagnosis. Also, the proportion of children with asthma that is 
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hospitalised because of asthma during their lifetime is still unknown, i.e., no studies have ever 
been published on the prevalence of lifetime hospitalisations of children with asthma. This 
means that the proportion of asthmatic pediatric population with, at least, one hospital 
inpatient admission during childhood is not known. 
Kattan et al. 58 studied an inner-city population of asthmatic children aged 4 to 9 years and 
concluded that the proportion of hospitalisations in one year was 17% and that of 
unscheduled medical visits (to emergency department or clinics) was 66%. Different 
estimates were reported for 7- to 8-year old children from New York City: 26.7% had urgent 
medical visits for asthma in the previous 12 months 59. In a Polish study, asthmatic children 
between 6 and 16 years old were characterized according to several healthcare services 
utilizations in the previous 12 months: 5.4% needed hospitalisation, 44.1% were seen by a 
physician and 35.5% performed asthma-related diagnostic tests. 
Healthcare access in asthma 
In many health systems, health insurance status plays an important role in the access to 
healthcare services, including for asthmatic children: uninsured children are more likely to 
have restricted medical care and impaired access to healthcare services 60,61. Data on the 
2007-2009 US recession has shown that children that experienced a gap on health insurance 
coverage had poorer asthma control.62 In Europe there are different healthcare systems 
and financing modalities among and within countries, but no study evaluated the influence 
of the children’s health insurance status on asthma outcomes in European countries. 
The Portuguese Health System has universal coverage with mixed public-private payers. It is 
financed by taxes and by health insurances, complemented by out-of-pocket expenses. 
Health insurances are not only private, but also state-owned, paid by state employees (e.g. 
ADSE - Instituto de Proteção e Assistência na Doença). All Portuguese citizens have access 
to medical care services in public primary care and hospital units. The public care access is 
primarily based on visits to primary care physicians that can refer patients to hospital 
specialities; this is limited by the waiting time and geographic referral areas that prevent the 
patients from choosing the place where they will be cared for. Private practice/hospital 
access is dependent on the patient’s will to attend these institutions or by health insurance 
plans. As out-of-pocket expenses can be significant, access is better for those with 
complementary health insurance coverage. Therefore, citizens with healthcare insurance 
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may easily choose the site of medical care that they perceive as the best, with easier access 
to medical specialities and lower waiting time for medical observations and diagnostic tests. 
As state-owned insurance is available for all state employees (if wanted by them) and some 
private companies provide health insurance to all their employees, the socioeconomic 
status is probably only partially related to having health insurance. Regarding medication, 
prices are the same for every Portuguese child, regardless of health insurance status. 
Medicines commercialized in Portugal are partly paid by the public health system with a 
fixed percentage for every drug; the remaining value is supported by citizens, without any 
payment by health insurance companies. 
  
26 | Burden of childhood asthma in Portugal 
1.6 Asthma control in children 
The main goal of asthma management is to achieve disease control, meaning, good 
control of symptoms, normal activity levels, normal sleep, no exacerbations, no fixed airflow 
limitation and no medication side-effects 6. A good control of asthma symptoms is the main 
goal, not only in treating asthma, but also in reducing asthma burden. In children, the 
proportion of poor asthma control varies widely, from 15% to 90%, depending on the age 
groups included, countries, settings and control definition 52,63–68. In the USA (2008), the 
proportion of uncontrolled asthma in 4- to 17-year-old children with asthma who visited a 
pediatric health care provider was 46% 66. Dahlen et al showed a proportion of 47% of 
uncontrolled asthma in Swedish adolescents (2013) 51. In Dutch (2007) 6- to 16-year-old 
asthmatic children with a follow-up in outpatient clinic, the proportion of poor control was 
55% 68. In French pre-schoolers (2006), uncontrolled asthma based on frequent occurring 
symptoms was present in 42% 67. In Portugal, there were no published data on the 
prevalence of childhood asthma control. 
Several factors have been associated with lack of asthma control in children, such as rhinitis 
69, eczema 65, obesity 70, lower socioeconomic status 71, or parents’ impaired perception of 
asthma control 68. Specifically, the strong link between upper and lower airway disease is 
recognized 26,72. In Dutch asthmatics aged 5 to 18 years, the prevalence of nasal symptoms 
was 76% and there was an association with poorer asthma control in children in those with 
untreated nasal symptoms 69. Other studies identified that underdiagnosis and 
undertreatment of rhinitis in asthmatic children was associated with lack of parental 
recognition and poorer asthma control 73,74. Also, recently published data showed that 
increased body mass index (BMI) was associated to lack of asthma control 63, to a higher 
use of inhaled β-agonists or oral corticosteroids,70 and to worse asthma control in children 
with higher airway inflammation 75. 
Children with uncontrolled asthma need to use more asthma medication and are more 
likely to use healthcare services for asthma, especially unscheduled medical visits and 
hospital admissions 53,76. This points towards a higher burden of the disease in children with 
uncontrolled asthma. Improving knowledge on asthma control, including its prevalence 
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and related factors, is needed to assess the extent of the asthma-related burden and to 
inform policymakers, aiming to achieve better results in health.   
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1.7 Quality of life in childhood asthma 
The quality of life (QoL) is a multidimensional concept that encompasses the well-being of 
a population in several aspects of life (e.g. health, education, finances), as perceived by 
the individuals, and according to their socio-cultural environment  77. QoL can be measured 
and health is one major determinant of this assessment. Health-related quality of life (HRQoL) 
was defined by Patrick and Erickson as ‘the value assigned to duration of life as modified by 
the impairments, functional states, perceptions and social opportunities that are influenced 
by disease, injury, treatment or policy’ 78. 
Asthma affects the well-being of the patients. One Australian report showed that asthma 
was associated to significantly lower scores in all the domains of the 8-Item Short Form Health 
Survey (SF-8), when compare with healthy people 79. Also, after mental illnesses, asthma was 
one of the second conditions that had major impact on QoL, including in the domains of 
‘Physical functioning’, ‘Role physical’, ‘Bodily pain’, ‘General Health’ and ‘Vitality’. 
In childhood asthma, there are several tools for the evaluation of quality of life, namely, 
Pediatric Asthma Quality of Life Questionnaire (PAQLQ), Life Activities Questionnaire for 
Childhood Asthma, Pediatric Quality of Life Asthma Module 4.0 (PedsQLTM4.0) or The Living 
with Asthma Questionnaire (LWAQ) 80. One recent meta-analysis in QoL in childhood asthma 
reported lower scores of QoL in ‘Physical functioning’, ‘Social functioning’ and 
‘Psychological functioning’ when considering children’s perception, but only found 
differences in ‘Physical functioning’ when considering parents’ perception 81. In fact,  it is 
not well established the utility of these QoL tools in childhood asthma because of the lack 
of validity or reproducibility between children and/or caregivers 82,83. Moreover, the quality 
of life in asthma patients, namely in children, is known to be closely linked to asthma control 
or seek for medical attention 76. In Brazil, children with controlled or partly controlled asthma 
showed a significant increased in all the domains of PAQLQ (activities limitation, symptoms 
and emotional function) when compared with children with uncontrolled asthma 84. In the 
same direction, in Portugal, a study on asthmatic children followed in referral hospitals, using 
a global QoL tool (DISABKIDS-37), showed that children’s perspectives and parents’ 
perspectives differed in several domains and that children with uncontrolled asthma had 
lower scores in HRQoL 85.  
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1.8 Cost of asthma  
Health-related costs are an important part of a disease burden assessment. Health 
economics analysis is highly relevant because of rising healthcare costs and the consequent 
threat to the sustainability of healthcare systems around the world  86. Therefore, health 
economics studies are needed to support local decision-makers in defining health priorities 
87. As governmental health policies become more cost restrictive, it is important to know 
where is possible to act in order to reduce costs while maintaining or enhancing healthcare 
quality. In Portugal, health-related costs represented 9,9% of the gross domestic product in 
2010 88, highlighting the importance of being thoughtful with healthcare resource allocation. 
Cost-of-illness studies are the foundation of health economics, informing posterior studies 
aiming to measure preferences and interventions 89,90. 
In childhood asthma, important direct costs (diagnostic tests, medications, medical visits, 
hospitalisations or emergency department admissions) and indirect costs (mainly 
caregivers’ loss of work days and transportation to healthcare services) are relevant and 
can be high, especially in severe disease 91. Having a comprehensive picture of childhood 
asthma burden, including costs, will allow physicians and policymakers to analyse 
susceptible points that can be managed in order to have gains in the efficiency of asthma 
management. 
In 2002, Druss et al have coted asthma as the 13th most expensive medical condition in USA 
92. In 2011, Barnett and Nurmagambetov estimated, by a regression-based method, $56 
billion (in 2009 dollars) of incremental costs of asthma in all-age asthmatic USA population, 
representing a value of $3,259 by person/year 93. In the same year, Bravo et al published an 
estimated cost of asthma in 0- to 15-years-old children, in Spain, of €532 million, meaning a 
cost of €1,149 person/year 91. In this study, the authors also analysed the costs within each 
category of asthma severity, ranging from €403 for the mildest to €5,930 for the severest 
(costs person/year). Many other economic studies were conducted in asthma all-over the 
world, with different methodologies, different variables, and different age ranges. However, 
there are few population-based and comprehensive pediatric studies 55. 
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2. AIMS 
The main objective of this research project was to study the burden of asthma in Portuguese 
children. 
 
As specific aims, we intended to estimate:  
1. The prevalence of asthma and asthma-like symptoms in Portuguese children (Paper 1) 
2. The number of hospitalisations for asthma in Portuguese children with asthma (Paper 2) 
3. The proportion of asthma-related ambulatory healthcare services and medication use in 
Portuguese children with asthma (Paper 3) 
4. The proportion of asthma control and the determinants of control in Portuguese children 
with asthma (Paper 3) 
5. The cost of illness of asthma in Portuguese children and to assess cost variations with level 
of asthma control (Paper 4) 
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3. PhD STUDIES 
The studies from the present PhD thesis were designed to perform a comprehensive 
assessment of childhood asthma burden in Portugal. Data from two studies were collected 
and analysed: 
1) Portuguese National Asthma Survey (INAsma), a nationwide study developed in two 
phases: 
a. Portuguese National Asthma Prevalence Survey (INPA), aimed to estimate 
asthma and asthma-like symptoms prevalence, as well as cost of childhood 
asthma, in Portuguese population; 
b. Portuguese National Asthma Control Survey (INCA), aimed to estimate 
proportion of asthma control and cost of childhood asthma in Portuguese 
population; 
2) Asthma in school-aged children: the Guimarães study (CED2013), designed for 
empower the results on cost of asthma in school-aged children using a questionnaire 
and objective assessment. 
 
Data from INAsma, CED2013 and, also, secondary data from specific national databases 
on healthcare resources costs (healthcare services, diagnostic tests and medication) and 
occupational costs were compiled in order to study the cost of childhood asthma in 
Portugal (CASCA Project).The next diagram (Figure 1) shows the studies from the Ph.D. thesis:  
  
Figure 1  
Venn diagram of the 
different studies of the Ph.D. 
thesis. 
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ABSTRACT  
Objective: This study aimed to estimate the prevalence of asthma-like symptoms, current 
asthma, asthma diagnostic tests, and inhaled medication use in a nationwide pediatric 
population (<18 years). 
Methods: Pediatric-specific data from a cross-sectional, population-based telephone 
survey (INAsma study) in Portugal were analysed. current asthma was defined as lifetime 
asthma and (1) wheezing, (2) waking with breathlessness, or (3) asthma attack in the 
previous 12 months, and/or (4) taking asthma medication at the time of the interview. 
Results: In total, 716 children were included. The prevalence of asthma-like symptoms was 
39.4% [95% confidence interval (95%CI), 35.7–43.3]. The most common symptoms were 
waking with cough (30.9%) and wheezing (19.1%). The prevalence of current asthma was 
8.4% (95%CI, 6.6–10.7). Among children with current asthma, 79.9% and 52.9% reported prior 
allergy testing and pulmonary function testing (PFT), respectively. Inhaled medication use in 
the previous 12 months was reported by 67.6% (reliever inhalers, 40.1%; controller inhalers, 
41.5%). Those who only used inhaled reliever medications experienced more asthma attacks 
[odds ratio (OR), 2.69]. Significantly fewer children with current asthma living in rural areas 
than those living in urban areas had undergone PFT or used inhaled medication (OR: 0.06 
for PFT, 0.20 for medication]. 
Conclusions: The prevalence of current asthma in the Portuguese pediatric population was 
8.4%. Only half of children with current asthma had ever undergone PFT; more than half did 
not use controller inhalers, and those who only used reliever inhalers reported more asthma 
attacks. These findings suggest that asthma management has been substandard, mainly in 
rural areas.  
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AIMS 
In 2010, we conducted the first Portuguese National Asthma Survey (INAsma) 94. In the 
present paper, we focus on the results obtained from the INAsma pediatric population. 
Specifically, our primary aim was to estimate the prevalence of asthma-like symptoms and 
current asthma in the Portuguese pediatric population (<18 years). Our secondary aims 
were to describe the differences in current asthma prevalence estimates according to 
different definitions to allow for comparisons with other studies and to assess the proportion 
of the use of diagnostic tests and inhaled medication among children with current asthma.  
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METHODS 
Study design and setting 
The INAsma was a population-based, nationwide, cross-sectional survey applied by 
telephone interview in Portugal, in 2010. The study methodology has been previously 
described 94. 
This study was reviewed and approved by the Ethics Committee of Centro Hospitalar de 
São João, Porto, Portugal. Informed consent was obtained from the parent(s) or legal 
guardian(s) of the children included in this study. We followed the STROBE statement for 
reporting observational studies 95. 
In this study, we included all the individuals aged <18 years old (henceforth referred to as 
“children” for simplification). 
Sample size 
The study sample size was calculated for the total Portuguese population and was based 
on confidence intervals of proportions. Thus, for the general all-age population, for an 
estimated a priori asthma prevalence of 6% and narrow error margin of 0.015, a sample of 
1067 individuals was required. However, the sample size of this study was calculated 
considering the two phases of the research project. In the first phase, we aimed to estimate 
the current asthma prevalence in the Portuguese population. In the second phase, we 
aimed to estimate the proportion of patients with controlled asthma symptoms. Thus, in the 
second phase of the project, to estimate the proportion of patients with controlled asthma 
with a 3% margin of error and 95% confidence level, and assuming a proportion of 20% of 
patients with uncontrolled asthma in the population, we required a sample of at least 554 
patients with asthma identified in the first phase of the project. Assuming a 20% loss to follow-
up, we required at least 665 patients with asthma during the first phase. Within these 
premises, and assuming a prevalence of 6% in the Portuguese population and a margin of 
error of 0.65%, we required a sample of at least 6000 persons from the general, all-age, 
Portuguese population willing to participate in the first phase of the project. 
Households were then randomly selected from the 2010 residential White Pages telephone 
directory. Four different lists of telephone numbers were randomly selected for each 
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municipality to allow for substitution of nonresidential telephone numbers. In total, 24,412 
telephone numbers were retrieved. One participant (the last person to have had a birthday) 
was randomly selected from each household. 
The inclusion of 716 children allowed us to estimate the current asthma prevalence with an 
error margin of 0.02 and a 95% confidence level. 
Participants 
The INAsma target population was the Portuguese general population, and the available 
population included citizens of all ages living in households with a landline telephone 
(sampling frame). A cluster sampling design was used to obtain a representative sample of 
the population. All municipalities were used as natural strata, and a sample of households 
was then selected with a probability proportional to the municipality population as 
estimated in the 2001 National Census. 
First, all municipalities were used as natural strata; in each municipality, a sample of 
households with a landline telephone number was selected with a probability proportional 
to the municipality population as estimated in the 2001 National Census. The target number 
of households was set at 6,103. The sample of households was derived from the directory 
listed in the residential White Pages from 2010. A list of all telephone numbers in a specific 
municipality was compiled to draw a sample of telephone numbers within that municipality. 
A sample of household telephone numbers was randomly selected from the whole list in 
each municipality. Because part of the selected telephone numbers were from companies 
or were not allocated, four lists were randomly selected for each municipality to allow for 
substitution of non-residential telephone numbers. In total, 24 412 telephone numbers were 
retrieved. 
After the selection and identification of a residential number, one participant was randomly 
selected from each household. After identification of all residents in the household, the 
selected participant in each household was the last person to have had a birthday. When 
the selected individual was younger than 15 years, the respondent was the usual caregiver. 
Individuals were excluded if they did not understand spoken Portuguese or had cognitive 
or physical conditions that could hamper the interview. In the final 20% of the sample, an 
oversampling strategy of male adults and younger adults was used to correct the common 
overrepresentation of female and older participants observed in the interim analysis. 
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Instruments and data collection 
The instrument for data collection was the Portuguese version of the questionnaire used in 
the GA2LEN survey, which includes the European Community Respiratory Health Survey 
questions on asthma symptoms 96. Several questions were added regarding socio-
educational variables, medications, and diagnostic test use for asthma. 
An experienced private company administered the questionnaire through computer-
assisted telephone interviews performed by trained and experienced interviewers. 
Interviews were conducted from March to May of 2010, mostly from 17:00 to 22:00 h on 
weekdays and 11:00 to 22:00 h on weekends and holidays. No telephone number was 
abandoned until a minimum of 10 attempts had been made on different occasions. The 
interviews had a mean duration of 15 min. 
To minimize other potential biases in data collection, several quality assurance measures 
were followed: interviewers were selected based on their previous experience with health-
related data collection; each question was discussed in training sessions held between 
researchers and all interviewers; a research assistant was present during the setup, training, 
and daily work of the interviewers, motivating and checking compliance with standardized 
operational procedures; data validity was periodically verified soon after being collected, 
and custom statistic algorithms were used to detect extreme, illogical, and missing values; 
and the clarity of the questionnaire and its telephonic administration were assessed in a pilot 
study involving 25 individuals before starting the data collection. 
Variables 
Asthma definition variables were defined based on previous studies 22,25. The outcomes were 
defined as follows: 
 lifetime asthma: positive answer to “Have you ever had asthma?”. 
current asthma: lifetime asthma plus at least one of the following four features: 1) wheezing, 
2) waking with breathlessness or 3) having an asthma attack in the last 12 months, or 4) 
taking asthma medication at the time of the interview. 
Nocturnal symptoms: at least one of three symptoms in the last 12 months: waking with 
breathlessness, waking with chest tightness, or waking with coughing. 
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Asthma-like symptoms: at least one of three symptoms in the last 12 months: wheezing, 
nocturnal symptoms, or asthma attacks (wheezing was further described as wheezing with 
breathlessness or wheezing without a cold). 
PFT: positive answer to “Have you ever undergone any test to assess your lung function?” 
(the interviewer further explained that “it refers to an exam that assesses the breathing 
capacity, i.e., spirometry, or blowing harder into a machine, or breathing inside a glass box, 
other than blowing quickly to a plastic tube or peak flow meter”). 
Skin prick tests: positive answer to “Have you ever undergone any skin test to assess your 
allergies?”. 
Blood allergy tests: positive answer to “Have you ever undergone any blood test to assess 
your allergies?”. 
Any asthma medication at present: positive answer to “Are you currently taking medication 
(inhaled, nebulized or oral) for asthma/breathlessness?”. 
Inhaled therapy in the last 12 months: positive answer to “In the last 12 months, did you take 
any inhaled medication for asthma/breathlessness?”. Further characterization of inhaled 
medication was based on the auto-reported medication name. 
Allergic rhinitis: Positive answer to “Do you have any nasal allergies, including hay fever?”. 
Atopic dermatitis/eczema: Positive answer to “Have you ever had eczema or skin allergy?”. 
Food allergy: Positive answer to “Have you been diagnosed with food allergy by a doctor?”. 
Environmental tobacco smoke (ETS): Positive answer to “Does anyone smoke inside your 
home?”. 
Municipality was classified as urban if the residence was located in a municipality with at 
least one city (cities must have at least 8000 citizens), according to Portuguese legislation 97. 
Statistical analysis 
The sample estimates were weighted according to the 2001 National Census aiming for 
generalization to the target population 98, with the exception of the participants’ 
characteristics description, which was performed without weighting procedures. Statistical 
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analyses were weighted for the Portuguese pediatric population and performed using the 
complex samples tool of SPSS version 21 (SPSS IBM, New York, NY, USA). 
A sequential simple random sampling method without replacement was used to select a 
random sample of households with a landline telephone within each stratum (municipality) 
and then one random eligible household resident. Two types of weights were used: 1) 
prestratification weights to adjust for the sampling design and 2) poststratification weights 
to adjust for the true sex and age distribution of the target population, thus partially 
correcting for nonresponse and noncoverage bias. 
Categorical variables were described using absolute and relative frequencies with 95% 
confidence intervals (95%CI); comparisons were performed with Pearson’s chi-squared test. 
Univariate logistic regression models for outcomes were developed using independent 
variables as risk/predictive factors. Multivariate logistic regression models were developed 
to adjust for possible confounders. Results of multivariate logistic regression models were 
presented as odds ratios (ORs) with 95% CIs. A p-value of <0.05 was considered statistically 
significant. 
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RESULTS 
Participants 
The corrected response rate of the INAsma was 50%. Of the 6,003 participants in the INAsma 
survey, 716 (11.9%) were children. A flowchart of all participants is shown in Figure 2. One-
fifth (21.4%) of the children were younger than 6 years of age, and 39% were 13 to 17 years 
old; most (80.6%) were from urban areas. The children’s characteristics are summarized in 
Table 3. 
 
 
 
 
 
 
 
Figure 2 Participants’ flowchart. 
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Table 3 Participants’ characteristics in a pediatric sample. Weighted proportion and odds ratio (95% 
confidence intervals) of current asthma according to sociodemographic and clinical variables. 
 Total participants, n (%) 
Current asthma, 
% (95%CI) 
Odds Ratioa 
(95%CI) 
All Pediatric Population 716 (100.0)   8.4  (6.6-10.7)  
Gender    
Female 270  (37.7)   6.7   (4.3-10.1) 1.00  (Ref) 
Male 446  (62.3) 10.1   (7.5-13.4) 1.59  (0.92-2.75) 
Age groups    
0-5 years 153  (21.4)   6.5   (3.5-11.6) 1.00  (Ref) 
6-12 years 284  (39.7)   9.7   (6.8-13.8) 1.53  (0.73-3.23) 
13-17 years 279  (39.0)   8.7   (5.9-12.5) 1.36  (0.64-2.90) 
National Region    
North 284  (39.7)   7.2   (4.6-11.1) 1.00  (Ref) 
Centre and Islands 179  (25.0)   9.7   (6.3-14.7) 1.35  (0.67-2.74) 
South 253  (35.3)   8.7   (5.7-12.9) 1.21  (0.61-2.38) 
Municipalityc    
Urban 577  (80.6)   8.0   (5.9-10.8) 1.00  (Ref) 
Rural 139  (19.4)   9.8   (6.6-14.3) 1.12  (0.59-2.11) 
ETSb    
No 454 (63.4)   8.2   (5.9-11.3) 1.00  (Ref) 
Yes 262 (36.6)   8.8   (6.1-12.6) 1.06  (0.61-1.84) 
Allergic rhinitis    
No 558 (77.9)   5.0     (3.4-7.4) 1.00  (Ref) 
Yes 158 (22.1) 22.3 (16.6-29.2) 5.15  (3.02-8.78)* 
Eczema    
No 517 (72.2)   5.0     (3.4-7.4) 1.00  (Ref) 
Yes 199 (27.8) 18.3 (13.6-24.2) 4.08  (2.35-7.08)* 
Food allergy    
No 676 (94.4)   8.3   (6.4-10.8) 1.00  (Ref) 
Yes   40   (5.6)   9.6   (5.4-16.4) 0.94  (0.45-1.95) 
aAdjusted odds ratio for gender, age, region, municipality and ETS; bEnvironmental tobacco smoke. cMunicipality 
was classified as urban if residence was located in municipalities with at least one city (cities must have at least 
8000 citizens) according to Portuguese law. 
*Statistically significant 
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Prevalence of asthma-like symptoms 
The prevalence of asthma-like symptoms among Portuguese children was 39.4% (95%CI, 
35.7–43.3) (Table 4). Asthma-like symptoms were highest in children aged <6 years (47.9%; 
95%CI, 40.0–56.0) and lowest in those aged 13 to 17 years (31.8%; 95%CI, 26.3–37.8; p = 0.005) 
(Table 3). Waking during the night with cough was the most prevalent symptom (30.9%; 
95%CI, 27.5–34.5), followed by wheezing (19.1%; 95%CI, 16.4–22.1). 
Table 4 Weighted prevalence of asthma-like symptoms in the previous 12 months in the Portuguese 
pediatric population. 
  Current asthma 
 Total population %   (95%CI) 
Yes % 
(n=66) 
No % 
(n=750) 
Any symptoma 39.4  (35.7-43.3) 91.4  (82.4-96.1) 34.7  (30.9-38.6) 
Wheezing 19.1  (16.4-22.1) 76.5  (65.4-84.9) 13.8  (11.4-16.6) 
     Wheeze w/o cold   8.2    (6.5-10.4) 49.2  (37.2-61.3)   4.5      (3.1-6.3) 
Nocturnal symptoms 34.7  (31.1-38.5) 79.2  (68.0-87.3) 30.7  (27.0-34.6) 
     Waking with breathlessness   5.0      (3.6-7.1) 24.7  (16.1-35.9)   3.2      (2.0-5.3) 
     Waking with chest tightness   6.7      (5.1-8.8) 27.4  (17.8-39.6)   4.8      (3.4-6.8) 
     Waking with cough 30.9  (27.5-34.5) 68.7  (56.6-78.7) 27.4  (24.0-31.2) 
Asthma attack   3.7      (2.6-5.4) 44.4  (32.6-56.9)   0.0      (0.0-0.0) 
aWheezing or waking with breathlessness or waking with chest tightness or waking with cough or asthma attacks 
 
 
The prevalence of nocturnal symptoms was higher in children aged <6 years (39.8%; 95%CI, 
32.1–48.1) than in those aged 13 to 17 years (OR, 0.61; 95%CI, 0.40–0.94), although the 
prevalence was not significantly different from that of children aged 6 to 12 years (OR, 0.84; 
95%CI, 0.55–1.28). The prevalence of wheezing was highest in children aged <6 years (31.0%; 
95%CI, 24.4–38.5) and significantly decreased with age (OR, 0.46; 95%CI, 0.30–0.70 in the 6- 
to 12-year-old age group; and OR, 0.24; 95%CI, 0.15–0.40 in the 13- to 17-year-old age 
group) (Figure 3). Among children who reported wheezing in the last 12 months, the 
symptoms of wheezing without a cold and wheezing with breathlessness were higher in 
children aged 6 to 12 years than in those aged <6 years (p < 0.001) (Figure 4). 
The presence of rhinitis and eczema were associated with a higher prevalence of having 
any asthma-like symptom (OR, 3.67; 95%CI, 2.52–5.39 for rhinitis; and OR, 2.11; 95%CI, 1.51–
2.94 for eczema). Supplementary information on asthma-like symptoms is presented in 
Tables 5 and 6
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Table 5 Weighted proportion of asthma-like symptoms and corresponding odds ratio in the Portuguese paediatric population in the previous 12 months according 
to sociodemographic variables. 
 Any symptoma  Wheezing  Nocturnal symptoms  Asthma attack 
% 
(95%CI) 
Odds Ratiob 
(95%CI) 
 % 
(95%CI) 
Odds Ratiob 
(95%CI) 
 % 
(95%CI) 
Odds Ratiob 
(95%CI) 
 % 
(95%CI) 
Odds Ratiob 
(95%CI) 
Sex            
Female 36.3 
(30.6-42.3) 
1.00 
(Ref) 
 14.0 
(10.6-18.4) 
1.00 
(Ref) p<0.001 
 
32.6 
(27.1-38.6) 
1.00 
(Ref) 
 3.3 
(1.8-5.9) 
1.00 
(Ref) 
Male 42.5 
(37.9-47.2) 
1.29 
(0.94-1.79) 
 
 
23.9 
(20.1-28.2) 
1.96 
(1.30-2.97)* 
36.8 
(32.3-41.6) 
1.20 
(0.86-1.68) 
 4.2 
(2.7-6.5) 
1.29 
(0.60-2.78) 
Age            
0-5 years 47.9 
(40.0-56.0) 
1.00 
(Ref) 
 31.0 
(24.4-38.5) 
1.00 
(Ref)          
p<0.001 
39.8 
(32.1-48.1) 
1.00 
(Ref)      
p<0.001 
2.8 
(1.2-6.8) 
1.00 
(Ref) 
6-12 years 39.2 
(33.5-45.2) 
0.70 
(0.47-1.05) 
p=0.005 17.3 
(13.7-21.5) 
0.46 
(0.30-0.70)* 
35.7 
(30.3-41.6) 
0.84 
(0.55-1.28) 
5.5 
(3.4-8.9) 
2.00 
(0.71-5.65) 
13-17 years 31.8 
(26.3-37.8) 
0.51 
(0.33-0.77)* 
 9.9 
(7.0-13.9) 
0.24 
(0.15-0.40)*  
28.8 
(23.5-34.7) 
0.61 
(0.40-0.94)* 
 2.5 
(1.3-4.6) 
0.88 
(0.29-2.63) 
National region            
North 38.2 
(32.3-44.5) 
1.00 
(Ref) 
 20.5 
(16.0-26.0) 
1.00 
(Ref)  
33.3 
(27.7-39.5) 
1.00 
(Ref) 
 3.1 
(1.7-5.9) 
1.00 
(Ref) 
Center and Islands 43.3 
(36.0-50.9) 
1.25 
(0.84-1.86) 
 17.4 
(13.0-22.9) 
0.81 
(0.51-1.29)  
38.6 
(31.6-46.1) 
1.26 
(0.84-1.89) 
 2.8 
(1.2-6.3) 
0.88 
(0.30-2.59) 
South 37.6 
(31.6-44.1) 
0.96 
(0.66-1.41) 
 18.8 
(14.4-24.0) 
0.87 
(0.55-1.36)  
33.2 
(27.3-39.6) 
0.99 
(0.67-1.46) 
 5.2 
(3.0-8.7) 
1.68 
(0.71-3.97) 
Municipalityc            
Urban 40.5 
(36.1-45.0) 
1.00 
(Ref) 
 19.3 
(16.1-23.0) 
1.00 
(Ref)  
36.0 
(31.7-40.5) 
1.00 
(Ref) 
 3.4 
(2.1-5.3) 
1.00 
(Ref) 
Rural 35.4 
(29.6-41.7) 
0.81 
(0.58-1.12) 
 18.0 
(14.5-22.2) 
0.91 
(0.63-1.33)  
29.9 
(24.3-36.1) 
0.76 
(0.54-1.07) 
 5.2 
(2.9-9.1) 
0.90 
(0.53-1.52) 
ETSd            
No 38.2 
(33.7-43.0) 
1.00 
(Ref) 
 19.7 
(16.3-23.5) 
1.00 
(Ref)  
32.9 
(28.5-37.7) 
1.00 
(Ref) 
 3.7 
(2.2-6.1) 
1.00 
(Ref) 
Yes 41.6 
(35.2-48.3) 
1.16 
(0.82-1.63) 
 18.0 
(13.8-23.2) 
0.89 
(0.59-1.33)  
37.8 
(31.7-44.4) 
1.24 
(0.88-1.75) 
 3.9 
(2.3-6.3) 
1.06 
(0.50-2.23) 
aWheezing or waking with breathlessness or waking with chest tightness or waking with cough or asthma attacks. bAdjusted odds ratio for gender and age. cMunicipality was classified 
as urban if residence was located in municipalities with at least one city (cities must have at least 8000 citizens) according to Portuguese law. dEnvironmental tobacco smoke. 
*statistically significant 
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Table 6 Weighted proportion of asthma-like symptoms and corresponding odds ratio in the Portuguese paediatric population in the previous 12 months according 
to associated comorbidities. 
 
 
Any symptoma  Wheezing  Nocturnal symptoms  Asthma attack  
% 
(95%CI) 
Odds ratiob 
(95%CI) 
 % 
(95%CI) 
Odds Ratiob 
(95%CI) 
 % 
(95%CI) 
Odds Ratiob 
(95%CI) 
 % 
(95%CI) 
Odds Ratiob 
(95%CI) 
 
Rhinitis             
No 34.1 
(30.1-38.5) 
1.00 
(Ref) 
 
p<0.001 
14.3 
(11.6-17.6) 
1.00 
(Ref) 
 
 p<0.001 
29.8 
(25.9-34.0) 
1.00 
(Ref) 
 
p<0.001 
2.6 
(1.5-4.5) 
1.00 
(Ref) 
 
p<0.001 
Yes 61.2 
(53.2-68.7) 
3.67 
(2.52-5.39)* 
 38.5 
(31.1-46.4) 
6.01 
(3.82-9.46)* 
55.1 
(47.1-62.8) 
3.36 
(2.31-4.89)* 
8.3 
(5.4-12.7) 
3.48 
 (1.69-7.17)* 
Eczema             
No 35.0 
(30.8-39.5) 
1.00 
(Ref) 
 
p<0.001 
15.0 
(12.3-18.3) 
1.00 
(Ref) 
 
 p<0.001 
31.0 
(26.9-35.3) 
1.00 
(Ref) 
 
p<0.001 
2.0 
(1.1-3.6) 
1.00 
(Ref) 
 
p<0.001 
Yes 52.4 
(45.6-59.2) 
2.11 
(1.51-2.94)* 
 30.8 
(24.8-37.6) 
2.77 
(1.85-4.15)* 
45.8 
(38.9-52.9) 
1.92 
(1.36-2.71)* 
8.8 
(5.6-13.7) 
4.74 
(2.16-10.39)* 
Food allergy             
No 39.0 
(35.1-42.9) 
1.00 
(Ref) 
 18.9 
(16.1-22.0) 
1.00 
(Ref) 
 34.4 
(30.7-38.4) 
1.00 
(Ref) 
 3.7 
(2.5-5.4) 
1.00 
(Ref) 
 
 
Yes 48.3 
(34.4-62.5) 
1.58 
(0.87-2.88) 
 22.8 
(13.2-36.6) 
1.52 
(0.78-2.98) 
40.0 
(27.1-44.5) 
1.35 
(0.72-2.50) 
4.9 
(2.1-11.0) 
1.35 
(0.53-3.44) 
aWheezing or waking with breathlessness or waking with chest tightness or waking with cough or asthma attacks. bAdjusted odds ratio for gender and age. *Statistically significant
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Figure 3 Weighted prevalence of asthma-like symptoms within the previous 12 months, according to 
age group (%, 95%CI). 
 
Symbols represent prevalence of: ¢ nocturnal symptoms (waking with breathlessness or waking with chest tightness 
or waking with cough); n wheezing;  asthma attack. 
*Difference between age groups with p < 0.001; ‡Difference between age groups with p < 0.001. 
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Figure 4 Weighted prevalence of wheezing with breathlessness and wheezing without a cold in the 
Portuguese pediatric population. *p < 0.001, ‡p = 0.03. 
 
Prevalence of wheezing in all Portuguese children: 31.0% in 0- to 5-year age group (OR, 1.00); 17.3% in 6- to 12-year 
age group (OR, 0.46; 95%CI, 0.30–0.72); 9.9% in 13- to 17-year age group (OR, 0.25; 95%CI, 0.15–0.41). Prevalence 
of wheezing with breathlessness in all Portuguese children: 13.6% in 0- to 5-year age group; 12.8% in 6- to 12-year 
age group; 5.7% in 13- to 17-year age group. Prevalence of wheezing without a cold in all Portuguese children: 
9.9% in 0- to 5-year age group; 9.5% in 6- to 12-year age group; 5.1% in 13- to 17-year age group. Prevalence of 
wheezing with breathlessness among all children who wheezed: 43.7% in 0- to 5-year age group (OR, 1.00); 74.4% 
in 6- to 12-year age group (OR, 3.73; 95%CI, 1.79–7.78); 57.0% in 13- to 17-year age group (OR, 1.71; 95%CI, 0.83–
3.50). Prevalence of wheezing without a cold among all children who wheezed: 31.9% in 0- to 5-year age group 
(OR, 1.00); 55.2% in 6- to 12-year age group (OR, 2.64; 95%CI, 1.27–5.48); 51.7% in 13- to 17-year age group (OR, 
2.28; 95%CI, 0.96–5.43). 
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Asthma prevalence 
The prevalence of lifetime asthma was 11.2% (95%CI, 9.1–13.7), and that of current asthma 
was 8.4% (95%CI, 6.6–10.7). No statistically significant differences were found in the 
prevalence of current asthma according to region or other sociodemographic variables 
(Table 3). A higher risk for current asthma was found in children with rhinitis and eczema (OR, 
5.20; 95%CI, 3.05–8.85 for rhinitis; and OR, 4.17; 95%CI, 2.41–7.19 for eczema). Table 7 shows 
an overview of different asthma definitions according to the inclusion of different proxies of 
asthma prevalence. 
 
 
Table 7 Mean changes in serum myeloperoxidase per unit of several general and cardiovascular risk 
variables, in the normal weight and overweight/obesity groups. 
 Population % (95%CI) 
Total weighted 
population 
(2,066,953) 
Lifetime asthma 11.2   (9.1-13.7) 230,886 
Current asthma 
(with symptoms in the previous 12 months) 
  
     Wheezing w/o cold 8.2   (6.5-10.4) 169,991 
     Lifetime asthma + wheezing 6.4     (4.8-8.6) 132,848 
     Lifetime asthma + wheezing OR waking 
     with breathlessness 7.0     (5.3-9.1) 143,958 
     Lifetime asthma + wheezing OR asthma attack 
     OR waking with breathlessness 7.2     (5.5-9.4) 149,199 
     Lifetime asthma + wheezing OR waking with breathlessness 
     OR waking chest tightness OR waking cough 8.3    (6.5-10.6) 171,829 
     Lifetime asthma + wheezing OR asthma attack OR waking 
     with breathlessness OR current asthma medication a 8.4    (6.6-10.7) 173,681 
     Lifetime asthma + wheezing OR asthma attack OR 
     waking with breathlessness / chest tightness / cough 8.4   (6.6-10.7) 173,963 
     Lifetime asthma + wheezing OR asthma attack OR 
     current asthma medication OR waking with breathlessness/ 
     chest tightness / cough 
9.1   (7.2-11.5) 188,819 
a Definition used as current asthma 
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Diagnostic tests and medication for asthma 
PFT and allergy tests (skin prick tests and/or blood allergy tests) were performed in 12.6% 
(95%CI, 10.3–15.2) and 28.3% (95%CI, 24.9–31.9) of children, respectively. About half of 
children with current asthma aged ≥6 years had undergone PFT (52.9%; 95%CI, 46.0–59.8), 
and this prevalence did not change if they have had an asthma attack in the previous 12 
months. Children with current asthma who lived in rural areas were less likely to report 
diagnostic testing than those from urban areas (OR, 0.06; 95%CI, 0.04–0.09 for PFT; and OR, 
0.39; 95%CI, 0.22–0.69 for allergy tests) (Table 8). 
Among children with current asthma, the frequency of any asthma medication at the time 
of the interview was 76.4% (95%CI, 64.4–85.3). Inhaled reliever and controller therapy were 
used in the previous 12 months by 40.1% (95%CI, 28.5–53.0) and 41.5% (95%CI, 29.6–54.5) of 
children with current asthma, respectively (Table 9). Children who reported using only 
inhaled reliever medication in the previous year, without any inhaled controllers, were more 
likely to experience an asthma attack in the same time period (OR, 2.69; 95%CI, 1.24–5.84). 
Children with current asthma from rural areas were less likely to report using any inhaled 
therapy in the previous 12 months (OR, 0.20; 95%CI, 0.09–0.43). 
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Table 8 Weighted proportions (95% confidence interval) of pulmonary function tests, allergy tests (skin 
or blood), and inhaled medication use in Portuguese children with current asthma. Bold values are 
statistically significant differences between row subgroups. 
 
PFTa 
ever % 
(95%CI) 
Allergy testsb 
ever % 
(95%CI) 
Inhaled medsc in the last 
12 months % 
(95%CI) 
All 45.7  (33.8-58.1) 79.9  (67.9-88.2) 67.6  (58.4-75.7) 
Gender    
Female 36.9  (26.0-49.3) 87.0  (67.5-95.5) 74.9  (70.7-79.3) 
Male 51.4  (41.3-61.4) 75.3  (70.2-79.8) 62.9  (49.1-74.9) 
Age groups    
0-5 years old 21.9  (13.5-33.6) 48.4  (27.1-70.3) 72.1  (38.7-91.4) 
6-12 years old 46.4  (40.2-52.7) 97.1  (96.8-97.5) 72.5  (64.8-79.1) 
13-17 years old 61.5  (47.4-73.9) 79.4  (69.0-87.0) 58.1  (47.4-68.1) 
National region    
North 44.0  (29.6-59.4) 93.3  (82.4-97.7) 57.9  (36.5-76.8) 
Centre and Islands 38.6  (29.5-48.5) 75.6  (75.2-75.9) 69.8  (69.3-70.2) 
South 53.9  (41.0-66.2) 71.3  (56.2-82.7) 74.7  (61.2-84.7) 
Municipalityd    
Urban 57.6  (46.9-67.7) 83.9  (74.8-90.1) 76.4  (63.4-85.9) 
Rural  7.3      (7.2-7.3)* 67.0  (66.6-67.5)* 39.2  (29.5-49.9)* 
Allergic rhinitis    
No 43.8  (33.8-54.4) 71.4  (59.5-81.0) 67.6  (51.8-80.1) 
Yes 47.4  (38.9-56.1) 87.7  (84.0-90.7) 67.7  (59.5-74.9) 
Food allergy    
No 46.2  (38.4-54.2) 78.6  (72.0-84.0) 67.6  (57.8-76.1) 
Yes 37.6  (37.6-37.6) 100.0           (n/a) 67.8  (67.8-67.8) 
aPFT: pulmonary function tests. bAllergy tests: blood and/or skin tests. cInhaled meds: inhaled medication use. n/a: 
not applicable; dMunicipality was classified as urban if residence was located in municipalities with at least one 
city (cities must have at least 8000 citizens) according to Portuguese law. *statistically significant. 
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Table 9 Weighted proportion of medication use in children with lifetime asthma or current asthma. 
 Lifetime asthma %   (95%CI) 
Current asthma 
%   (95%CI) 
Pulmonary function tests 41.4 (31.6-51.9) 45.7 (33.8-58.1) 
Allergy tests (skin and/or blood) 72.1 (62.1-80.3) 79.9 (67.9-88.2) 
Any asthma medication at the time of surveya 57.5 (47.3-67.1) 76.4 (64.4-85.3) 
Inhaled therapy in previous 12 months 48.1 (38.1-58.3) 67.6 (55.5-77.8) 
Reliever inhaled meds in previous 12 months 30.2 (21.1-41.1) 40.1 (28.5-53.0) 
       SABAb 23.7 (15.6-34.3) 31.5 (21.0-44.4) 
       Anticholinergics 6.4   (2.6-15.2) 8.6   (3.4-19.8) 
Controller inhaled meds in previous 12 months  31.2 (22.0-42.3)  41.5 (29.6-54.5) 
       LABAc 4.8   (1.6-13.8) 6.4   (2.1-17.9) 
       Fluticasone 11.2   (5.7-20.9) 14.9   (7.6-27.1) 
       Budesonide 4.9   (2.1-10.6) 6.5   (2.8-14.0) 
       Budesonide/Formoterol 5.1   (2.3-11.1) 6.8   (3.0-14.7) 
       Fluticasone/Salmeterol 9.9   (4.6-19.8) 13.1   (6.2-25.6) 
ONLY Reliever inhaled therapy in previous 12 monthsd  17.9 (10.9-27.9)  23.8 (14.6-36.3) 
aReference to any asthma medication (inhaled, nebulized, or oral); bSABA: short-acting β-agonist; cLABA: long-
acting β-agonist; dWithout use of inhaled controller therapy (no specific information on oral control therapy was 
available) 
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CONCLUSION 
A high prevalence of asthma-like symptoms was found in the Portuguese pediatric 
population (39.4%; 95%CI, 35.7–43.3), and the prevalence of current asthma was 8.4% 
(95%CI, 6.6–10.7). This study showed that less than half of children with current asthma had 
been on inhaled controller medication in the previous 12 months and that only 52.9% of 
those aged ≥6 years had undergone PFT. 
Asthma-like symptoms were present in more than one-third of Portuguese children, and the 
prevalence of current asthma was 8.4%. Age influenced asthma-like symptoms patterns, 
and asthma prevalence varied according to different definitions. Therefore, using 
composite measures and reporting different operational estimates is advisable. Fewer than 
half of the children with current asthma had used inhaled controller medications in the 
previous year, and those who used inhaled relievers alone had experienced twice more 
asthma attacks. PFT were underused among asthmatic children. Also, the findings on low 
inhaled controller medication and PFT use were more prevalent in children living in rural 
areas.  
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AIMS 
In 2010, we conducted the first Portuguese National Asthma Survey (INAsma) 94. In the 
present paper, we focus on the results obtained from the INAsma pediatric population. In 
this paper, our aim was to report the proportion of lifetime hospitalisations for asthma in 
Portuguese children and adolescents aged 6- to 17-years-old (hereafter referred as 
“children”). 
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METHODS 
Study design and setting 
INAsma was a cross-sectional, population-based, all-age, nationwide telephone survey 
conducted in 2010 to estimate asthma prevalence and control in Portugal. Details on the 
first phase of INAsma methods are described above (see “Methods” section from “Paper 
1”). 
This study was reviewed and approved by the Ethics Committee of Centro Hospitalar de 
São João, Porto, Portugal. Informed consent was obtained from the parent(s) or legal 
guardian(s) of the children included in this study. 
Participants and sample size 
INAsma’s first phase population was described above (see “Methods” section from “Paper 
1”). The INAsma target population was the Portuguese general population, and the 
available population included citizens of all ages living in households with a landline 
telephone. A cluster sampling design was used to obtain a representative sample of the 
population. Briefly, all municipalities were used as natural strata, and a sample of households 
was then selected with a probability proportional to the municipality population as 
estimated in the 2001 National Census. Households were randomly selected from the 2010 
residential White Pages telephone directory. Four different lists of telephone numbers were 
randomly selected for each municipality to allow for substitution of nonresidential telephone 
numbers. In total, 24 412 telephone numbers were retrieved. One participant (the last person 
to have had a birthday) was randomly selected from each household. In this study, we 
considered all included individuals aged <18 years old (henceforth referred to as “children” 
for simplification). 
For this specific paper, we included all the INAsma participants aged 6- to 17-years-old 
(n=563); this sample was representative of the Portuguese children 98. This sample size 
allowed us to estimate the prevalence of lifetime hospitalisations with a margin of error of 
0.1, considering a 95% confidence level. 
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Instruments and data collection 
Instruments and data collection were the ones described above for the first phase of 
INASma (see “Methods” section from “Paper 1”). 
The instrument for data collection was the Portuguese version of the questionnaire used in 
the GA2LEN survey, which includes the European Community Respiratory Health Survey 
questions on asthma symptoms 96. Several questions were added regarding socio-
educational variables, medications, diagnostic test, and healthcare services use for 
asthma. Data were collected by computer-assisted telephone interviews from March to 
May 2010. Selected participants directly answered the questionnaire. However, in 
accordance with Portuguese legislation, when the selected individual was younger than 15 
years old, the respondent was the usual and most knowledgeable caregiver. To minimize 
potential bias in data collection, several quality-assurance measures were followed (for 
details, see “Methods” section from “Paper 1”). 
Variables 
The main variables and outcomes were defined as follows: 
 Lifetime hospitalisations was defined as a positive answer to “Have you ever been 
hospitalised for asthma (inpatient admission >24 hours)?”. 
Lifetime asthma was defined as a positive answer to “Have you ever had asthma?”. 
current asthma was defined as lifetime asthma plus, at least, one of the following in the 
previous 12 months: wheezing, waking with breathlessness, asthma attack; or currently 
taking asthma medication. 
The other variables were described above (see “Methods” section from “Paper 1”). 
Statistical analysis 
The sample estimates were weighted according to the 2001 National Census aiming for 
generalization to the target population 98. Statistical analyses were performed using the 
complex samples tool of SPSS version 21 (SPSS IBM, New York, NY, USA). 
Categorical variables were described using relative frequencies with 95%CI; comparisons 
were performed with Pearson’s chi-squared test. Univariate logistic regression models for 
64 | Burden of childhood asthma in Portugal 
outcomes were developed using independent variables as risk/predictive factors. 
Multivariate logistic regression models were developed to adjust for possible confounders. 
Results of multivariate logistic regression models were presented as odds ratios (ORs) with 
95% CIs. A p-value of <0.05 was considered statistically significant.  
Paper 2 | 65 
RESULTS 
The prevalence of lifetime hospitalisations for asthma in Portuguese children was 3.9% 
(95%CI, 2.6–5.7). In children with lifetime asthma, this prevalence was 29.7% (95%CI, 23.6–
36.7) (Table 10). Children with current asthma had a higher prevalence of hospitalisations 
(36.5; 95%CI, 28.8-44.9) than children with history of lifetime asthma but without current 
asthma (prevalence, 13.4; 95%CI, 11.5-15.6) (OR, 3.70; 95%CI, 2.64–5.20). The presence of 
any asthma-like symptom in the previous 12 months increased the proportion of lifetime 
hospitalisations (OR 1.85; 95%CI, 1.16-2.95). Female children had more hospitalisations than 
males (OR 1.97; 95%CI, 1.22-3.18). No differences in the prevalence of lifetime 
hospitalisations were observed with socioeconomic status or in children with rhinitis, sinusitis, 
or food or drug allergies. 
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Table 10 Proportion and odds ratio (95%CI) for lifetime hospitalisations for asthma in Portuguese 
children aged 6- to 17-years-old with lifetime asthma. Bold values are statistically significant. 
 
Lifetime 
hospitalisations % 
(95%CI) 
Odds Ratio for 
lifetime 
hospitalisations 
(95%CI) 
Overall 29.7  (23.6-36.7)  
Sex   
Male 24.1  (18.0-31.5) 1.00  (Ref) 
Female 38.5  (28.8-49.2) 1.97  (1.22-3.18) 
Age groups   
  6-12 years old 33.0  (24.2-43.1) 1.00  (Ref) 
13-17 years old 26.4  (19.0-35.5) 0.73 (0.40-1.34) 
Regions   
North 26.1  (20.0-33.2) 1.00  (Ref) 
Centre and Islands 46.8  (33.8-60.3) 2.10  (1.31-4.76) 
South 14.5    (6.2-30.2) 0.48  (0.18-1.31) 
Municipality   
Urban 27.3  (19.1-37.4) 1.00  (Ref) 
Rural 35.9  (35.9-35.9) 1.49  (0.94-2.37) 
Socioeconomic status‡   
Low 34.1  (25.3-44.3) 1.00  (Ref) 
Medium 19.7  (11.3-32.1) 0.47  (0.19-1.19) 
High 23.5    (3.4-73.1) 0.59  (0.06-5.47) 
ETS‡‡   
No 34.4  (24.5-45.7) 1.00  (Ref) 
Yes 24.0  (17.9-31.3) 0.60  (0.31-1.17) 
‘Wheezing’   
No 18.8  (15.2-23.0) 1.00 (Ref) 
Yes 41.1  (32.7-50.1) 3.03 (2.15-4.26) 
‘Nocturnal symptoms’¥   
No 21.8  (11.8-36.7) 1.00 (Ref) 
Yes 34.6  (27.6-42.4) 1.90 (0.85-4.25) 
‘Asthma attack’   
No 23.4  (17.0-31.3) 1.00 (Ref) 
Yes 43.5  (33.0-54.5) 2.52 (1.46-4.34) 
‘Asthma-like symptoms’†   
No 21.2  (15.4-28.5) 1.00 (Ref) 
Yes 33.2  (25.9-41.5) 1.85 (1.16-2.95) 
‘Current asthma’   
No 13.4  (11.5-15.6) 1.00 (Ref) 
Yes 36.5  (28.8-44.9) 3.70 (2.64-5.20) 
‡Socioeconomic status was categorized based on occupation and school education of the person who 
contributed most to the household income. ‡‡Environmental tobacco smoke. ¥ “Nocturnal symptoms” in the last 12 
months: waking with breathlessness or waking with cough or waking with chest tightness. † “Asthma-like symptoms” 
in the last 12 months: wheezing or nocturnal symptoms or asthma attacks. 
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CONCLUSION 
For the first time, the proportion of lifetime hospitalisations for asthma was reported for a 
national population-based paediatric sample. In the present study, a high number of 
hospitalisations for asthma were observed, with more than 55,000 Portuguese children aged 
6- to 17-years-old hospitalised for asthma during their lifetime. Moreover, of the children with 
current asthma more than one third had been hospitalised for asthma, at least once in their 
lifetime. Our results should contribute to improve knowledge on asthma-related 
hospitalisations in children, leading to the development of healthcare programs aiming to 
reduce their frequency.  
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ABSTRACT  
Background: This study aimed to estimate the prevalence of asthma control and 
determinants of poor control in the Portuguese pediatric population (<18 years); 
secondarily, we described asthma-related healthcare services and medication use. 
Methods: Data of 98 children with current asthma, from the second phase of a nationwide 
population-based telephone survey (INAsma study), were analysed. Asthma control 
definition was based on GINA criteria, grouping partially controlled and uncontrolled 
asthma as ‘not-controlled asthma’ (NCA). We used multivariate logistic regression to study 
factors associated with NCA and with unscheduled medical visits for asthma. 
Results: About half of the children had NCA (49%, 95%CI 39-59%). In the multivariate model, 
risk factors for NCA were: substantial nasal symptoms (aOR 6.80), overweight/obesity (aOR 
3.44) and not having health insurance (aOR 3.78). All the children with NCA had nasal 
symptoms, and the lack of asthma control was also associated with the increasing number 
of nasal symptoms (p<0.001). 
In the previous year, 90% (95%CI 84-96%) of children with current asthma had healthcare 
visits and 67% (95%CI 58-77%) used medication for asthma. The risk of unscheduled medical 
visits was higher in children with nasal symptoms (aOR 3.63) and in those without health 
insurance (aOR 2.79), and lower in adolescents (aOR 0.19). 
Conclusions: Half of the children with asthma were poorly controlled. Nasal symptoms and 
obesity are important determinants of asthma control. Children without health insurance 
are at greater risk of poor asthma outcomes; this association is reported for the first time in 
a European country.   
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AIMS 
In 2010, we conducted the first Portuguese National Asthma Survey (INAsma), a two-phase 
nationwide study aiming to estimate asthma prevalence and control.94 In the present 
paper, we report data from children and adolescents included in the second phase of the 
study. Our aims were to estimate the prevalence of asthma control and determinants of 
poor control in the Portuguese pediatric population (<18 years old). Secondary aims were 
to describe asthma-related healthcare services and medication use. 
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METHODS 
Study design and setting 
INAsma was a nationwide survey from the general population applied by telephone 
interview to individuals living in Portugal in 2010. 
This study was approved by the Ethics Committee of Centro Hospitalar de São João, Porto, 
Portugal. Oral informed consent was obtained from parent(s) or legal guardian(s). We 
followed the STROBE statement for reporting observational studies 95. 
Sample size 
The sample size calculation was based on confidence intervals for proportions. The sample 
size for this study was calculated considering the two phases of the INAsma research project. 
In the first phase, we aimed to estimate the current asthma prevalence in the Portuguese 
population. In the second phase, we aimed to estimate the proportion of patients with 
controlled asthma symptoms. Thus, in the second phase of the project, to estimate the 
proportion of patients with controlled asthma with a 3% margin of error and 95% confidence 
level, and assuming a proportion of 20% of patients with uncontrolled asthma in the 
population, we required a sample of at least 554 patients with asthma identified in the first 
phase of the project. Assuming a 20% loss to follow-up, we required at least 665 patients with 
asthma during the first phase. Within these premises, and assuming a prevalence of 6% in 
the Portuguese population and a margin of error of 0.65%, we required a sample of at least 
6,000 persons from the general Portuguese population willing to participate in the first phase 
of the project. 
Participants 
The target population was the Portuguese general population. The available population 
included all individuals living in Portugal in households with a landline telephone (sampling 
frame). To obtain a representative sample of the population, a stratified cluster sampling 
design was used. 
In the first phase of INAsma, all municipalities were used as natural strata; in each 
municipality, a sample of households with a landline telephone number was selected with 
a probability proportional to the municipality population as estimated in the 2001 National 
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Census. The target number of households was set at 6,103. The sample of households was 
derived from the directory listed in the residential White Pages from 2010. A list of all 
telephone numbers in a specific municipality was compiled to draw a sample of telephone 
numbers within that municipality. A sample of household telephone numbers was randomly 
selected from the whole list in each municipality. Because part of the selected telephone 
numbers were from companies or were not allocated, four lists were randomly selected for 
each municipality to allow for substitution of non-residential telephone numbers. In total, 
24,412 telephone numbers were retrieved. 
After the selection and identification of a residential number, one participant was randomly 
selected from each household. After identification of all residents in the household, the 
selected participant in each household was the last person to have had a birthday. When 
the selected individual was younger than 15 years, the respondent was the usual caregiver. 
Individuals were excluded if they did not understand spoken Portuguese or had cognitive 
or physical conditions that could hamper the interview. In the final 20% of the sample, an 
oversampling strategy of male adults and younger adults subjects was used to correct the 
common overrepresentation of female and older participants observed in the interim 
analysis. 
In the second phase of INAsma, all the participants that were identified as having current 
asthma in this first phase of the INAsma study were eligible for participation in the second 
phase. Additional asthmatics identified in the participant households were also contacted. 
Individuals identified as having rhinitis only or as healthy that agreed to participate in the 
second phase of the study were re-contacted and used for comparison purposes (not used 
for this paper purposes). 
Instruments and data collection 
The instrument for data collection in the second phase of INAsma was based on the 
Portuguese version of the GA2LEN survey questionnaire 96; it also included the Control of 
Allergic Rhinitis and Asthma Test (CARAT)99 and questions on socio-educational factors and 
use of healthcare resources. 
An experienced private company administered the questionnaire, using computer-assisted 
telephone interviews performed by trained and experienced interviewers. In the first phase, 
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interviews were conducted from March to May of 2010. In the second phase, interviews 
were conducted from June to October of 2010. 
Interviews were conducted mostly from 17:00 to 22:00 h on weekdays and 11:00 to 22:00 h 
on weekends and holidays. No telephone number was abandoned until a minimum of 10 
attempts had been made on different occasions. To minimize other potential biases in data 
collection, several quality assurance measures were followed: interviewers were selected 
based on their previous experience with health-related data collection; each question was 
discussed in training sessions held between researchers and all interviewers; a research 
assistant was present during the setup, training, and daily work of the interviewers, 
motivating and checking compliance with standardized operational procedures; data 
validity was periodically verified soon after being collected, and custom statistic algorithms 
were used to detect extreme, illogical, and missing values; and the clarity of the 
questionnaire and its telephonic administration were assessed in a pilot study involving 25 
individuals before starting the data collection. 
Variables and outcomes definition 
Current asthma was defined as children with lifetime asthma plus at least one of the 
following: wheezing, awakening with breathlessness or having an asthma attack in the last 
12 months, or taking asthma medication at the time of the interview. 
Asthma control definition was based on GINA criteria for asthma symptom control 100: ‘Well-
controlled asthma’ (WCA) corresponds to “well controlled” from GINA guidelines; and 
partially controlled and uncontrolled were grouped as ‘Not controlled asthma’ (NCA). 
Unscheduled medical visits for asthma was defined as having at least one emergency 
department and/or any unscheduled medical attendance because of asthma 
worsening/exacerbation in the previous 12 months. 
Nasal symptoms were classified as ‘mild/absent’ or ‘substantial’ based on the daily 
frequency of 4 isolated symptoms - runny nose, stuffy nose, itchy nose or sneeze in the 
previous 4 weeks. Each symptom was scored as: 0, if present “almost every day”; 1, if “≥ 2 
days a week”; 2, if “1 or 2 days a week”; or 3, if “never”. When the sum of all symptoms was 
> 7, nasal symptoms were classified as ‘mild/absent; when ≤ 7 they were considered 
‘substantial’. 
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Overweight/obesity was defined as a z-score >1 for body-mass index (BMI), using WHO 
Growth reference 2007 macros.101 
Having health insurance was defined as a positive answer to “Do you/your child have/has 
any healthcare insurance?”. 
Previous medical diagnosis of rhinitis was defined as a positive answer to “Have you been 
diagnose as having rhinitis by a doctor?”. 
Night awakening with symptoms was defined as at least one of 3 symptoms in the last 12 
months: waking with breathlessness, waking with chest tightness or waking with coughing. 
Controller medication was defined as use of any inhaled steroid, inhaled long-acting β-
agonist, inhaled association of steroid and β-agonist or leukotriene receptor antagonist. 
Reliever medication: use of any inhaled/nebulized short-acting β-agonist or anticholinergic, 
oral short-acting β-agonist or oral steroid. 
Other medication was defined as use of any antihistamine or cough medication for asthma-
like symptoms. 
Any asthma medication was defined as use of any controller, reliever or other medication 
for asthma-like symptoms. 
Municipality was classified as urban, if residence was located in municipality with at least 
one city (cities must have at least 8000 citizens), according to Portuguese law 97. 
Socioeconomic Status was categorized based on family income, occupation and school 
education of the person who contributes more for the household income. 
ETS: was defined as a positive answer to “Does anyone smoke inside your home?”. 
Study sample and statistical analysis 
The sample size was calculated considering the two phases of the INAsma study 94. The 
proportion of not controlled asthma was estimated with a margin of error of 0.098, 
considering a 95% confidence level (95%CI). Statistical analyses were performed using SPSS 
version 22 (SPSS IBM, New York, NY, USA). Categorical variables were described using 
frequencies and compared with Pearson’s chi-squared test. We used multivariate logistic 
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regression analysis to evaluate which variables were associated with 1) NCA and with 2) 
asthma-related unscheduled medical visits. For each outcome, we used a data-driven 
backward approach, with a priori inclusion of predictive variables with p-value <0.20 in 
univariate analysis. The two final multivariate models included the statistically significant 
variables. Results from the logistic regressions were presented as adjusted odds ratio (aOR) 
with 95%CI. A p-value <0.05 was considered statistically significant. Hosmer-Lemeshow test 
and percentage of correctly predicted cases were used to assess goodness-of-fit for logistic 
regression models.   
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RESULTS 
Overall, 716 children completed the first phase of the INAsma study (Figure 2); all the 
participants identified as having current asthma were eligible for participation in the second 
phase. Additional asthmatics identified in the participants’ households were also 
contacted. The flowchart (Figure 6) summarizes the children included in INAsma study. The 
participant’s characteristics are summarized in Table 11. 
 
Figure 6 Participants’ flowchart. 
1Current asthma - Lifetime asthma + (wheezing OR asthma attack OR awakening with breathlessness OR current 
asthma medication).  
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Table 11 Participants characteristics - n(%). There are not statistical differences between diagnostic 
groups. Statistically significant differences in asthma control are presented in bold. 
 
Current asthma 
(n=98) 
Asthma Control  
Well Controlled 
(n=48) 
Not controlled 
(n=46) 
 
Gender     
Female 33 (33%) 14 (45%) 17 (55%)  
Male 65 (66%) 34 (54%) 29 (46%)  
Age groups     
0-5 years old 18 (18%) 11 (65%)   6 (35%)  
6-12 years old 46 (47%) 22 (50%) 22 (50%)  
13-17 years old 34 (35%) 15 (46%) 18 (55%)  
Region     
North 46 (47%) 21 (49%) 22 (51%)  
Centre/Islands 22 (22%)   9 (41%) 13 (59%)  
South 30 (30.6) 18 (62%) 11 (38%)  
Municipality†     
Rural 24 (25%) 10 (44%) 13 (57%)  
Urban 74 (76%) 38 (54%) 33 (47%)  
SES#     
High 15 (15%) 11 (73%)   4 (27%)  
Medium 33 (34%) 18 (60%) 12 (40%) * 
Low 50 (51%) 19 (39%) 30 (61%)  
Health insurance     
Yes 47 (50%) 30 (68%) 14 (32%)  
No 47 (50%) 17 (36%) 30 (64%) ** 
Body mass index     
Thinness   3   (3%)   1 (33%)   2 (67%)  
Normal 57 (60%) 33 (62%) 20 (38%) *** 
Overweight/Obesity 35 (37%) 11 (31%) 24 (69%) 
ETS‡     
Yes 40 (41%) 23 (59%) 16 (41%)  
No 58 (59%) 25 (46%) 30 (55%)  
†Municipality was classified as urban if residence was located in municipalities with at least one city (cities must 
have at least 8000 citizens) according to Portuguese law; #Socioeconomic Status, categorized based on family 
income, occupation and school education of the person who contributes more for the household income. 
‡Environmental Tobacco Smoke. *p=0.03. **p=0.002. ***p=0.005. 
 
 
 
 
About half of the children with current asthma had NCA (49%, 95%CI 39-59%; Table 11). Nasal 
symptoms in the previous 4 weeks were present in 89% (95%CI 83-95%) of children with current 
asthma (Table 12). Nevertheless, previous medical diagnosis of rhinitis was made in only 45% 
(95%CI 35-55%) of children with current asthma. All asthma-like and nasal symptoms were 
more frequent in children with NCA (p<0.001; Figure 7 and Table 13), when compared with 
WCA. In children with a parent/self-report of good asthma control, only 52% fulfilled the 
criteria for WCA. 
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Table 12 Rhinitis diagnosis ever and nasal symptoms in the previous 4 weeks, in children with current 
asthma, % (95%CI); and level of asthma control within children with rhinitis diagnosis ever and nasal 
symptoms in the previous 4 weeks, % (95%CI). 
 Current asthma children 
Asthma Control 
p 
Well controlled Not controlled 
Doctor diagnosis of rhinitis     
       No 55% (45-65)   49% (33-65) 51% (35-68) 
0.42        Yes 45% (35-55)   53% (40-66) 47% (34-60) 
Any nasal symptom*     
       No 11%   (5-17) 100%     (n/a)   0%     (n/a) 
0.001        Yes 89% (83-95)   45% (34-55) 55% (45-66) 
Itchy nose     
       No 34% (25-42)   77% (63-92) 23%   (8-37) 
<0.001        Yes 66% (57-75)   38% (26-50) 62% (50-74) 
Sneeze     
       No 33% (23-42)   67% (50-84) 33% (16-50) 
0.04        Yes 67% (58-77)   44% (32-56) 56% (44-69) 
Runny nose     
       No 56% (46-66)   64% (52-77) 36% (23-48) 
0.004        Yes 44% (34-54)   33% (19-48) 67% (52-82) 
Stuffy nose     
       No 48% (38-58)   73% (60-86) 27% (14-41) 
<0.001        Yes 52% (42-62)   31% (18-44) 69% (57-82) 
Number of nasal symptoms     
       0 11%   (5-17) 100%     (n/a)   0%    (n.a.) 
<0.001 
       1 10%   (4-15) 100%     (n/a)   0%    (n.a.) 
       2 37% (27-46)   50%  (33-67) 50% (33-69) 
       3 24% (16-33)   32%  (12-51) 68% (49-88) 
       4 19% (11-27)   22%    (3-41) 78% (59-97) 
*’Any nasal symptom’: runny nose or stuffy nose or itchy nose or sneeze. n/a: not applicable. 
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Table 13 Proportion (%) of children with asthma-like symptoms, nasal symptoms and life impairment 
by asthma-like/nasal symptoms in the previous 4 weeks (never, ≤2 days/week or >2 days/week), 
according to asthma control. 
 
Well Controlled  Not controlled 
Never ≤2 >2  Never ≤2 >2 
Any asthma like-symptom*   83% 17%   0%  13% 33% 54% 
Wheezing   88% 13%   0%  44% 24% 31% 
Breathlessness   92%   8%   0%  52% 27% 21% 
Chest tightness during exercise 100%   0%   0%  42% 29% 29% 
Any nasal symptom*   23% 29% 48%    0% 11% 89% 
Runny nose   73% 15% 13%  44% 22% 35% 
Stuffy nose   48% 28% 24%  26% 35% 39% 
Itchy nose   50% 13% 38%  15% 22% 63% 
Sneeze   42% 27% 31%  22% 20% 59% 
Any daily limitation* 100%   0%   0%  28% 26% 46% 
Night wakening w/ symptoms‡ 100%   0%   0%  52% 17% 30% 
Daily activities limitation‡ 100%   0%   0%  50% 20% 30% 
* p<0.001 between WCA and NCA. ‡ because of asthma-like or nasal symptoms 
 
 
 
Figure 7 Prevalence of isolated nasal symptoms in asthmatic children, stratified by asthma control 
(prevalence and 95%CI). 
Full line – controlled asthma; Dotted line – not controlled asthma. 
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Determinants of poor asthma control 
Control of asthma was significantly worse in children with substantial nasal symptoms, 
overweight/obesity, lower socioeconomic status, unscheduled medical attendance for 
asthma or in those without health insurance coverage, in univariate analysis (Table 14). 
Children with any nasal symptom had significantly more NCA (p=0.001; Table 13). Moreover, 
as the number of nasal symptoms increased, the proportion of children with NCA also 
increased (Figure 8): none of the children with 0 or 1 nasal symptom had NCA, while 50% of 
those with 2 symptoms, 68% of those with 3 symptoms and 78% of those with 4 different nasal 
symptoms had NCA. 
In the final multivariate model, the risk factors for NCA were: having substantial nasal 
symptoms (aOR 6.80, 95%CI 2.34-19.80), overweight/obesity (aOR 3.60, 95%CI 1.46-10.13) and 
not having health insurance (aOR 3.78, 95%CI 1.36-10.92). 
 
 
Figure 8 Frequency of number of nasal symptoms in asthmatic children, according to asthma control. 
Full line – well-controlled asthma; Dotted line – not controlled asthma. 
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Table 14 Crude and adjusted odds ratio for not controlled asthma and unscheduled medical visits. 
 
Not controlled asthma  Unscheduled visits 
Crude 
odds ratio 
(95%CI) 
Adjusted 
odds ratio 
(95%CI) 
 
Crude 
odds ratio 
(95%CI) 
Adjusted 
odds ratio 
(95%CI) 
Gender      
Female 1.00             (ref) 
n.i. 
 1.00             (ref) 
n.i Male 0.70  (0.30-1.67)  1.54  (0.66-3.61) 
Age      
0-5 years old 1.00              (ref) 
n.i. 
 1.00             (ref) 1.00             (ref) 
6-12 years old 1.83   (0.58-5.83)  1.16  (0.38-3.53) 0.72  (0.21-2.43) 
13-17 years old 2.20   (0.66-7.36)  0.37  (0.11-1.24) 0.19  (0.05-0.78) 
Body mass index      
Normal 1.00              (ref) 1.00              (ref)  1.00             (ref) 
n.i. Overweight/Obese 3.60   (1.46-8.89) 3.44 (1.17-10.13)  0.74  (0.32-1.73) 
Nasal symptoms      
Absent/mild 1.00              (ref) 1.00              (ref)  1.00             (ref) 1.00             (ref) 
Substantial 4.42 (1.85-10.56) 6.80 (2.34-19.80)  2.82  (1.22-6.53) 3.63  (1.39-9.51) 
Municipality†      
Rural 1.00              (ref) 
n.i. 
 1.00             (ref) 
n.i. Urban 0.67   (0.26-1.72)  0.66  (0.26-1.67) 
SES#      
High 1.00              (ref)   1.00             (ref)  
Medium 1.83   (0.47-7.13)   2.08  (0.54-8.01)  
Low 4.34 (1.21-15.63) n.i.  2.71  (0.75-9.80) n.i. 
Health insurance      
Yes 1.00              (ref) 1.00               (ref)  1.00             (ref) 1.00             (ref) 
No 3.78   (1.59-9.02) 3.85  (1.36-10.92)  2.10  (0.92-4.81) 2.79  (1.08-7.21) 
Local of asthma care      
Public 1.00              (ref) 
n.i. 
 1.00             (ref) 
n.i. Private 0.71   (0.31-1.60)  0.68  (0.30-1.53) 
Scheduled medical visits      
Yes 1.00              (ref)   1.00             (ref)  
No 0.30   (0.08-1.20) n.i.  0.30  (0.08-1.17) n.i. 
Unscheduled medical visits      
Yes 1.00              (ref)   - - 
No 0.44   (0.19-0.99) n.i.  - - 
Asthma control      
Controlled - -  1.00             (ref) 
n.i. Not controlled - -  2.29  (1.01-5.28) 
Bold values show statistical significant differences. n.i.: not included in the model (non-significant variables) 
†Municipality was classified as urban if residence was located in municipalities with at least one city  (cities must 
have at least 8000 citizens) according to Portuguese law; #Socioeconomic Status, categorized based on family 
income, occupation and school education of the person who contributes more for the household income. 
Asthma control model: Hosmer-Lemeshow test = 0.37 and 75% of correctly predicted cases. 
Unscheduled visits model: Hosmer-Lemeshow test = 0.95 and 67% of correctly predicted cases. 
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Healthcare visits and medication use by children with current asthma 
Healthcare medical visits for asthma are discriminated in Table 15. In the previous 12 months, 
90% (95%CI 84-96%) of children with current asthma had at least one asthma-related visit to 
healthcare services (Table 15): 86% (95%CI 79-93%) had scheduled medical visits, 39% (95%CI 
29-48%) had emergency room visits and 25% (95%CI 16-33%) had at least one unscheduled 
medical visit to a doctor. All the pre-schoolers had asthma-related healthcare visits 
(scheduled or unscheduled) in the last year, compared to 94% (95%CI 86-100%) of school 
age children and 79% (95%CI 66-93%) of adolescents (p=0.04). The determinants of 
unscheduled medical visits, in the multivariate model, were substantial nasal symptoms (aOR 
3.63, 95%CI 1.39-9.51), not having health insurance (aOR 2.79, 95%CI 1.08-7.21) and age 13- 
to 17-years-old (aOR 0.19, 95%CI 0.05-0.78; Table 14). Children with NCA had significant more 
unscheduled medical visits and hospitalisations. 
In children with current asthma, 67% (95%CI 58-77%) used asthma medication in the previous 
4 weeks (Table 16): controller medication was used by 58% (95%CI 48-68%) and reliever 
medication by 31% (95%CI 22-40%). Children with NCA had a non-significant higher 
frequency of any medication use (76%, 95%CI 64-88%) when compared with those with 
WCA (58%, 95%CI 44-72%); no statistically significant differences were seen in the use of 
controller or reliever medication. Over-the-counter medications (e.g.: antihistamines and 
cough medication) were used more frequently by children with NCA (p<0.02; Table 17). 
School-aged children used more asthma medication (p=0.03), comparing with pre-
schoolers and adolescents (Table 16).  
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Table 15 Healthcare medical visits for asthma in the previous 12 months, % (95%CI). Statistically 
significant differences in asthma control are presented in bold. 
 Healthcare medical visits Scheduled Unscheduled 
Emergency 
Department Hospitalisations 
Overall 90%   (84-96) 86% (79-93) 25% (16-33) 39% (29-48)   5%   (1-10) 
Gender      
Female 91% (81-100) 87% (81-94) 18% (10-25) 33% (23-42)   0%    (n.a.) 
  Male 89%   (82-97) 85% (78-92) 29% (19-38) 42% (32-52)   7%   (2-13) 
Age groups      
0-5 years old    100%      (n/a)* 88% (82-95) 23% (15-32) 47% (37-57) 11%   (4-17) 
6-12 years old 93% (86-100)* 91% (85-96) 32% (23-42) 46% (36-56)   4%     (0-8) 
13-17 years old 79%   (66-93)* 78% (69-86) 15%   (8-22) 25% (16-33)   3%     (0-6) 
Region      
North 93% (86-100) 84% (77-92) 26% (17-35) 37% (27-46)   0%    (n.a.) 
Centre/Islands 86% (72-100) 90% (84-96) 33% (23-42) 52% (42-62) 19% (11-26) 
South 87%   (75-99) 86% (79-93)     17%   (9-24) 34% (25-44)   3%     (0-7) 
Municipality      
Rural 83%   (68-98) 75% (58-92) 21%   (5-37) 50% (30-70)  5%   (0-14) 
Urban 92%   (86-98) 89% (81-96) 26% (16-36) 35% (24-46)  5%   (0-10) 
SES†      
High 86% (67-100) 73% (51-95) 14%   (7-21) 21% (1-42)  7%   (0-20) 
Medium 88%   (77-99) 82% (69-95) 24%   (9-39) 36% (20-52)  0%    (n.a.) 
Low 92% (85-100) 92% (85-99) 28% (16-40) 45% (31-59)  8%   (1-16) 
Health insurance      
No 94% (86-100) 84% (76-91) 27% (18-36) 51% (41-61)  9%   (3-14) 
Yes 89%   (81-98) 91% (86-97) 25% (16-34) 31% (22-41)  2%     (0-5) 
ETS‡      
No 90%   (80-99) 88% (83-95) 24% (16-33) 39% (29-48)  4%     (0-7) 
Yes 90%   (82-98) 83% (74-90) 26% (18-34) 39% (29-48)  8%   (2-12) 
Asthma control      
Controlled 87%   (78-97) 81% (70-92) 15%   (5-25) 30% (17-43)  0%    (n.a.) 
Not controlled 96% (90-100) 94%(87-100) 35%(21-49)# 46% (32-60)   11%  (2-20)# 
‡Environmental Tobacco Smoke. †Socioeconomic Status, categorized in high (A social class), medium (B and C 
social classes) and low (D social class) based on occupation and school education of the person who contributes 
more for the household income. *p=0.04. #p=0.03 
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Table 16 Medication use for asthma in the previous 4 weeks, in children with current asthma, % 
(95%CI). Statistically significant differences in asthma control are presented in bold. 
 
Any asthma 
medication 
Controller 
medication 
Reliever 
medication 
All children with current asthma 67%  (58-77) 58% (48-68) 31% (22-40) 
Gender    
Female 76%  (61-90) 67% (51-83) 36% (20-53) 
Male 63%  (51-75) 54% (42-66) 28% (17-39) 
Age groups    
0-5 years old 56%  (33-79) 50% (27-73) 22%   (3-41) 
6-12 years old 80% (69-92)# 67% (54-81) 37% (23-51) 
13-17 years old 56%  (39-73) 50% (33-67) 27% (12-41) 
Region    
North 72%  (59-85) 67% (54-81) 28% (15-41) 
Centre/Islands 68%  (49-88) 46% (25-66) 41% (20-61) 
South 60%  (43-78) 53% (36-71) 27% (11-43) 
Municipality†    
Rural 58%  (39-78) 46% (26-66) 29% (11-47) 
Urban 70%  (60-81) 62% (51-73) 31% (21-42) 
SES#    
High 73%  (51-96) 60% (35-85) 47% (22-72) 
Medium 67%  (51-83) 67% (51-83) 21%   (7-35) 
Low 66%  (53-79) 52% (38-66) 32% (19-45) 
Health insurance    
Yes 62%  (48-76) 57% (43-72) 28% (15-41) 
No 72%  (60-85) 57% (43-72) 36% (23-50) 
ETS‡    
Yes 65%  (50-80) 48% (32-63) 38% (23-53) 
No 69%  (57-81) 66% (53-78) 26% (15-37) 
Asthma control    
Controlled 58%  (44-72) 52% (38-66) 25% (13-37) 
Not controlled 76%  (64-88) 63% (49-77) 39% (25-53) 
†Municipality was classified as urban if residence was located in municipalities with at least one city (cities must 
have at least 8000 citizens) according to Portuguese law. #Socioeconomic Status, categorized based on family 
income, occupation and school education of the person who contributes more for the household income. 
‡Environmental Tobacco Smoke. n/a: not applicable. #p=0.03 
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Table 17 Asthma medication use in the previous 4 weeks, in children with current asthma, % (95%CI). 
Statistically significant differences in asthma control are presented in bold. 
 
 Asthmatics 
Asthma Control 
p-value 
Well controlled Not controlled 
Any asthma meds 67%  (58-77)   58% (44-72) 76%   (64-88) 0.07 
Rescue meds† 31%  (22-40)   25% (13-37) 39%   (25-53) 0.14 
   SABA inh/nbz 30%  (21-39)   25% (13-37) 37%   (23-51) 0.21 
   Ipatrop inh/nbz 10%    (4-16)   10%   (2-19) 11%     (2-20) 0.94 
   Oral SABA   1%      (0-3)     0%     (n/a)   2%       (0-6) 0.49 
   Oral steroids   1%      (0-3)     0%     (n/a)   2%       (0-6) 0.49 
Control meds‡ 58%  (48-68)   52% (38-66) 63%   (49-77) 0.28 
   ICS inh alone 24%  (15-32)   19%   (8-30) 28%   (15-41) 0.28 
   ICS + LABA inh 21%  (13-30)   19%   (8-30) 24%   (12-36) 0.54 
   LABA inh alone 98% (95-100) 100%    (n/a) 96% (90-100) 0.24 
   LTRA 30%  (21-39)   29% (16-42) 26%   (13-39) 0.74 
Other meds 32%  (23-41)   21%   (9-32) 43%   (29-58) 0.02 
   Antihistamine 29%  (20-38)   21%   (9-32) 39%   (25-53) 0.05 
   Cough meds   2%      (0-5)     0%     (n/a)   4%     (0-10) 0.24 
SABA: short-acting b-agonist. Inh: inhaled. nbz: nebulized. ICS: inhaled corticosteroids. LABA: long-acting b-agonist. 
LTRA: leukotriene receptor antagonist (LTRA). n/a: not applicable. 
†SABA or ipratropium or oral steroids. ‡ICS alone or LABA alone or ICS + LABA or LTRA 
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Healthcare insurance and healthcare services access 
The frequency of children with health insurance coverage followed in private 
practice/hospital for their asthma was significantly higher than those followed in public 
settings (p<0.001; Table 18). 
 
 
Table 18 Proportion of healthcare insurance coverage, n (%). Statistically significant differences in 
asthma control are presented in bold. 
 
Healthcare insurance 
No 
(n=47) 
Yes 
(n=47) 
 
Region    
North 20  (44%) 25  (56%)  
Centre/Islands 15  (71%)   6  (29%)  
South 12  (43%) 16  (57%)  
Municipality†    
Urban 32  (45%) 39  (55%)  
Rural 15  (65%)   8  (35%)  
SES#    
Low 37  (77%) 11  (23%)  
Medium   8  (26%) 23  (74%) * 
High   2  (13%) 13  (87%)  
Local of asthma care    
Public 34  (72%) 13  (28%)  
Primary care 12  (80%)   3  (20%)  
Hospital 22  (69%) 10  (31%) * 
Private 12  (27%) 33  (73%)  
Practice 12  (28%) 31  (72%)  
Hospital   0    (0%)   2 (100%)  
Scheduled medical visits    
No   8  (67%)   4  (33%)  
Yes 39  (48%) 43  (52%)  
Unscheduled medical visits    
No 20  (42%) 28  (58%)  
Yes 17  (60%) 18  (40%)  
†Municipality was classified as urban if residence was located in municipalities with at least one city (cities must 
have at least 8000 citizens) according to Portuguese law; #Socioeconomic Status, categorized based on family 
income, occupation and school education of the person who contributes more for the household income. 
*p<0.001 
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CONCLUSION 
Only half of children with asthma were controlled in this nationwide study. Determinants for 
not controlled asthma were the presence of substantial nasal symptoms, 
overweight/obesity and not having healthcare insurance. Our results support the 
importance of modifiable factors, namely nasal symptoms and obesity, as determinants of 
asthma control in children. Healthcare insurance status was related to asthma control; in 
our healthcare system, this association may be related to parents’ options in choosing the 
site of medical asthma care for their children. More studies are needed to understand the 
effect on asthma control of the access to different types of asthma care services and 
of being able to choose where the child is cared for asthma. 
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ABSTRACT  
Background: This study aimed to estimate the cost of asthma in Portuguese children; 
furthermore, we studied the factors associated with cost of asthma and the costs per level 
of asthma control. 
Methods: A nationwide, population- and prevalence-based cost-of-illness study with a 
societal perspective was conducted. We measured direct and indirect costs using a 
bottom-up approach and a human capital method, respectively, for 208 children (<18 
years), from two national repositories. Generalised linear modelling for analysis of asthma 
costs’ determinants and sensitivity analysis to assess uncertainty were performed. 
Results: The mean annualised asthma cost per child was €929.35 (95%CI, 809.65–1,061.11): 
€698.65 (95%CI, 600.88–798.27) for direct costs, and €230.70 (95%CI, 197.36–263.81) for 
indirect costs. Extrapolations for the Portuguese children amounted to €161,410,007.61 
(95%CI, 140,620,769.55–184,293,968.55) for total costs. Direct costs represent 75.2% with the 
costliest domain (51.1% of total costs) being the healthcare service use: 20.7% for scheduled 
medical visits and 30.4% for acute asthma care – non-scheduled medical visits (7.9%, 
€12,766,203.20), emergency department visits (11.7%, €18,932,464.80) and hospitalisations 
(10.8%, €17,406,946.00). 
Children with partly controlled and uncontrolled asthma had higher mean costs per year 
(adjusted coefficients: 1.46 [95%CI, 1.12-1.90] and 2.25 [95%CI, 1.56-3.24], respectively). 
Conclusions: Costs of childhood asthma are high (0.9% of the healthcare expenditures in 
Portugal). Direct costs represented 3/4 of total costs, mainly related to the use of healthcare 
services for acute asthma care. Policies and interventions to improve asthma control and 
reduce acute use of healthcare services have the potential to reduce asthma costs.  
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AIMS 
This study aimed to estimate the cost of childhood asthma in Portugal. Secondary aims were: 
1) to describe direct and indirect costs, 2) to determine factors associated with costs, and 
3) to assess the variance of costs with the level of asthma control. 
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METHODS 
Study design and setting 
The Cost of Childhood Asthma in Portugal (CASCA project) was a Portuguese, nationwide, 
population- and prevalence-based, cost-of-illness study with a societal perspective. This 
project was reviewed and approved by the Ethics Committee of Centro Hospitalar de São 
João, Porto, Portugal. Informed consent was obtained from parent(s) or legal guardian(s). 
This project was approved and granted by Calouste Gulbenkian Foundation (P-125964). 
Participants 
Data from participants of two studies (INAsma and CED2013) was analysed. The flowchart 
(Figure 9) summarizes the children included in the CASCA project. 
INAsma was a nationwide survey, from the general population, applied by telephone 
interview to individuals living in Portugal in 2010. The study methodology has been previously 
described 102,103. Briefly, to obtain a representative sample of the general population, a two-
stage cluster and stratified sampling design was performed, using municipality as stratum 
and randomly selecting participants from households. When the selected individual had <15 
years old, the respondent was the usual and most knowledgeable caregiver. Overall, 716 
children (0- to 17-years-old) completed the first phase of the INAsma study; all the 
participants identified as having current asthma were eligible for participation in the second 
phase. Additional asthmatics identified in the participants’ households were also contacted 
in the second phase. 
To increase the sample size in school-aged children, data from a survey on childhood 
asthma conducted in the city of Guimarães (CED2013 study) was used. CED2013 study was 
a population-based survey applied to children attending primary public schools in a 
Portuguese city (Guimarães), in 2013. In order to obtain a representative sample from the 
population, we performed a two-stage randomization based on the city council’s official 
database of schools and students: 1) randomization of schools and 2) randomization of 
children within each included school. From an approximated universe of 6,000 children 
attending primary public schools in Guimarães, 4,300 written self-administered 
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questionnaires were distributed to caregivers. At the end of the CED2013 study, 
questionnaires of 2,550 children (5- to 12-years-old) were available for analysis. 
For the cost-of-illness analysis we included 208 children with current asthma: 98 (0- to 17-
years old) from the second phase of INAsma Study, and 110 school-aged children (5- to 12-
years old) from the CED2013 Study (Figure 9). 
 
 
Figure 9 Participants’ flowchart of children included in the cost-if-ilness analysis. 
1Current asthma - Lifetime asthma + (wheezing OR asthma attack OR awakening with breathlessness OR current 
asthma medication). 
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Instruments and data collection 
The instrument for data collection on asthma prevalence, associated factors and cost 
domains were similar in INAsma study and CED2013 study. The questionnaire was design in 
6 parts: 1) questions on socio-educational factors; 2) questions on asthma-like symptoms in 
the previous 12 months; 3) questions on use of healthcare resources because of asthma in 
the previous 12 months; 4) question on asthma medication in the previous 12 months; 5) 
questions on asthma control; and 6) questions on asthma associated comorbidities. 
Questions on diagnostic tests performed in the previous 12 months, type and number, were 
only included in the CED2013 study. 
In INAsma study, the questionnaire was administered using computer-assisted telephone 
interviews performed by trained and experienced interviewers. In the first phase of INAsma 
study, interviews were conducted from March to May of 2010. In the second phase, 
interviews were conducted from June to October of 2010. Interviews were conducted 
mostly from 17:00 to 22:00 h on weekdays and 11:00 to 22:00 h on weekends and holidays. 
No telephone number was abandoned until a minimum of 10 attempts had been made on 
different occasions. To minimize other potential biases in data collection, several quality 
assurance measures were followed: interviewers were selected based on their previous 
experience with health-related data collection; each question was discussed in training 
sessions held between researchers and all interviewers; a research assistant was present 
during the setup, training, and daily work of the interviewers, motivating and checking 
compliance with standardized operational procedures; data validity was periodically 
verified soon after being collected, and custom statistic algorithms were used to detect 
extreme, illogical, and missing values; and the clarity of the questionnaire and its telephonic 
administration were assessed in a pilot study involving 25 individuals before starting the data 
collection. 
In CED2013 study, a written self-administered questionnaire was given to the usual and most 
knowledgeable caregiver. First, the CED2013 study coordinator had meetings with school 
delegates and teachers from each school included. In the meetings, the study procedures 
were explained and the questionnaires / parental informed consents were distributed. Then, 
each teacher distributed the questionnaire and informed consent to each randomized 
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child. The questionnaires and informed consents were taken home by the children and, in 
case of consent, brought back to the teacher after the parents completed them. Then the 
questionnaires were collected by the study coordinator. Data collection was conducted 
from November 2013 to February 2014. To minimize potential biases in data collection, 
several quality assurance measures were followed: each procedure was discussed during 
the meeting with school delegates and teachers; periodic phone calls to the school 
delegates were made in order to assess the ongoing data collection; data validity and 
randomization numbers were double checked during the electronic reading of the 
questionnaires. 
Data collection of prices of healthcare services, diagnostic tests, medication, holding 
chambers, absenteeism, transportation and subsidies were performed in different sources 
and databases as described below. 
Cost estimation methods 
Direct healthcare costs of childhood asthma were estimated using a bottom-up approach 
(person-based). The cost domains included in direct costs were: 1) healthcare services; 2) 
diagnostic tests; and 3) treatment. 
1) Healthcare services (scheduled medical visits, non-scheduled medical visits, 
emergency department visits and hospitalisations) costs were based on the national 
values defined by Portuguese Central Administration of Health system (ACSS) in 2010 
88. For INAsma sample, the unitary costs were those from the healthcare services of 
their own catchment area. If no official values existed for one catchment area (in 
our sample there was a lack of tariffs for five hospitals), average market prices were 
used. For CED2013 sample, the unitary costs used were the mean prices from INAsma 
estimates (for each healthcare service), in order to maintain the National mean 
estimates and avoiding being biased from one particular catchment area. 
2) Diagnostic tests (blood workout, skin prick test, spirometry and chest x-ray) costs were 
based on national values for 2010 defined by the Ministry of Health 104. 
Treatment included costs with asthma-specific medication, other asthma-related 
medication and holding chambers. Costs of medication (asthma-specific and other 
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asthma-related medication) were based on national values defined by National Authority 
of Medicines and Health Products (INFARMED) and published in Infomed – Medical products 
database 105. The cost of one dose of each pharmacologic group was calculated by the 
arithmetic mean cost for each group (using all the medications available in each 
pharmacologic group). Table 19 shows the dosage and mean cost for each 
pharmacological group of asthma-specific medication. For determination of the number of 
doses needed by a child per year, and per asthma exacerbation, a consensus was 
achieved by two allergologists and two pediatricians, in accordance to international 
guidelines and based on a conservative estimation of adherence 6; the mean use was the 
scenario considered for cost calculation; minimum and maximum usage scenarios were 
used for sensitivity analysis (Table 20). The use of reliever medication was considered if: 1) 
use was reported in the previous 12 months; 2) use was reported in the previous 4 weeks; 3) 
an asthma attack was reported in the previous 12 months. The use of controller medication 
was considered based on parent/self-reported use in the previous 12 months. The value of 
one year of allergen immunotherapy was set by consensus by two pediatricians and two 
allergologists, after consulting the market prices of the mostly used specific 
immunotherapies for childhood asthma in Portugal. The price was established as 400€ and 
200€/year for sublingual and subcutaneous administration, respectively. For assessing the 
prices of the holding chambers, the average of three market prices, from three different 
companies, was used. 
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Table 19 Prices of asthma-specific medication available in Portugal used in this cost-of-illness study. 
Pharmacological group Dose* Mean price per dose 
Inhaled steroids   
       Fluticasone 125µg 0.1957 € 
       Fluticasone 250µg 0.3447 € 
       Fluticasone 500µg 0.6660 € 
       Budesonide 200µg 0.1034 € 
       Budesonide 400µg 0.2079 € 
       Budesonide 800µg 0.4198 € 
Inhaled steroids plus LABA   
       Fluticasone/Salmeterol 125/25µg 0.7752 € 
       Fluticasone/Salmeterol 250/50µg 0.4931 € 
       Fluticasone/Salmeterol 500/100µg 0.9862 € 
       Budesonide/Formoterol 80/4.5µg 0.3557 € 
       Budesonide/Formoterol 160/4.5µg 0.4135 € 
       Budesonide/Formoterol 320/9µg 0.8182 € 
LTRA   
       Montelukaste 4mg 0.8109 € 
       Montelukaste 5mg 0.8296 € 
       Montelukaste 10mg 0.6232 € 
SABA   
       Salbutamol 200µg 0.0626 € 
Oral steroid   
       Betamathasone/Deflazacort  
       (oral solution) 
Equivalent to 1mg of 
prednisone 
0.0305 € 
       Prednisolone/Deflazacort  
       (oral pill) 
Equivalent to 1mg of 
prednisone 
0.0324 € 
*Assumed used dose per day as described in Table 20. 
LABA: long-acting b2-agonist; LTRA: leukotriene-receptor antagonist; SABA: short-acting b2-agonist. 
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Table 20 Estimation of the mean number of doses of asthma medication use. For reliever medication, 
the mean, minimum and maximum use are referred to each asthma exacerbation. For controller 
medication, the mean, minimum and maximum use are referred to the use in one year. 
 
Type of use Description 
RE
LI
EV
ER
  M
ED
IC
A
TIO
N
 
Mean use per exacerbation  
       SABA 200µg, 3id, 5 days 
       Inhaled steroid step-up 125µg fluticasone or 200µg budesonide, 1id, 2 weeks 
       Oral steroid 1mg/Kg/day of prednisone equivalent, 5 days 
Minimum use per exacerbation  
       SABA 200µg, 3id, 2 days 
       Inhaled steroid step-up 125µg fluticasone or 200µg budesonide, 1id, 1 week 
       Oral steroid 1mg/Kg/day of prednisone equivalent, 3 days 
Maximum use per exacerbation  
       SABA 200µg, 3id, 10 days 
       Inhaled steroid step-up 125µg fluticasone or 200µg budesonide, 1id, 4 weeks 
       Oral steroid 1mg/Kg/day of prednisone equivalent, 7 days 
C
O
N
TR
O
LL
ER
  M
ED
IC
A
TIO
N
 
Mean use per year  
       Inhaled steroid 125µg fluticasone or 200µg budesonide, bid, 6 months 
       Inhaled steroid / LABA 125µg fluticasone or 160µg budesonide, bid, 6 months 
       LTRA 1 pill, 1id, 6 months 
Minimum use per year  
       Inhaled steroid 125µg fluticasone or 200µg budesonide, 1id, 2 months 
       Inhaled steroid / LABA 125µg fluticasone or 80µg budesonide, 1id, 2 months 
       LTRA 1 pill, 1id, 2 months 
Maximum use per year  
       Inhaled steroid 250µg fluticasone or 400µg budesonide, bid, 12 months 
       Inhaled steroid / LABA 250µg fluticasone or 160µg budesonide, bid, 12 months 
       LTRA 1 pill, 1id, 12 months 
LABA: long-acting b2-agonist; LTRA: leukotriene-receptor antagonist; SABA: short-acting b2-agonist. 
 
 
Indirect healthcare costs of childhood asthma were estimated using the human capital 
method. The cost domains included in indirect costs were: 1) absenteeism; 2) transportation 
and 3) subsidies because of asthma. 
1) Reported professions of the caregiver were categorized according to the 
Portuguese Classification of Occupations 2010 from the National Statistics Institute 
(INE) 106. The monthly income was based on the national reports from the Ministry of 
Social Security and matched to each professional category 107. The daily income 
was achieved by dividing the monthly income by 22 workdays in a month. Costs 
related to absenteeism of parents or legal guardians were then calculated by 
multiplying the daily income for the number of reported absent days. 
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2) Costs with transportation for medical visits were estimated using the road distances 
between postal code of the participants and the respective referral public hospital 
as assessed by Google maps®. The value used for 1 kilometre was 0.36€, based on 
the price defined by the Portuguese government. 
3) The subsidy value per child with asthma was that established by the Portuguese 
government for 2010 108 and was considered if reported in the questionnaire. 
Each cost item was calculated for each participant by multiplying the parent/self-reported 
amount of resources used by the unitary costs of the resources. The total cost was then 
calculated for each participant by adding direct and indirect costs. Mean cost per patient 
was achieved by the sum of the total cost of each participant, dividing for the total number 
of asthmatic children in our sample. Costs were indexed to 2010 Portuguese prices in euros. 
Definitions 
Current asthma was defined as children with ‘ever had asthma’ plus at least one of the 
following: wheezing, awakening with breathlessness or having an asthma attack in the 
previous 12 months, or taking asthma medication at the time of the interview. 
Nocturnal symptoms: at least one of three symptoms in the previous 12 months: waking with 
breathlessness, waking with chest tightness, or waking with coughing. 
Asthma control definition was based on GINA criteria for asthma symptom control 100, and 
categorized as ‘controlled’, ‘partially controlled’ and ‘uncontrolled’. 
Scheduled medical visits for asthma: having at least one routine appointment because of 
asthma routine follow-up, in the previous 12 months. 
Unscheduled medical visits for asthma: having at least one unscheduled medical 
attendance (not in an emergency department) because of asthma 
worsening/exacerbation, in the previous 12 months. 
Emergency department visits for asthma: having at least one emergency department visit 
because of asthma worsening/exacerbation, in the previous 12 months. 
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Hospitalisation for asthma: having at least one hospital inpatient admission for more than 24 
hours because of asthma worsening/exacerbation, in the previous 12 months. 
Blood workout: having performed blood workout for asthma in the previous 12 months. 
Blood workout was assumed to include complete blood count, quantification of total 
immunoglobulin E and Phadiatop®. 
Chest x-ray: having performed chest x-ray because of asthma in the previous 12 months. 
Skin prick tests: having performed skin prick tests because of asthma or allergies ever in life. 
The cost of skin prick test per child, per year, was achieved by dividing the price of the skin 
prick test by the number of years of asthma diagnosis. 
Pulmonary function tests: having performed pulmonary function tests because of asthma in 
the previous 12 months. It was assumed that pulmonary function tests included a spirometry 
with bronchodilation test. 
Controller medication: use of any inhaled steroid, inhaled long-acting β-agonist, inhaled 
association of steroid and β-agonist or leukotriene receptor antagonist in the previous 12 
months. 
Reliever medication: use of any inhaled/nebulized short-acting β-agonist or oral steroid in 
the previous 12 months. 
Immunotherapy: use of any kind of “anti-allergic vaccines” (allergy specific or non-specific), 
oral or subcutaneous, in the previous 12 months (CED2013 participants), or ever in life 
(INAsma participants). For INAsma participants, the cost of immunotherapy per child, per 
year, was achieved by dividing the price of the immunotherapy by the number of years of 
asthma diagnosis. It was assumed by consensus the following distribution within the positive 
responders: in the 0- to 6-year old group, 40% performed sublingual specific immunotherapy 
and 60% non-specific immunotherapy; in the 7- to 17-year old group, 40% performed 
subcutaneous specific immunotherapy, 30% sublingual specific immunotherapy and 20% 
non-specific immunotherapy. 
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Antihistamine: was assumed by consensus that 66% of asthmatic children with nasal 
symptoms, and 10% of those without nasal symptoms, took one dose of antihistamine for 120 
days, in a 12-month period. 
Antibiotic: was assumed by consensus that antibiotic was used in half of asthma 
exacerbations. 
Flu vaccine: was assumed by consensus that 10% of children with asthma took flu shot in the 
previous 12 months, in 2010. 
Missed schooldays: number of days missed by the child to the school because of asthma in 
the previous 12 months. 
Missed workdays: number of days missed by the caregiver to the work because of the 
child’s asthma in the previous 12 months. 
Subsidy: been granted with a monetary subsidy because of asthma in the previous 12 
months. This monthly grant given by Portuguese Social Security can be granted to a family 
of an asthmatic child after the parents and the physician sign and submit official form. 
Holding chambers: every participant who used inhaler medication was assumed to ever 
had a spacer, until a maximum of three spacers. The number of spacers used was 
dependent of the age of the child and the age of the first asthma diagnosis: if 0- to 1-year-
old, one spacer used; if 2- to 5-year-old, one or two spacers (depending on the time of 
diagnosis); if >= 6 years-old, one to three spacers used (depending on the time of diagnosis). 
Then the value of the spacers was divided by the years since asthma diagnosis, in order to 
obtain the price per year. 
Statistical analysis 
Statistical analysis was performed using SPSS version 23 (SPSS IBM, New York, NY, USA). 
General characteristics of the included participants were described using absolute and 
relative frequencies. 
Cost variables were all annualised and presented as mean and standard deviation (SD) or 
95% confidence interval (95%CI), calculated using bootstrap methods because of their 
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skewed distributions 109,110. For each cost item and domain, extrapolated estimates for the 
Portuguese population were calculated. Extrapolation estimates were based on a 
prevalence estimate of current asthma from INAsma Study (8.4% [95%CI, 6.6-10.7]), 
corresponding to a total weighted population of 173,681 Portuguese children with current 
asthma 102. The factors associated with costs of childhood asthma were assessed using 
mixed Poisson-gamma models. We analysed crude and adjusted associations; for the final 
model of adjusted coefficients we included the variables with a p-value <0.05 and age 
groups (not statistically significant) because of the potential overrepresentation of school-
aged children. Cost differences in levels of asthma control were also analysed using mixed 
Poisson-gamma models. A p-value of <0.05 was considered statistically significant. 
We additionally used decision analytic modelling to perform univariate and multivariate 
deterministic sensitivity analysis, in order to evaluate how the uncertainty would impact the 
estimates of national annualised costs of childhood asthma in Portugal. Univariate 
deterministic sensitivity analysis was performed with the 95%CI of the proportion estimates of 
occurrence of each item in Portuguese population. The multivariate deterministic sensitivity 
analysis was set with two case scenarios. The best-/worst-case scenario were set, 
respectively, with: the lower/upper limit of the 95%CI of current asthma prevalence in 
Portuguese children; scenario of minimum/maximum use of asthma medications; and the 
lower/upper limit of the 95%CI for the proportion of occurrence of each item in Portuguese 
population. 
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RESULTS 
Characteristics of the children included in cost-of-illness analysis are summarized in Table 21. 
Differences between the mean annualised costs of the two studied populations are shown 
in Table 22; differences were only seen in the ‘Treatment’ domain and total costs were not 
significantly different. 
Estimates of mean annualised costs for each cost domain are presented in Table 23. The 
mean annualised total costs per child were €929.35 (95%CI, 809.65–1,061.11), with €698.65 
(95%CI, 600.88–798.27) for direct costs, and €230.70 (95%CI, 197.36–263.81) for indirect costs. 
The extrapolations for Portuguese children amount to absolute total costs of €161,410,007.61 
(95%CI, 140,620,769.55–184,293,968.55), with direct costs of €121,341,498.02 (95%CI, 
104,362,186.11–138,645,096.07) and indirect costs of €40,068,509.59 (95%CI, 34,276,935.33–
45,819,027.76). 
Direct costs represent 75% and indirect costs 25% of the total costs. The most expensive 
domain was healthcare services use (€82,519,684.10; 51% of total costs), specifically 
scheduled medical visits (€33,414,070.10; 21% of total costs) and those related to acute 
asthma care (€49,105,614.06; 30% of total costs): non-scheduled medical visits 
(€12,766,203.20), emergency department visits (€18,932,464.80) and hospitalisations 
(€17,406,946.00).  
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Table 21 Participants characteristics - n(%). 
 
Children with 
current asthma TOTAL 
(n=208) INCA 
(n=98) 
CASCA 
(n=110) 
Gender    
Female 33 (33%) 43 (39%)   76 (37%) 
Male 65 (66%) 67 (61%)     132 (63%) 
Age groups    
  0- 5 years old 18 (18%)    3   (3%)   21 (10%) 
  6-12 years old 46 (47%)      107 (97%) 153 (74%) 
13-17 years old 34 (35%)    0   (0%)   34 (16%) 
Caregiver education    
No education 15 (16%)   0   (0%)   15   (7%) 
0-4 years (basic 1st cycle) 33 (34%)   6   (6%)   39 (19%) 
5-9 years (basic 2nd and 3rd cycle)) 42 (43%) 27 (25%)   69 (34%) 
10-12 years (secondary)   7   (7%) 27 (25%)   34 (17%) 
>12 years (higher)   0   (0%) 47 (44%)   47 (23%) 
Mensal income of caregiver    
< 650.00 € 18 (19%) 34 (32%)   52 (26%) 
650.00 – 749.99 € 36 (38%) 21 (20%)   57 (28%) 
750.00 – 1,199.99€ 11 (12%) 21 (20%)   32 (16%) 
>= 1,200.00 € 31 (32%) 30 (28%)   61 (30%) 
Asthma-like symptoms    
Wheezing 77 (79%) 95 (88%) 172 (84%) 
Nocturnal symptoms 70 (71%) 84 (78%) 154 (74%) 
Asthma attacks 44 (46%) 73 (68%) 127 (61%) 
Healthcare use    
Scheduled medical visits 84 (86%) 91 (83%) 175 (83%) 
Unscheduled medical visits 24 (25%) 51 (46%)  75 (36%) 
Emergency department visits 37 (39%) 49 (45%)  86 (41%) 
Hospitalisation   5   (5%)   5   (5%)  10   (5%) 
Diagnostic tests    
Blood workout - 28 (26%) - 
Chest x-ray - 32 (30%) - 
Spirometry - 34 (32%) - 
Skin prick tests (ever) 71 (72%) 87 (79%) 156 (73%) 
Medication    
Controller medication 68 (69%) 84 (76%) 152 (73%) 
Reliever medication 52 (53%) 85 (77%) 137 (66%) 
Allergen-specific immunotherapy - 35 (32%) - 
Absenteeism    
Missed schooldays 32 (33%) 65 (59%) 97 (47%) 
Missed workdays - 50 (46%) - 
Subsidy    
Yes 16 (17%) - - 
No 80 (83%) - - 
Asthma control    
Well controlled 48 (51%) 66 (68%)    114 (60%) 
Partly controlled 37 (40%) 21 (22%)   58 (31%) 
Uncontrolled   8   (9%) 10 (10%)  18   (9%) 
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Table 22 Mean costs per child, per year, in the two primary studies. 
 Mean cost per patient 
(euros) 
 
 
INAsma CED2013 
p 
TOTAL COSTS 875.99 976.88 0.443 
DIRECT COSTS 637.03 753.54 0.326 
     Healthcare services use 440.93 505.59 0.558 
         Scheduled medical visits 193.67 191.25 0.926 
         Acute asthma care 247.26 314.34 0.500 
                 Non-scheduled medical visits 52.79 91.96 0.059 
                 Emergency department visits 122.54 96.95 0.552 
                 Hospitalisation 71.93 125.43 0.408 
     Diagnostic tests 55.41 50.02 0.511 
          Blood workout 15.80 13.12 0.401 
          Chest x-ray 5.50 4.54 0.324 
          Pulmonary function tests 29.23 26.66 0.639 
          Skin prick tests 4.87 5.71 0.308 
     Treatment 140.70 197.93 <0.001* 
         Asthma-specific medication 90.48 93.65 0.779 
                 Controller medication 83.75 85.77 0.856 
                 Reliever medication 6.73 7.88 0.239 
         Other asthma medication 35.19 
 
86.12 <0.001* 
                 Immunotherapy 17.88 64.68 <0.001* 
                 Antihistamines 11.74 9.06 <0.001* 
                 Antibiotics 4.99 11.80 <0.001* 
                Flu vaccine 0.59 0.59 1.00 
         Holding chamber 15.02 18.17 0.024 
INDIRECT COSTS 238.96 223.34 0.660 
     Parental absenteeism 77.75 79.78 0.915 
     Transportation 21.42 23.72 0.553 
     Subsidies 139.80 119.84 0.496 
*statistically significant differences between the two studies. 
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Table 23 Annualised costs (in euros) of childhood asthma in Portugal: total costs, mean cost per child 
with current asthma and percentage of total costs for each domain/variable. 
 
Total costs in Portuguese 
children* 
(95%CI#) 
Mean cost per 
patient† 
(95%CI#) 
Percentage of 
total costs 
TOTAL COSTS 161,410,007.61            
(142,367,218.84 -181,369,857.87) 
929.35                    
(819.71 - 1,044.27) 
100% 
DIRECT COSTS 121,341,498.02     
(104,319,912.15 -139,851,241.14) 
698.65                    
(600.64 - 805.22) 
75.2% 
     Healthcare services use 82,519,684.10 
(67,027,110.46 – 99,248,305.38) 
475.12 
(385.92 - 571.46) 
51.1% 
         Scheduled medical visits 33,414,070.10 
(29,192,806.15 - 38,204,470.63) 
192.39 
(168.08 - 219.97) 
20.7% 
         Acute asthma care 49,105,614.06 
(35,070,014.88 - 64,089,678.45) 
282.73 
(201.92 - 369.01) 
30.4% 
                 Non-scheduled medical visits 12,766,203.20 
(9,809,363.94 - 15,874,252.35) 
73.50 
(56.48 - 91.40) 
7.9% 
                 Emergency department visits 18,932,464.80 
(13,136,536.12 - 26,300,288.04) 
109.01 
(75.64 - 151.43) 
11.7% 
                 Hospitalisation 17,406,946.00 
(6,189,712.95 – 30,072,795.68) 
100.22 
(35.64 - 173.15) 
10.8% 
     Diagnostic tests 9,128,914.10 
(7,988,735.48 - 10,293,812.35) 
52.56 
(46.00 - 59.27) 
5.7% 
          Blood workout 2,498,121.71 
(2,056,174.62 - 3,027,259.83) 
14.38 
(11.84 - 17.43) 
1.5% 
          Chest x-ray 867,148.15 
(726,594.46 - 1,012,508.13) 
4.99 
(4.18 - 5.83) 
0.5% 
          Pulmonary function tests 4,840,864.14 
(4,047,079.93 - 5,594,160.80) 
27.87 
(23.30 - 32.21) 
3.0% 
          Skin prick tests 922,780.11 
(787,921.22 - 1,060,409.35) 
5.31 
(4.54 - 6.11) 
0.6% 
     Treatment 29,692,899.78 
(26,638,427.58 - 32,734,734.89) 
170.96 
(153.38 - 188.48) 
18.4% 
         Asthma-specific medication 16,005,602.20 
(14,170,511.21 - 16,552,789.28) 
92.16 
(81.59 - 102.71) 
9.9% 
                 Controller medication 14,731,639.10 
(12,945,695.43 - 16,516,489.95) 
84.82 
(74.54 - 95.31) 
9.1% 
                 Reliever medication 1,273,963.08 
(1,122,865.03 - 1,433,510.87) 
7.34 
(6.47 - 8.25) 
0.8% 
         Other asthma medication 10,789,280.82 
(8,948,166.70 - 12,786,638.37) 
62.12 
(51.52 - 73.62) 
6.7% 
                 Immunotherapy 7,403,386.43 
(5,663,424.78 - 9,313,209.42) 
42,63 
(32.61 - 53.62) 
4.6% 
                 Antihistamines 1,792,454.72 
(1,663,308.20 - 1,910,421.53) 
10.32 
(9.58 - 11.00) 
1.1% 
                 Antibiotics 1,491,836.29 
(1,264,692.94 - 1,736,306.33) 
8.59 
(7.28 - 10.00) 
0.9% 
                Flu vaccine 101,603.39 
(n.a.) 
0.59 
(n.a.) 
0.1% 
         Holding chamber 2,898,016.76 
(2,659,281.90 - 3,159,830.54) 
16.69 
(15.31 - 18.19) 
1.8% 
INDIRECT COSTS 40,068,509.59         
(34,117,635.12 - 46,811,024.16) 
230.70                      
(196.44 - 269.52) 
24.8% 
     Parental absenteeism 13,689,797.60 
(10,775,047.66 - 16,906,907.47) 
78.82 
(62.04 - 97.34) 
8.5% 
     Transportation 3,931,536.64 
(3,397,478.25 - 4,553,290.57) 
22.64 
(19.56 - 26.22) 
2.4% 
     Subsidies 22,447.175.39 
(17,551,402.93 - 27,735,327.31) 
129.24 
(101.06 - 159.69) 
13.9% 
Each cost item was calculated for each participant by multiplying the parent/self-reported amount of resources 
used by the unitary costs of the resources. Costs were indexed to 2010 Portuguese prices in euros. 
*Total costs were extrapolated to total Portuguese children with current asthma (n=173,681)(9);#Bootstrapped 
95%CI; n.a, not applicable; †Mean cost per patient: sum of the total cost of each participant, dividing for the total 
number of asthmatic children in our sample 
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Factors associated with costs of childhood asthma 
We observed significant crude associations between total annualised costs of childhood 
asthma and nocturnal symptoms, asthma attacks and level of asthma control (Table 24). 
However, only asthma attacks and level of asthma control had significant and independent 
associations with total annualised costs of childhood asthma in the final multivariate model 
adjusted for age. 
Children with asthma attacks in the previous 12 months had higher costs than those without 
asthma attacks (adjusted exponential model coefficients: 1.57 [95%CI, 1.22-2.02]). Children 
with partly controlled asthma and uncontrolled asthma had higher mean costs per year 
with adjusted exponential model coefficients of 1.46 [95%CI, 1.12-1.90] and 2.25 [95%CI, 
1.56-3.24], respectively. The mean annualised costs per asthmatic child were €747.63 in 
those with controlled asthma, €1,120.50 in partly controlled and 1,758.44 in uncontrolled 
(p<0.001) (Figure 10; Table 25). Total costs and direct costs, specifically healthcare services 
use by acute asthma care and diagnostic tests domains were significantly higher in children 
with uncontrolled asthma (Figure 11; Table 25). Scheduled medical visits, treatment or 
indirect costs were not different between asthma control groups. 
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Table 24 Factors associated with annualised total costs of childhood asthma in Portugal. 
 Mean cost (SD) 
Factors associated with childhood 
Crude association 
(95%CI) 
Adjusted 
association* 
(95%CI) 
Gender    
     Female 999.44  (1,155.01)           1.00            (ref) n.i. 
     Male 888.99     (806.34) 0.89  (0.67-1.18) n.i. 
Age groups    
       0- 5 years old 1,035.91  (1,146.11)            1.00           (ref)        1.00           (ref) 
       6-12 years old 969.84     (974.54) 0.94 (0.60-1.46)   0.86  (0.59 -1.26) 
     13-17 years old 681.33     (618.04) 0.66 (0.39-1.14)   0.64  (0.40-1.03) 
Caregiver education    
     No education 1,190.65  (1,311.41)           1.00            (ref) n.i. 
     0-4 years (basic 1st cycle) 1,011.55  (1,151.59) 0.85  (0.49-1.47) n.i. 
     5-9 years (basic 2nd and 3rd cycle) 1,010.83  (1,136.31) 0.85  (0.51-1.42) n.i. 
     10-12 years (secondary) 669.32     (442.65) 0.56  (0.32-1.01) n.i. 
     >12 years (higher) 840.07     (477.72) 0.71  (0.41-1.21) n.i. 
Mensal income of caregiver    
     < 650.00 € 1,064.76  (1,187.16)           1.00            (ref) n.i. 
     650.00 – 749.99 € 1,009.69     (909.77) 0.95  (0.67-1.35) n.i. 
     750.00 – 1,199.99€ 839.60     (972.68) 0.79  (0.52-1.21) n.i. 
     >= 1,200.00 € 755.10     (550.96) 0.71  (0.50-1.02) n.i. 
Wheezing    
     No 776.19     (746.83)          1.00             (ref) n.i. 
     Yes 964.25     (985.50) 1.24   (0.84-1.83) n.i. 
Nocturnal symptoms    
     No 685.41     (588.66)          1.00             (ref) n.i. 
     Yes 1,014.00  (1,034.80) 1.48  (1.07-2.05) n.i. 
Asthma attacks    
     No 677.58     (713.02)          1.00             (ref)       1.00           (ref) 
     Yes 1,136.82  (1,058.60) 1.68  (1.27-2.22) 1.57  (1.22-2.02) 
Asthma control    
     Controlled 747.63     (562.79)          1.00             (ref)       1.00           (ref) 
     Partly controlled 1,120.50  (1,135.96) 1.50  (1.14-1.98) 1.46  (1.12-1.90) 
     Uncontrolled 1,758.44  (1,795.65)          2.35  (1.60-3.47)  2.25  (1.56-3.24) 
Bold values show statistical significant differences. n.i.: not included in the model (non-significant variables) 
*Adjusted coefficients were calculated using multivariate mixed Poisson-gamma (Tweedie distribution family) 
generalised linear models. Goodness-of-fit statistics for the multivariate regression model: scaled deviance (D = 
214.8; df = 174); scaled Pearson chi-square (v2 = 258.7; df = 174); AIC = 2,818.9; consistent AIC = 2,865.3)  
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Table 25 Variations of annualised costs (in euros) of childhood asthma in Portugal with level of asthma 
control. 
 Costs in Portuguese 
childhood asthma, 
Mean per patient 
(Total) 
Costs by level of asthma control, 
Mean per patient (Total) 
 
Controlled Partly controlled Uncontrolled p 
TOTAL COSTS 929.35      (161,410,007.61) 
747.63 
(71,167,055.27) 
1,120.50 
(54,266,054.08) 
1,758.44 
(26,429,556.38) <0.001 
DIRECT COSTS 698.65      
(121,341,498.02) 
530.33 
(50,482,832.36) 
867.49 
(42,012,844.31) 
1,440.75 
(21,654,576.11) 
<0.001 
     Healthcare services use 475.12 
(82,519,684.10) 
319.57 
(30,419,891.60) 
623.39 
(30,190,811.20) 
1,165.13 
(17,511,979.70) 
<0.001 
         Scheduled medical visits 192.39 
(33,414,070.10) 
181.15 
(17,244,101.80) 
206.10 
(9,981,647.47) 
217.53 
(3,269,427.92) 
0.568 
         Acute asthma care 282.73 
(49,105,614.06) 
138.41 
(13,175,789.78) 
417.29 
(20,209,163.72) 
947.60 
(14,242,551.75) 
<0.001 
                 Non-scheduled medical visits 73.50 
(12,766,203.20) 
44.87 
(4,271,498.91) 
110.45 
(5,349,124.30) 
151.77 
(2,281,183.03) 
0.001 
                 Emergency department visits 109.01 
(18,932,464.80) 
66.65 
(6,344,166.13) 
132.43 
(6,413,529.98) 
370.00 
(5,561,056.87) 
<0.001 
                 Hospitalisation 100.22 
(17,406,946.00) 
26.89 
(2,560,124.74) 
174.41 
(8,446,509.44) 
425.83 
(6,400,311.85) 
0.012 
     Diagnostic tests 52.56 
(9,128,914.10) 
37.18 
(3,539,650.55) 
72.98 
(3,534,604.54) 
100.31 
(1,507,731.49) 
<0.001 
          Blood workout 14.38 
(2,498,121.71) 
8.49 
(808,204.49) 
23.06 
(1,116,640.16) 
31.52 
(473,725.95) 
<0.001 
          Chest x-ray 4.99 
(867,148.15) 
3.08 
(293,310.97) 
8.45 
(409,391.50) 
8.09 
(121,576.70) 
<0.001 
          Pulmonary function tests 27.87 
(4,840,864.14) 
20.29 
(1,931,110.53) 
35.42 
(1,715,577.41) 
57.44 
(863,394.97) 
<0.001 
          Skin prick tests 5.31 
(922,780.11) 
5.33 
(507,024.56) 
6.05 
(292,995.46) 
3.26 
(49,033.87) 
0.147 
     Treatment 170.96 
(29,692,899.78) 
173.58 
(16,523,290.25) 
171.12 
(8,287,428.60) 
175.31 
(2,634,864.95) 
0.989 
         Asthma-specific medication 92.16 
(16,005,602.20) 
89.83 
(8,550,662.78) 
98.12 
(4,751,962.26) 
97.30 
(1,462,487.33) 
0.799 
                 Controller medication 84.82 
(14,731,639.10) 
82.86 
(7,887,138.11) 
89.57 
(4,337,774.83) 
88.93 
(1,336,583.85) 
0.859 
                 Reliever medication 7.34 
(1,273,963.08) 
6.97 
(663,524.67) 
8.55 
(414,187.43) 
8.38 
(125,903.49) 
0.375 
         Other asthma medication 62.12 
(10,789,280.82) 
67.06 
(6,383,728.66) 
54.77 
(2,652,576.47) 
64.94 
(976,087.22) 
0.607 
                 Immunotherapy 42.63 
(7,403,386.43) 
48.46 
(4,612,917.26) 
33.33 
(1,614,131.09) 
42.50 
(638,787.03) 
0.433 
                 Antihistamines 10.32 
(1,792,454.72) 
9.81 
(933,602.18) 
11.12 
(538,544.70) 
11.30 
(169,773.18) 
0.189 
                 Antibiotics 8.59 
(1,491,836.29) 
8.21 
(781,522.75) 
9.74 
(471,568.97) 
10.56 
(158,734.41) 
0.560 
                Flu vaccine 0.59 
(101,603.39) 
0.59 
(85,686) 
0.59 
(28,331.71) 
0.59 
(8,792.60) 
1.00 
         Holding chamber 16.69 
(2,898,016.76) 
16.69 
(1,588,898.81) 
18.23 
(882,889.86) 
13.06 
(196,290.39) 
0.119 
INDIRECT COSTS 230.70        
(40,068,509.59) 
217.29 
(20,684,222.92) 
253.01 
(12,253,209.76) 
317.69 
(4,774,980.26) 
0.322 
     Parental absenteeism 78.82 
(13,689,797.60) 
85.73 
(8,161,146.46) 
69.27 
(3,354,538.48) 
86.63 
(1,302,125.13) 
0.749 
     Transportation 22.64 
(3,931,536.64) 
20.03 
(1,907,125.93) 
26.04 
(1,261,007.56) 
34.53 
(518,942.13) 
0.106 
     Subsidies 129.24 
(22,447,175.39) 
111.52 
(10,615,950.52) 
157.70 
(7,637,663.73) 
196.53 
(2,953,913.01) 
0.237 
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Figure 10 Mean cost per child with current asthma, per year; mean cost variation according to the 
level of asthma control. Mean costs are marked in euros and the lines represent 95%CI. *p<0.001 
between groups of asthma control. 
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Figure 11 Mean cost per 
child with current asthma, 
per year, in each domain. 
Panel A: total costs. Panel 
B: cost variation according 
to the level of asthma 
control. *p<0.001 between 
groups of asthma control. 
thesis. 
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Sensitivity analysis 
In univariate deterministic sensitivity analysis (Table 26), each lower and upper limit was 
estimated by using the 95%CI of the proportion of occurrence in Portuguese population for 
each variable, as estimated previously 102. The adjusted estimates for the mean of 
annualised costs per child with asthma varied between €657.79 and €1,223.99 in total costs: 
between €497.24 and €915.53 in direct costs, and €160.55 and €308.45 in indirect costs. The 
extrapolations of the total annualised costs for the Portuguese children varied between 
€114,245,801.21 and €212,583,389.35 in total costs: between €86,360,787.25 and 
€159,010,961.96 in direct costs, and €27,885,013.95 and €53,572,427.39 in indirect costs. 
In multivariate deterministic sensitivity analysis (Table 27), the adjusted estimates for the 
mean of annualised costs per child with asthma varied between €606.99 and €1,424.38 in 
total costs: between €446.44 and €1,140.07 in direct costs, and €160.55 and €284.31 in 
indirect costs. The extrapolations of the total annualised costs for the Portuguese children 
varied between €79,585,960.00 and €308,018,952.55 in total costs: between €58,535,047.13 
and €246,538,052.49 in direct costs, and €21,050,912.88 and €61,480,900.06 in indirect costs. 
The adjusted estimates for the mean of annualised costs per child with asthma in total costs 
varied between -35% and +53%, in direct costs between -36 and +63%, and in indirect costs 
between -30 and +23%. 
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Table 26 Univariate deterministic sensitivity analysis – Annualised total costs extrapolated to total 
Portuguese children with current asthma and mean costs per patient. 
 
Costs in Portuguese 
childhood asthma 
Total (mean per patient) 
Univariate deterministic sensitivity analysis* 
Total (mean per patient) 
Lower limit* Upper limit* 
TOTAL COSTS 161,410,007.61             
(929.35) 
114,245,801.21              
(657.79) 
212,583,389.35           
(1,223.99) 
DIRECT COSTS 121,341,498.02                
(698.65) 
86,360,787.25                
(497.24) 
159,010,961.96              
(915.53) 
     Healthcare services use 82,519,684.14 
(475.12) 
56,424,066.12 
(324.87) 
111,100,595.44 
(639.68) 
         Scheduled medical visits 33,414,070.09 
(192.39) 
30,694,320.20 
(176.73) 
36,133,819.98 
(208.05) 
         Acute asthma care 49,105,614.06 
(282.73) 
25,729,745.92 
(148.14) 
74,966,775.46 
(431.63) 
                 Non-scheduled medical visits 12,766,203.22 
(73.50) 
8,170,370.06 
(47.04) 
16,851,388.25 
(97.02) 
                 Emergency department visits 18,932,464.81 
(109.01) 
14,077,986.65 
(81.06) 
23,301,495.15 
(134.16) 
                 Hospitalisation 17,406,946.03 
(100.22) 
3,481,389.21 
(20.04) 
34,813,892.06 
(200.45) 
     Diagnostic tests 9,128,914.10 
(52.56) 
6,623,276.28 
(38.13) 
11,634,551.94 
(66.99) 
          Blood workout 2,498,121.71 
(14.38) 
1,729,468.88 
(9.96) 
3,266,774.54 
(18.81) 
          Chest x-ray 867,148.15 
(4.99) 
607,003.71 
(3.49) 
1,127,292.60 
(6.49) 
          Pulmonary function tests 4,840,864.14 
(27.87) 
3,479,371.10 
(20.03) 
6,202,357.18 
(35.71) 
          Skin prick tests 922,780.11 
(5.31) 
807,432.60 
(4.65) 
1,038,127.62 
(5.98) 
     Treatment 29,692,899.78 
(170.96) 
23,313,444.86 
(134.23) 
36,275,814.58 
(208.86) 
         Asthma-specific medication 16,005,602.20 
(92.16) 
13,095,804.16 
(75.40) 
18,915,400.20 
(108.91) 
                 Controller medication 14,731,639.10 
(84.82) 
12,191,701.32 
(70.20) 
17,271,576.88 
(99.44) 
                 Reliever medication 1,273,963.08 
(7.34) 
904,102.83 
(5.21) 
1,643,823.33 
(9.46) 
         Other asthma medication 10,789,280.82 
(62.12) 
7,708,909.77 
(44.39) 
14,029,857.80 
(80.78) 
                 Immunotherapy 7,403,386.43 
(42.63) 
5,321,184.00 
(30.64) 
9,485,588.86 
(54.62) 
                 Antihistamines 1,792,454.72 
(10.32) 
1,493,712.27 
(8.60) 
2,091,197.17 
(12.04) 
                 Antibiotics 1,491,836.29 
(8.59) 
843,211.82 
(4.85) 
2,270,185.66 
(13.07) 
                Flu vaccine 101,603.39 
(0.59) 
50,801.70 
(0.29) 
182,886.10 
(1.05) 
         Holding chamber 2,898,016.76 
(16.69) 
2,508,730.93 
(14.44) 
3,330,556.57 
(19.18) 
INDIRECT COSTS 40,068,509.59                  
(230.70) 
27,885,013.95                   
(160.55) 
53,572,427.39                
(308.45) 
     Parental absenteeism 13,689,797.60 
(78.82) 
11,011,358.94 
(63.40) 
16,368,236.26 
(94.24) 
     Transportation 3,931,536.64 
(22.64) 
3,669,434.20 
(21.13) 
4,193,639.08 
(24.15) 
     Subsidies 22,447,175.39 
(129.24) 
12,500,522.82 
(71.97) 
32,393,827.96 
(186.51) 
*Each upper and lower limit was estimated by using the 95%CI of the proportion of occurrence in Portuguese 
population for each item. 
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Table 27 Multivariate deterministic sensitivity analysis – Annualised total costs extrapolated to total 
Portuguese children with current asthma and mean costs per patient. 
 Costs in Portuguese childhood asthma 
Multivariate sensitivity analysis 
Best-case scenario* Worst-case scenario# 
TOTAL COSTS 161,410,007.61         
(929.35) 
79,585,960.00         
(606.99) 
308,018,952.55    
(1,424.38)   
DIRECT COSTS 121,341,498.02         
(698.65) 
58,535,047.13          
(446.44) 
246,538,052.49       
(1,140.07) 
     Healthcare services use 82,519,684.10 
(475.12) 
42,595,571.35 
(324.87) 
138,329,936.99 
(639.68) 
         Scheduled medical visits 33,414,070.10 
(192.39) 
23,171,710.16 
(176.73) 
44,989,758.82 
(208.05) 
         Acute asthma care 49,105,614.00 
(282.73) 
19,423,861.19 
(148.14) 
93,340,178.17 
(431.63) 
                 Non-scheduled medical visits 12,766,203.20 
(73.50) 
6,167,963.51 
(47.04) 
20,981,450.09 
(97.02) 
                 Emergency department visits 18,932,464.80 
(109.01) 
10,627,732.56 
(81.06) 
29,012,394.70 
(134.16) 
                 Hospitalisation 17,406,946.00 
(100.22) 
2,628,165.12 
(20.04) 
43,346,333.38 
(200.45) 
     Diagnostic tests 9,128,914.10 
(52.56) 
5,000,033.78 
(38.13) 
14,486,032.35 
(66.99) 
          Blood workout 2,498,121.71 
(14.38) 
1,305,608.05 
(9.96) 
4,067,419.36 
(18.81) 
          Chest x-ray 867,148.15 
(4.99) 
458,238.33 
(3.49) 
1,403,577.64 
(6.49) 
          Pulmonary function tests 4,840,864.14 
(27.87) 
2,626,641.61 
(20.03) 
7,722,475.88 
(35.71) 
          Skin prick tests 922,780.11 
(5.31) 
609,545.80 
(4.65) 
1,292,559.47 
(5.98) 
     Treatment 29,692,899.78 
(170.96) 
10,939,442.00 
(83.43) 
93,722,083.15 
(433.40) 
         Asthma-specific medication 16,005,602.20 
(92.16) 
3,225,956.01 
(24.60) 
67,162,295.84 
(310.58) 
                 Controller medication 14,731,639.10 
(84.82) 
2,883,526.64 
(21.99) 
63,387,483.49 
(293.12) 
                 Reliever medication 1,273,963.08 
(7.34) 
342,429.37 
(2.61) 
3,774,812.35 
(17.46) 
         Other asthma medication 10,789,280.82 
(62.12) 
5,819,598.60 
(44.39) 
22,412,953.76 
(103.64) 
                 Immunotherapy 7,403,386.43 
(42.63) 
4,017,060.24 
(30.64) 
16,754,942.43 
(77.48) 
                 Antihistamines 1,792,454.72 
(10.32) 
1,127,631.03 
(8.60) 
2,603,722.95 
(12.04) 
                 Antibiotics 1,491,836.29 
(8.59) 
636,556.20 
(4.85) 
2,826,579.23 
(13.07) 
                Flu vaccine 101,603.39 
(0.59) 
38,351.14 
(0.29) 
227,709.14 
(1.05) 
         Holding chamber 2,898,016.76 
(16.69) 
1,893,887.38 
(14.44) 
4,146,833.55 
(19.18) 
INDIRECT COSTS 40,068,509.59              
(230.70) 
21,050,912.88          
(160.55) 
61,480,900.06          
(284.31) 
     Parental absenteeism 13,689,797.60 
(78.82) 
8,312,678.55 
(63.40) 
20,379,882.34 
(94.24) 
     Transportation 3,931,536.64 
(22.64) 
2,770,123.76 
(21.13) 
5,221,446.58 
(24.15) 
     Subsidies 22,447,175.39 
(129.24) 
9,968,110.57 
(76.03) 
41,101,017.72 
(190.06) 
*Best-case scenario was set with: the lower limit of the 95%CI of CA prevalence in Portuguese children; scenario 
of minimum use of asthma medications; and the lower limit of the 95%CI for the proportion of occurrence of 
each variable in Portuguese population. #Worst-case scenario was set with: the upper limit of the 95%CI of CA 
prevalence in Portuguese children; scenario of maximum use of asthma medications; and the upper limit of the 
95%CI for the proportion of occurrence of each variable in Portuguese population. 
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CONCLUSION 
Childhood asthma in Portugal costs €161,410,007.61 per year, corresponding to €929.35 per 
child with current asthma. The total cost estimate of childhood asthma corresponds to 0.91% 
of the Portuguese expenses in health in 2010. Direct costs were 3/4 of total costs, mainly 
related to acute asthma care (non-scheduled visits, emergency and hospitalisations). The 
most important factors determining higher costs were asthma attacks in the previous 12 
months (1.6-fold) and uncontrolled asthma (2.3-fold). A better asthma control, with a 
consequent reduction in the acute use of healthcare services, should be the major target 
for potential savings in this disease. 
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5. DISCUSSION  
In the present dissertation, the aim was to assess to burden of childhood asthma in Portugal. 
For this purpose, five main domains were covered: 
1) childhood asthma prevalence; 
2) diagnostic tests and medication in childhood asthma; 
3) healthcare services use in childhood asthma; 
4) childhood asthma control; 
5) childhood asthma costs. 
The PhD project was designed to describe the childhood asthma burden in Portugal in a 
comprehensive manner. The main study was a cross-sectional, nationwide, all-age study, 
designed to study several asthma domains in the Portuguese general population (INAsma 
study). A post-hoc analysis of pediatric population (0- to 17-years old, inclusive) was 
performed. For the strengthening of the cost analysis, a cross-sectional study on asthma was 
conducted in children from primary schools of a Portuguese city. Additionally, secondary 
data on direct costs were used.  
Asthma prevalence and burden are high among children. However, there is a paucity of 
data on this topic. This PhD project brought some important and comprehensive data on 
Portuguese childhood asthma.   
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5.1 Major findings 
A high prevalence of asthma-like symptoms was found in the Portuguese pediatric 
population (39.4%; 95%CI, 35.7–43.3). The prevalence of lifetime asthma was 11.2 (95%CI, 
9.1-13.7) and current asthma was 8.4% (95%CI, 6.6–10.7). Less than half of children with 
current asthma had been on inhaled controller medication in the previous 12 months and 
only 52.9% of those at or above the age of 6 years had undergone PFT. 
A high proportion of healthcare services use for asthma, in the previous 12 months, was 
observed: 86% (95%CI, 79–93%) had scheduled medical visits, 25% (95%CI, 16–33%) had 
unscheduled medical visits, 39% (95%CI, 29–48%) had emergency department visits and 5% 
(95%CI, 1–10%) were hospitalised. Importantly, more than one third of children with asthma, 
or over 55,000 Portuguese children, aged 6 to 17 years were hospitalised for asthma during 
their lifetime. 
Half of children with current asthma were not controlled (49%, 95%CI 39-59%). Determinants 
for ‘not controlled asthma’ were the presence of substantial nasal symptoms (aOR 6.8, 95%CI 
2.34-19.80), overweight/obesity (aOR 3.60, 95%CI 1.46-10.13) and not having health 
insurance (aOR 3.78, 95%CI 1.36-10.92). The presence of a higher number of nasal symptoms 
was associated with poorer asthma control, in a cumulative way. Moreover, children with 
substantial nasal symptoms and without health insurance needed more unscheduled 
medical services, while adolescents needed less. 
Childhood asthma in Portugal costs €161,410,007 per year, corresponding to €929.35 per 
child with current asthma. Direct costs were the majority of costs (75.2% of total costs), 
especially healthcare services use (51.1% of total costs). The most important factors for 
higher costs were asthma attacks in the previous 12 months (1.6-fold) and uncontrolled 
asthma (2.3-fold). 
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5.2 Strengths and limitations 
Strengths 
The major strength of this PhD thesis is the generalisability of the results for the Portuguese 
population. The core study was a Portuguese cross-sectional nationwide study (INAsma) 
and the participants were randomly recruited from the general Portuguese population. Also, 
overall, our sample followed the same distribution of the Portuguese national pediatric 
population assessed by the INE 98. 
The study on asthma prevalence (Paper 1) was the first population-based nationwide 
epidemiological study aiming to estimate the asthma prevalence in Portugal. It included a 
large representative sample of the Portuguese population, among all municipalities and 
pediatric ages, allowing us to estimate the prevalence of asthma-like symptoms, current 
asthma, diagnostic tests, and medication use in asthmatic children. Nationwide studies on 
the prevalence of asthma across the entire pediatric population have only been previously 
performed in Germany and the United States 44–46; no previous study has reported the 
prevalence of asthma-like symptoms across all pediatric ages. 
For the first time, the proportion of lifetime hospitalisations for asthma was reported for a 
national population-based paediatric sample (Paper 2). In our country, about one-third of 
asthmatic children were hospitalised for asthma at least once in their lifetime. 
The study on asthma control (Paper 3) was the first study assessing childhood asthma control 
in Portugal and, for the first time, we reported the effect of health insurance coverage on 
asthma control in a European country. 
The cost of illness study (Paper 4) was the first Portuguese nationwide, population-based 
study on costs of childhood asthma. The cost domains analysed allowed us to create a 
comprehensive picture of childhood asthma costs in Portugal, as did the prevalence-based 
analysis and societal perspective. We performed a univariate and multivariate deterministic 
sensitivity analysis, aiming to understand different variations according to uncertainty. 
Sensitivity analysis is crucial to highlight variability, to make comparisons with other data, 
and is recommended in economic studies 111,112, but this was the first cost-of-illness study on 
childhood asthma to report a sensitivity analysis. 
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Limitations 
This PhD thesis on childhood asthma burden has limitations that need to be considered for 
an adequate interpretation of its results. The first limitation is the absence of a study on the 
quality of life in Portuguese childhood asthma. The assessment of this domain is important to 
understand the impact of the disease in children and caregivers’ lives. However, the utility 
of the available tools in the assessment of quality of life in asthma is not well established 
because of the lack of validity or reproducibility between children and/or caregivers 82,83. 
Moreover, the quality of life in asthmatic children is known to be closely linked to asthma 
control or seeking medical attention 76,85. We do have data on asthma control, healthcare 
services use and also on school absenteeism that can be an objective proxy of the impact 
on the quality of life due to asthma among these children. 
Also, each specific study as some limitations. The INAsma survey was designed for the overall 
Portuguese population; however, the questions included in the questionnaire and the 
definitions used are similar to others used in international and Portuguese pediatric studies 
113–115. The use of the 2001 National Census for sampling could not account for the reduction 
in the number of births that occurred since then; however, it was the most recently available 
data at the time of data collection (2010). Also, the study’s pediatric sample follows the 
characteristics of the Portuguese pediatric population 98. The use of landline telephones 
excludes households without residential telephones; nevertheless, it allowed us to guarantee 
a stratified cluster sample by region, and it was a method previously used in similar studies 
assessing asthma control in children 64. Answers were given by the main caregiver for 
participants under 15 years of age and by the adolescent when the participant was ≥15 
years old, as imposed by Portuguese law. This may limit comparisons between these age 
groups; however, changes from parent-reported to self-reported outcomes are 
recommended between school-age and adolescence 116, and other studies on asthma 
prevalence in pediatric ages had similar methodology 44. Finally, we could not obtain a 
clinical confirmation of the diagnosis; therefore, participants’ misclassification can be 
expected, as in any similar survey. 
In the study of asthma control (Paper 3), the sample size may have limited the precision of 
our estimates in subgroup analysis but we were able to construct logistic regression models 
with good fit for the main outcomes. Physician assessment could not be included in this type 
of study. Yet, we used an internationally recommended measure for asthma control – the 
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GINA guidelines – which are frequently used in epidemiological studies with similar 
methodology 117. Also, parents’ recall of doctor’s diagnosis, e.g. rhinitis, may lead to 
underestimation of concomitant diseases. 
In the cost of childhood asthma study (Paper 4) there were some limitations regarding the 
participants and the reported outcomes used for cost estimations. Participants were derived 
from INAsma and CED2013; school-age children may be overrepresented in our sample, 
nevertheless, this is the age group with the higher prevalence of asthma in our country 102. 
Also, differences in cost estimations between the two studies were only seen in the domain 
of ‘Treatment’ and total costs were not significantly different (Table 22). Data on diagnostic 
tests use and immunotherapy were only available in the CED2013 study and then 
extrapolated for the entire sample. The assumptions made in the treatment domain may 
also have masked higher cost differences between asthma control groups. Specifically, 
medication costs were based on the reported medicines used in the previous year, but we 
were unable to assess the number of doses taken by each participant; we used a clinical 
consensus approach for the number of doses of controller and reliever medication, based 
on GINA guidelines and on conservative estimations of adherence. In transportation, we 
used an official Portuguese price by kilometre, however we could not assess how many of 
the patients used public transports or ambulances. The absenteeism costs were based on a 
mean Portuguese daily income according to the parents’ professional occupation, not with 
a reported income; this could possibly underestimate the costs of absenteeism. Also, we 
could not assess parents’ presenteeism because of child’s asthma.  
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5.3 Epidemiology of childhood asthma 
Childhood asthma-like symptoms 
In our study, the prevalence of asthma-like symptoms among Portuguese children was 
39.4%. A multinational study of children aged 1 to 5 years showed that approximately one-
third had wheezing, coughing, or breathlessness 113, which was lower than our observation 
in children aged <6 years old (47.9%). However, the time period considered in that study 
was only 6 months, while the time period in our study was 12 months. Two recent Portuguese 
studies reported estimates of wheezing in preschoolers (24.5% and 27.5%) 43,118, similar to our 
results. Mvula et al. 28 found that 27.3% of children aged 5 to 18 had cough at night, apart 
from cold or chest infection. Our question did not distinguish different causes of cough and 
association to colds; however, our prevalence among children aged 0- to 17-years old 
(30.9%) was similar to that reported by Mvula et al. 28. 
The United States National Center for Health Statistics reported a 5.4% prevalence of asthma 
attacks among children aged 0- to 17-years old 29. The slightly lower prevalence among 
Portuguese children (3.7%) may be related to differences in the definition of asthma attacks 
in the two populations. 
The prevalence of wheezing and nocturnal symptoms decreased with age (Figure 3). 
However, after the age of 5 years, most children with wheezing exhibited wheezing without 
a cold and wheezing with breathlessness (Figure 4). These results suggest that age influences 
asthma-like symptom patterns. These findings are in agreement with previous studies 
suggesting that wheezing in younger children is more closely related to immature airways 
and viral respiratory illnesses 8, whereas older children tend to exhibit wheezing even without 
respiratory infections. 
Childhood asthma prevalence 
There is no consensus on the epidemiologic definition of current asthma, which leads to 
hardly comparable differences in reported prevalence estimates, depending on the 
definition used 22,30. Wheezing-based asthma definitions are limited by differences in the 
concept and perception of wheezing. Fernandes et al. 35 reported a lack of perception of 
the term “wheezing” among Portuguese parents and health professionals. To account for 
this problem, we used several synonyms of wheezing in Portuguese in wheezing-related 
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questions. Additionally, the presence of wheezing was not mandatory in our definition of 
current asthma. Therefore, we presented estimates using different combinations of asthma 
proxies (Table 7). The definition we chose includes the less frequent nocturnal symptom, 
‘waking with breathlessness’; the term ‘asthma attack’ to improve specificity; and ‘asthma 
medication’, because children with asthma may not experience symptoms when controlled 
with medication, and medication is a known valid proxy for asthma prevalence 119,120. By 
using several definitions of asthma used in different studies, our prevalence estimates varied 
from 6.4% (lifetime asthma plus wheezing in the last year) and 9.1% (lifetime asthma plus any 
asthma-like symptom in the last year or current asthma medication). These differences 
highlight the importance of setting standardized definitions to allow for comparisons 
between studies. 
Our estimate of lifetime asthma was based on the same question of ISAAC. Our estimate in 
the 6- to 12-year-old group (12.3%) was higher than that in the 6- to 7-year-old group in the 
Portuguese ISAAC survey (9.8%) 27, while our estimate for the 13- to 17-year-old group (13.9%) 
was similar to that in the 13- to 14-year-old group in the ISAAC survey (13.8%). In preschoolers, 
two recent Portuguese studies had also reported estimates of physician asthma diagnosis 
similar to ours: 4.6% in both studies 43,118. 
Schmitz et al. 44 reported a 4.7% prevalence of a doctor-diagnosed lifetime asthma in the 
German population of 0- to 17-year-old using data from the 2003-2006 German Health 
Interview and Examination Survey for Children and Adolescents (KiGGS). This prevalence 
was much lower than ours and is in agreement with the estimated prevalence of lifetime 
asthma among German children reported in the ISAAC, which was also much lower than 
that in Portugal (in Germany, 4.3% in 6- to 7-year-old children and 7.5% in 13- to 14-year-old 
children) 25. Data from the 2010 United States National Health Interview Survey for children 
under the age of 18 years reported an estimated doctor-diagnosed lifetime asthma 
prevalence of 13.6% and current asthma prevalence of 9.5% 45,46, which were similar to our 
estimations. 
There was an expected higher prevalence of current asthma in children with allergic rhinitis 
(OR 5.15) or eczema (OR 4.08). The impact of allergic rhinitis on asthma has long been 
recognized, 121 and a recent Portuguese study had also report an association between 
wheezing and rhinitis in pre-schoolers (OR 4.0)26. In a German study, similar results on rhinitis 
were found in school-aged children and adolescents (OR 4.51 and 5.99, respectively), but 
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the association with atopic dermatitis seemed to be lower (OR 1.30 and 1.50, in school-aged 
children and adolescents, respectively); however, methodology on data collection could 
have hampered these results, namely on the diagnosis of atopic dermatitis (ICD-10 diagnosis 
recorded in computer systems used in the practices of resident physicians)122. 
We found no significant differences in asthma prevalence between regions, municipality 
(urban vs. rural) or exposure to environmental tobacco smoke. Higher prevalence of 
childhood asthma is reported in the literature 123,124,  and causes for a this higher prevalence 
are discussed 125. However other works also found no significant differences between 
municipality areas 126. Differences in definition of rural and urban areas may play a role in 
the outcomes 127, as the degree of urbanisation / density of population can be related to 
these differences 128. In our studies, municipality was defined based on Portuguese 
legislation 97; thought this definition may not clearly differentiate rural and urban 
environments in Portugal. In what concerns environmental tobacco smoke, question on 
household exposure for tobacco may not be sufficient to identify differences in current 
asthma/asthma-like symptoms prevalence, as there are several forms of environmental 
tobacco smoke inside and outside households. 
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5.4 Diagnostic tests and medication use in childhood asthma 
In spite of the recommendations to perform spirometry as part of asthma management 6, 
only about half of the Portuguese children with current asthma at or over the age of  6 years 
had undergone PFT. Similarly, fewer than half of Portuguese children with current asthma 
had used inhaled controller medications within the previous 12 months, even considering a 
current asthma definition based on several symptoms occurring in the last 12 months, like 
the one used in our study. Moreover, those who only used reliever inhaled medication in the 
previous year, without any controller inhalers, were twice as likely to have experienced an 
asthma attack in the same time period. Similar results were found in Canada where only 
45% of children with asthma used inhalers on a regular basis 129. In Denmark, Moth et al 
showed that children who performed PFT and those medicated with controller medication 
experienced less hospitalisations 130. Our results in this domain of diagnostic tests and 
medication use are worrisome and shows how the burden of childhood asthma could be 
affected by these factors. 
As told previously, no differences in the prevalence of asthma or asthma-like symptoms were 
found between urban and rural municipalities; however, children living in rural areas were 
much less likely to have undergone PFT or allergy tests or used inhaled medication. In 
agreement with our data, a Greek study with school-aged children also showed that the 
prevalence of asthma diagnosis was the same between rural and urban areas despite 
findings on the narrowing of small airways in urban environments 131. Disparities in health care 
for rural-dwelling patients with asthma have been reported, indicating that those with 
asthma who live in rural areas receive substandard care for asthma; however, there are 
limited direct data on these findings 132. Taken together, our results and those of previous 
studies on diagnostic tests and medication use may be related to differences in healthcare 
access and may suggest substandard asthma care in Portuguese children, especially in less 
urbanized areas. 
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5.5 Healthcare services use in childhood asthma 
To the best of our knowledge, there are no nationwide Portuguese data on prevalence of 
healthcare medical visits because of asthma in childhood. Our results showed high 
proportion of scheduled medical visits (86%) in the previous 12 months; however, one-fourth 
had also had unscheduled medical visits because of asthma, 40% had emergency visits and 
5% were hospitalised. Interestingly, we observed a significant progressive decrease of overall 
asthma medical visits, in the older age groups. In USA, Kattan et al reported proportions of 
healthcare utilization in the previous year, in 1997: unscheduled/emergency medical visits 
(65%) and hospitalisation (17%) 58. These results were higher than ours, but we must 
acknowledge that this study was done in 90’s and the recruitment was made in emergency 
department and clinics, incurring in selection bias with possible overrepresentation of 
severer cases of asthma. A more recent study (2007), from National USA databases, had 
reported healthcare services utilization rates per 100 children with asthma: total ambulatory 
visits (87.2), emergency visits (9,9) and hospitalisations (1.6) 29. Differences to our results may 
be related with healthcare access differences between Portugal and the USA, as well as 
follow-up strategies of acute asthma in outpatient clinic vs. emergency department. 
We found a high number of hospitalisations for asthma throughout childhood, with more 
than 55,000 Portuguese children aged 6 to 17 years hospitalised for asthma during their 
lifetime. Moreover, of the children with current asthma more than one third had been 
hospitalised for asthma ever in life. We observed a trend towards a higher proportion of 
hospitalisations among children from lower socioeconomic status. This is a high number of 
hospitalisations, especially among the youngers, and more studies with comparable data 
from other countries and settings are needed. Surprisingly, this measure of societal burden 
of pediatric asthma has never been described for any pediatric population. Our results 
should contribute to improve knowledge on asthma-related hospitalisations in children, 
leading to the development of healthcare programs aiming to reduce their frequency. 
These results on lifetime hospitalisations is limited by the lack of diagnosis/lifetime 
hospitalisations confirmation by physician, as other epidemiological studies. So, we 
excluded participants aged 0 to 5 years from the analysis to avoid misclassification of 
hospital admissions for bronchiolitis and/or viral-induced wheezing. To our knowledge, only 
one other study reported the prevalence of lifetime hospitalisations in children 133; however, 
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it included only children aged 6 to 7 years from one Italian city, and the proportion on 
children with asthma that had lifetime hospitalisations was not reported. 
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5.6 Asthma control in children 
High frequency of not controlled asthma 
The proportion of Portuguese children with controlled asthma (51%) was similar to that found 
in  6- to 17-year-old children in the USA (46%) 66, in Dutch 6- to 16-year-old children (55%)68 or 
in French pre-schoolers (42%) 67; however, estimates on the prevalence of uncontrolled 
asthma in children are highly variable (15-90%) depending on the studies 52,63. In our report, 
only half of the children that were considered controlled by their caregivers had, in fact, 
controlled asthma. Carroll et al have shown that parents usually overestimate asthma 
control 134. Others reported a poorer asthma control 68, or medication underuse among 
parents that failed to correctly estimate control 64. 
The prevalence of nasal symptoms in children with current asthma (79%) was similar to that 
found in Dutch asthmatic aged 5- to 18-years-old (76%) 69. Despite the majority of our 
children with asthma having nasal symptoms, less than half of these (45%) reported a past 
medical diagnosis of rhinitis. Underdiagnosis and undertreatment of rhinitis in asthmatic 
children was associated with lack of parental recognition and poorer asthma control.73,74 
In our study, the increasing number of nasal symptoms was associated with a decrease in 
asthma control (Figure 8). We could not find previous papers assessing the association of 
the cumulative number of nasal symptoms with the lack of asthma control in children, 
nevertheless, previous studies supported a strong link between upper and lower airway 
disease 26,72. 
Worse asthma control in children with obesity, nasal symptoms and absence 
of health insurance 
Determinants for not controlled asthma were the presence of substantial nasal symptoms, 
overweight/obesity and not having health insurance (Table 14). Rhinitis is a known co-
morbidity associated with poorer asthma control in children, especially in those with 
untreated nasal symptoms.69 Our results are in line with these findings, as substantial nasal 
symptoms were associated to a six-fold higher probability of NCA. Recently published data 
also showed that increased BMI was associated to more asthma symptoms, activity 
limitation 135, lack of asthma control 63, higher use of inhaled β-agonists or oral corticosteroids 
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70, and to worst asthma control in children with higher airway inflammation 75. In our study, 
overweight/obesity was associated with a three-fold higher probability of NCA. 
As explained previously in Introduction, the Portuguese Health System is a mixed universal 
healthcare system. It is financed by taxes and by health insurances, both private and public 
(for state employees), complemented by out-of-pocket expenses. All Portuguese citizens 
have access to medical care services in public primary care and hospital units. The public 
care access is primarily based on visits to primary care physician that can refer to hospital 
specialities; this is limited by the waiting time and referral geographical areas that prevent 
the patients from fully choosing the place where they will be followed. Private 
practices/hospitals access is only dependent on patient will to attend these institutions; 
however, due to significant out-of-pocket expenses, access is easier for those with 
complementary health insurance coverage. In fact, citizens with healthcare insurance, 
regardless of the socioeconomic status, may easily choose the site of medical care that 
they perceive as the best, with easier access to medical specialities and lower waiting time 
for medical observations. Regarding medication, prices are the same for every Portuguese 
child, independently of health insurance status. 
In our model, not having health insurance was associated with a three-fold higher 
probability of NCA. Also, on exploratory univariate analysis, the frequency of children with 
health insurance coverage followed in private practice/hospital for their asthma was 
significantly higher than those followed in public settings (p<0.001; Table 18). Taking these 
results altogether, we may speculate that these relations between asthma control and 
health insurance status may address differences in types of asthma care that can be 
influenced by parents’ options in choosing the site of medical asthma care for their children 
(either public or private providers). 
Healthcare visits and medication use differences in asthma control 
We showed a trend towards more healthcare visits and medication use in children with 
NCA. Previous studies had already shown the association between healthcare visits and/or 
medication with uncontrolled asthma 52,53. Children with NCA used more antihistamines and 
cough medication than those with WCA; this association of NCA with a higher use of over-
the-counter medication was already observed in asthma patients 136, and it may point to a 
worse asthma care plan in children with NCA. 
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Unscheduled medical visits for asthma worsening/exacerbation were more frequent in 
children with substantial nasal symptoms and without health insurance, and less frequent in 
adolescents. This model on urgent medical care, which was also used as a proxy for poor 
asthma control, corroborates that uninsured children, as well as those with substantial nasal 
symptoms, were at a higher risk of uncontrolled asthma and use of urgent medical care. 
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5.7 Cost of childhood asthma 
Health economics studies are needed to support local decision-makers in defining priorities 
for public health programs 87. As governmental health policies become more cost-aware, it 
is important to know where is possible to act in order to reduce costs while maintaining or 
enhancing healthcare quality. In Portugal, health-related costs represented 9,9% of the 
gross domestic product in 2010 88, highlighting the importance of being cautious with 
healthcare resource allocation. As one of the most common chronic diseases in childhood, 
asthma should have good economic data available. Many economic studies were 
conducted in asthma all-over the world with different methodologies, different variables, 
and different age ranges. However, there are few population-based and comprehensive 
pediatric studies 55. 
We conducted a cost-of-illness analysis on Portuguese childhood asthma, with a 
prevalence-based, societal perspective, that allowed a broad economic analysis of the 
disease. We adopted a societal perspective, the most comprehensive approach, because 
it uses the direct and indirect costs for all members of the society 137. From a societal 
perspective, the childhood asthma in Portugal costs over €150 million per year, 
corresponding to more than €900 per child with CA. Childhood asthma costs correspond to 
0.91% of the Portuguese expenses in health in 2010. These expenditures are undertaken 
together by the patients, by the Portuguese state and by health insurance companies, 
depending on the type of healthcare services used. Direct costs were 3/4 of the costs, with 
the most being related to healthcare services use and specially to acute asthma care. The 
most important factors for higher costs were uncontrolled asthma (2.3-fold) and asthma 
attacks in the previous 12 months (1.6-fold). 
Total, direct and indirect costs of childhood asthma 
The cost estimates for childhood asthma in Portugal were slightly lower than the Spanish 
estimates in 2008 (€1,149 child/year) 91. Otherwise, USA estimates for 2008 prices of 5- to 17-
years old asthmatics were lower than ours: $791 child/year (direct costs, $401 child/year; 
indirect costs, $390 child/year) 138. In that study, the authors analysed data from the 1996 
Medical Expenditure Panel Survey and the type of asthma-related expenditures used in 
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direct costs were not clear. In Turkey, a study performed in 2006, in pediatric allergy and 
asthma referral centres, reported medical and non-medical costs of $1,597 per child/year 
(medical, $775; non-medical, $821), however, no formal indirect costs were reported 139. The 
definition of medical costs was similar to our definition of direct costs, and the results were 
also similar (assuming 1.23 exchange rate of dollar to euro, in 2006). Non-medical costs 
included transportation (not absenteeism), but were mainly driven by non-allergic 
household measures ($710) like air filters, special vacuum cleaners or anti-allergic bed 
covers, that we did not assess in our study, as the current guidelines do not recommend 
them 6. 
Direct costs were the majority of costs in our study (75% of total costs), especially healthcare 
services use (51% of total costs). Previously published studies reported proportions of direct 
costs between 61-88% 55. Healthcare services use in the context of asthma worsening (non-
scheduled medical visits, emergency and hospitalisations) were, altogether, 30% of the total 
costs of childhood asthma in Portugal. Reducing acute asthma care costs, should be one 
of the major targets for potential savings. Also, by reducing it other domains (e. g., indirect 
costs) could also be lowered. 
Indirect costs were one-fourth of the costs in childhood asthma. Other studies showed that 
indirect costs can be as high as 50% 55. The lack of assessment of costs related to 
presenteeism and lower salaries in Portugal may justify our proportion of indirect costs. 
Nevertheless, more than 13 million euros were spent yearly with parental absenteeism 
because of childhood asthma. This value can represent a potential higher burden to 
society, as loss of parental work can further impact the overall economy. 
Determinants of cost variation in childhood asthma 
The most important determinants for higher costs were the asthma attacks in the previous 
12 months (1.6-fold) and having uncontrolled asthma (2.3-fold). This reinforce the need for 
a higher control in asthmatic children, in order to reduce the associated costs. Also in the 
Spanish study, costs variations within each category of asthma severity ranged from €403 
for mild asthma to €5.930 for severe asthma (costs child/year) 91. 
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Direct costs were significantly higher in children with uncontrolled asthma, specifically 
healthcare services use and diagnostic test use. Interestingly, there were no significant 
differences in costs of scheduled medical visits and treatment for controlled vs. uncontrolled 
children. The domains with the higher cost raises from children with controlled vs. 
uncontrolled asthma were ‘non-scheduled visits’ (€45 to €152 child/year) and, mostly, 
‘emergency department visits’ (€67 to €370 child/year) and ‘hospitalisations’ (€27 to €426 
child/year) (Table 25). Indirect costs were also higher in uncontrolled asthmatics, although 
without a significant increase; absenteeism seems to be similar in the different levels of 
asthma control. 
Considering a hypothetic scenario (data not shown) in which all Portuguese children with 
asthma were controlled, the savings would be more than 30,000,000 € per year (20% 
reduction). As previously reported, children with not controlled asthma had significantly 
more unscheduled medical visits and hospitalisations 103,140; knowing that uncontrolled 
asthma is, also, the major determinant for higher costs, effective policies should be directed 
to improve asthma control and reduce acute care medical visits. 
 
  
138 | Burden of childhood asthma in Portugal 
5.8 Future directions 
In children, epidemiological asthma definitions and clinical asthma phenotypes are 
primarily based upon wheezing 31. However, Skytt et al. 33, based on data from the 
Copenhagen Prospective Study on Asthma in Childhood, addressed the lack of validity of 
wheezing for asthma diagnosis in children aged 0 to 3 years. They argued for a global 
description of asthma symptoms to reduce the risk of misclassification of asthma in children. 
We suggest that questionnaires directed at children and adolescents should include 
different measures to comprehensively assess asthma characteristics (previous diagnosis, 
several symptoms, and medication), thus aiming to obtain precise estimates of asthma 
prevalence, especially in younger children. In any case, standardization of epidemiologic 
asthma definitions and their clinical validation are needed 22. 
Also, it is important to create awareness to the importance of a good asthma control in 
children. The lack of control was, definitely, the major driver of high burden in childhood 
asthma. If the proportion of good asthma control increased, one can speculate that it will 
decrease the burden of this disease by lowering all the adverse outcomes. Good asthma 
control is associated to lower healthcare services use because of asthma worsening. Also, 
healthcare services use is the domain with the highest increase in costs in children with 
uncontrolled asthma. Previous studies have reported economic savings with outreach 
asthma programs for children 141, however, cost-effectiveness studies on asthma 
interventions directed to improving control and reducing costs will be of major interest for 
patients, parents, healthcare providers and policy-makers. 
Future studies should be designed to have multinational cost-of-illness data, aiming to 
understand differences between asthma care and to compare outcomes. Quality-of-life 
assessment in childhood asthma should also be improved and be part of a burden of 
disease analysis. A nationwide quality-of-life study on childhood asthma should be designed 
to assess the social impact of this disease. This type of approach will further characterize the 
disease burden in Portugal, helping in defining policies in local healthcare services or 
schools. 
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6. CONCLUSION  
This PhD thesis brought comprehensive estimates on the burden of childhood asthma in 
Portugal. 
Current asthma affects 8.4% of Portuguese children (173,681 Portuguese children with 
asthma) and 11.2% had lifetime asthma. Different asthma definitions lead to different 
prevalence estimates (from 6.3% to 9.1%). Our results showed that only half of children with 
current asthma had ever undergone pulmonary function tests and that management has 
been substandard, mainly in rural areas. Also, more than half of the children with current 
asthma did not use controller inhalers, and those who only used reliever inhalers reported 
more asthma attacks. 
Children with asthma had a high proportion of scheduled medical visits (86%) in the previous 
12 months. However, one-fourth had also unscheduled medical visits because of asthma, 
40% had emergency visits and 5% were hospitalised. Children with lack of asthma control 
had more unscheduled medical visits and hospitalisations. For the first time, it was described 
the proportion of asthmatic children hospitalised because of asthma, at least once, in their 
life: more than one third of Portuguese children with current asthma were hospitalised during 
their childhood. Our results should contribute to improve knowledge on asthma-related 
hospitalisations in children, leading to the development of healthcare programs aiming to 
reduce their frequency. 
The abovementioned facts can contribute, to the lack of control observed in half of the 
Portuguese children with asthma. Nasal symptoms and obesity were found to be important 
determinants of asthma control. Also, children without health insurance (private or state 
owned) are at greater risk of poor asthma outcomes; this association was not previously 
reported in a European country. 
The high clinical and healthcare burden of childhood asthma is reflected in the associated 
costs. The total cost estimate of childhood asthma corresponds to 0.91 % of the Portuguese 
expenses in health in 2010. The childhood asthma in Portugal costs €161,410,007 per year, 
corresponding to €929.35 per child with current asthma. Direct costs were the majority of 
costs (75% of total costs), especially healthcare services use (51% of total costs). The most 
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important factors for higher costs are asthma attacks in the previous 12 months (1.6-fold) 
and uncontrolled asthma (2.3-fold). 
The lack of control was the major driver of the high burden of childhood asthma. A poor 
asthma control in children was associated with: 1) more asthma-like symptoms, 2) more 
nasal symptoms, 3) more healthcare services use, 4) more asthma medication use, and 5) 
higher costs for the society.  
The burden of childhood asthma in Portugal is high and, altogether, these findings point 
towards the need for a better asthma control in Portuguese children to reduce the burden 
of childhood asthma for families, healthcare system and society in general. Policymakers, 
clinicians and the ones responsible for children’s care should define priorities and implement 
procedures towards the achievement of a better asthma control and reduction in the need 
of acute asthma care, aiming to reduce the high burden of this disease in Portugal. 
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8.1 PhD Tasks 
1) PhD Planning and Setup 
Dates: January 2012 - October 2015 
Work completed: 
a) Regular meetings with supervisor and co-supervisor; 
b) Definition of PhD project tasks; 
c) Strategies of dissemination of results; 
d) Presentation of PhD project in a scientific meeting (PhD output 7); 
e) Progression report of PhD project. 
 
 
 
2) Bibliographic review 
Dates: January 2012 - December 2012 
Work completed: 
a) Bibliographic review of relevant published evidence in children focused on: 
i. Asthma-like symptoms 
ii. Asthma prevalence 
iii. Asthma control 
iv. Asthma medication use 
v. Healthcare services use for asthma 
vi. Burden of asthma 
vii. Cost of asthma 
 
 
 
3a) INAsma Study: Analysis of pediatric-specific data 
Dates: May 2012 - April 2013 
Work completed: 
a) Estimates on asthma-like symptoms prevalence; 
b) Estimates on asthma prevalence; 
c) Estimates on use of asthma medication; 
d) Estimates on healthcare services use for asthma; 
e) Estimates on level of asthma control; 
f) Determinants of asthma control. 
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3b) INAsma Study: Dissemination of pediatric-specific results 
Dates: May 2013 - June 2015 
Work completed: 
a) Presentation of preliminary results of INAsma Study in congresses (PhD output 5 
and 6); 
b) Writing of manuscript drafts; 
c) Publication of PhD output 2; 
d) Publication of PhD output 3; 
e) Publication of PhD output 1. 
 
Work to be completed: 
a) Dissemination (paper publication) of the results within the aims of CASCA 
project (in submission). 
 
 
4a) CED2013 Study: Setup 
Dates: January 2013 - March 2014 
Work completed: 
a) Meetings with the researchers team of CED2013 Study; 
b) Completion of the final questionnaire; 
c) Completion of standard operational procedures; 
d) Submission to the Ethical Committee of University of Porto; 
e) Submission to Comissão Nacional de Proteção de Dados; 
f) Randomization of participants; 
g) Preparation of data collection of phase 1 and 2; 
h) Hiring of one researcher collaborator. 
 
 
4b) CED2013 Study: Data collection 
Dates: November 2013 - June 2014 
Work completed: 
a) Data collection of phase 1; 
b) Data collection of phase 2. 
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4c) CED2013 Study: Data analysis and Dissemination 
Dates: July 2014 - October 2015 
Work completed: 
a) Organisation of database; 
b) Preliminary analysis; 
c) Public presentation of preliminary results (PhD outputs 8, 9 and 10); 
d) Elaboration of an individual report of pulmonary function tests for each child 
assessed. 
 
Work to be completed: 
b) Dissemination (paper publication) of the results within the aims of CASCA 
project (in submission). 
 
 
5a) CASCA Project: Setup 
Dates: May 2012 – December 2013 
Work completed: 
a) Meetings with the researchers’ team of CASCA Project; 
b) Definition of study methodology; 
c) Definition of relevant direct and indirect costs; 
d) Submission to Gulbenkian Foundation Grant; 
e) Elaboration of CASCA project website. 
 
 
5b) CASCA Project: Data collection of secondary data 
Dates: July 2014 - December 2015 
Work completed: 
a) Data collection of ICAR; 
b) Data collection of CED2013; 
c) Asthma hospitalisations from databases from ACSS; 
d) Medication names, brands, doses and process from Infomed®; 
e) Professional activities classification and salaries from INE; 
f) Organisation of databases. 
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5c) CASCA Project: Data analysis and Dissemination 
Dates: January 2015 - December 2015 
Work completed: 
a) Cost-of-illness analysis of asthma in Portuguese children (PhD output 4); 
b) Public presentation of preliminary results (PhD output 9 and 10). 
 
Work to be completed: 
a) Dissemination (paper publication) of the results within the aims of CASCA 
project (in submission). 
 
 
6) PhD thesis completion 
Dates: January 2016 – July 2017 
Work completed: 
a) Draft of the final thesis of PhD; 
 
Work to be completed: 
a) Public presentation and discussion of PhD thesis. 
 
  
 Appendices I PhD Tasks | 161 
 
  
162 | Burden of childhood asthma in Portugal 
 
 
 Appendices I PhD Outputs | 163 
 
8.2 PhD Outputs 
PEER-REVIEW SCIENTIFIC PUBLICATIONS 
1 
“Asthma-like symptoms, diagnostic tests and asthma medication use in children and 
adolescents: a population-based nationwide survey” 
Full-paper published in Journal of Asthma [Impact factor 1.85 from JCR®, ISI WoS; 75th 
percentile of ‘Respiratory System’(journal n. 39th/58)] 
 
Ferreira-Magalhães M, Sá-Sousa A, Morais-Almeida M, Pité H, Azevedo LF, Azevedo I, Bugalho-
Almeida A, Fonseca JA. Asthma-like symptoms, diagnostic tests, and asthma medication use 
in children and adolescents: a population-based nationwide survey. J Asthma 2016; 53:269-
276. 
 
 
2 
“High prevalence of hospitalisation for asthma in a population-based paediatric sample” 
Original research letter published in Archives of Disease in Childhood [Impact factor 1.85 
from JCR®, ISI WoS; 15th percentile of ‘Pediatrics’ (journal n. 13th/120)] 
 
Ferreira-Magalhães M, Sá-Sousa A, Morais-Almeida M, Azevedo LF, Azevedo I, Pereira AM, 
Fonseca JA. High prevalence of hospitalisation for asthma in a population-based paediatric 
sample. Arch Dis Child 2015; 100:507–508. 
 
3 
“Asthma control in children is associated with nasal symptoms, obesity and health 
insurance: a nationwide survey” 
Full-paper published in Pediatric Allergy and Immunology [Impact factor 3.95 from JCR®, 
ISI WoS; 5th percentile of ‘Pediatrics’ (journal n. 5th/120)] 
 
Ferreira-Magalhães M, Pereira AM, Sá-Sousa A, Morais-Almeida M, Azevedo I, Azevedo LF, 
Fonseca JA. Asthma control in children is associated with nasal symptoms, obesity and health 
insurance: a nationwide survey. Pediatr Allergy Immunol 2015; 26(5):466-473. 
 
4 
“Cost of asthma in children: a nationwide, population-based, cost-of-illness study” 
Full-paper submitted 
 
Ferreira-Magalhães M, Amaral R, Pereira AM, Sá-Sousa A, Azevedo I, Azevedo LF, Fonseca JA. 
Cost of asthma in children: a nationwide, population-based, cost-of-illness study. 
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ORAL PRESENTATIONS AND POSTERS 
5 
“Prevalence and control of current asthma in Portuguese paediatric population” 
Poster presented at European Respiratory Society Congress, Amsterdam 2011 
Abstract published in European Respiratory Journal [7.13] 
Ferreira-Magalhães M, Sa-Sousa A, Morais-Almeida M, Azevedo L, Bugalho-Almeida A, 
Fonseca JA. Prevalence and control of current asthma in Portuguese paediatric population. 
Eur Resp J 2011: 38(55); 781S(p4254). 
 
6 
“Prevalência e controlo da asma na população pediátrica Portuguesa – Inquérito 
Nacional da Asma” 
Oral presentation at Congresso Nacional de Pediatria, Albufeira, 2011 
Abstract published in Acta Pediátrica Portuguesa 
Ferreira-Magalhães M, Sá-Sousa A, Morais-Almeida A, Azevedo LF, Bugalho-Almeida A, 
Fonseca JA. Prevalência e controlo de asma na população pediátrica portuguesa – Inquérito 
Nacional da Asma. Acta Pediatr Portuguesa 2011; 42(5):S21 (Sup. I). 
 
7 
“Diagnóstico, controlo e impacto da asma na criança” 
Oral presentation at Encontro Hispano-Luso de Internos de Pediatria, 2012 
 
8 
“Asma em crianças Vimaranenses do 1º ciclo: sintomas, medicação e utilização 
de serviços de saúde” 
Oral presentation at 35º Reunião Anual da Sociedade Portuguesa de Alergologia e 
Imunologia Clínica, Porto, 2014 
Ferreira-Magalhães M, Amaral R, Guimarães J, Moreira A, Vaz R, Moreira P, Fonseca J. Asma 
em crianças Vimaranenses do 1º ciclo: sintomas, medicação e utilização de serviços de 
saúde. Revista Portuguesa de Imunoalergologia 2014;XXII:18. 
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DISSEMINATION ACTIVITIES TO THE COMMUNITY 
9 
“Asma em crianças Vimaranenses do 1º ciclo: sintomas, medicação e utilização de 
serviços de saúde” 
Public open session in school for presentation of the results from the study performed in 
partnership with the European Capital of Sports 2013 (Guimarães - CED2013), Guimarães, 
2015 
 
10 
“Asma tira milhares de crianças à escola” 
Newspaper article published in Diário do Minho on 7th of May of 2015. 
 
11 
“Custo da asma na criança em Portugal” 
Press release on Worldwide Asthma Day 2016 about the preliminary results from cost of 
illness study of childhood asthma in Portugal. 
Several news were disseminated by newspaper (e.g. Publico, Diário de Notícias, Jornal 
de Notícias) and televisions (RTP). 
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8.3 Awards / Distinctions 
1 
2nd place for the best oral presentation of the session, SPAIC 2015 
The oral presentation “Asma em crianças Vimaranenses do 1º ciclo: sintomas, 
medicação e utilização de serviços de saúde” presented at the 35º Reunião Anual da 
Sociedade Portuguesa de Alergologia e Imunologia Clínica won the 2nd place for the 
best oral presentation of the session.  
 
 
2 
Editor’s Choice Series, Pediatric Allergy and Immunology, August 2015 
The PhD output 3 (Ferreira-Magalhães M, Pereira AM, Sá-Sousa A, Morais-Almeida M, 
Azevedo I, Azevedo LF, Fonseca JA. Asthma control in children is associated with nasal 
symptoms, obesity and health insurance: a nationwide survey. Pediatr Allergy Immunol 
2015) was selected to the “Editor’s Choice Series” of the August 2015 issue of Pediatric 
Allergy and Immunology Journal. 
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8.4 Published papers 
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Asthma-like symptoms, diagnostic tests, and asthma medication use in
children and adolescents: a population-based nationwide survey
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Abstract
Objective: This study aimed to estimate the prevalence of asthma-like symptoms, current
asthma (CA), asthma diagnostic tests, and inhaled medication use in a nationwide pediatric
population (518 years). Methods: Pediatric-specific data from a cross-sectional, population-
based telephone survey (INAsma study) in Portugal were analyzed. CA was defined as lifetime
asthma and (1) wheezing, (2) waking with breathlessness, or (3) asthma attack in the previous
12 months, and/or (4) taking asthma medication at the time of the interview. Results: In total,
716 children were included. The prevalence of asthma-like symptoms was 39.4% [95%
confidence interval (95% CI): 35.7–43.3]. The most common symptoms were waking with cough
(30.9%) and wheezing (19.1%). The prevalence of CA was 8.4% (95% CI: 6.6–10.7). Among
children with CA, 79.9% and 52.9% reported prior allergy testing and pulmonary function
testing (PFT), respectively. Inhaled medication use in the previous 12 months was reported by
67.6% (reliever inhalers, 40.1%; controller inhalers, 41.5%). Those who only used inhaled reliever
medications experienced more asthma attacks [odds ratio (OR): 2.69]. Significantly fewer
children with CA living in rural areas than those living in urban areas had undergone PFT or
used inhaled medication (OR: 0.06 for PFT, 0.20 for medication]. Conclusions: The prevalence of
CA in the Portuguese pediatric population was 8.4%. Only half of children with CA had ever
undergone PFT; more than half did not use controller inhalers, and those who only used
reliever inhalers reported more asthma attacks. These findings suggest that asthma
management has been substandard, mainly in rural areas.
Keywords
Cough, epidemiology, pediatrics, prevalence,
respiratory function tests, treatment,
wheezing
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Introduction
Asthma is one of the most common chronic diseases in
children [1]. According to the Global Initiative for Asthma,
asthma is a heterogeneous disease characterized by variable
symptoms [2]. Composite measures to define asthma are
increasingly necessary to obtain more accurate epidemio-
logical prevalence estimates [3], and population-based studies
are important for the assessment of these estimates [4].
The results of the 20-year International Study of Asthma
and Allergies in Childhood (ISAAC) have changed our
knowledge about the worldwide prevalence of asthma and
related symptoms [5]. The ISAAC included some Portuguese
cities [6], but neither the ISAAC nor other studies estimated
the prevalence of asthma across all pediatric ages (518 years)
or among a representative nationwide sample in Portugal
[7–10]. In fact, to the best of our knowledge, very few studies
have estimated the prevalence of asthma in this age range
using nationwide samples [11–13]. Moreover, different
asthma definitions are presented in the literature, making it
difficult to accurately compare estimates between studies
[3,14]. The patterns of asthma-like symptoms may also differ
among various pediatric ages. However, no data have been
published on the prevalence of specific asthma symptoms,
other than wheezing, in all pediatric ages.
A diagnosis of asthma is based on symptoms and
confirmation of variable expiratory flow limitation, making
pulmonary function testing (PFT) an important tool. A
Correspondence: Joa˜o Almeida Fonseca, MD, PhD, CINTESIS – Center
for Health Technology and Services Research, Centro de Investigac¸a˜o
Me´dica, Faculdade de Medicina da Universidade do Porto, Edifı´cio
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stepwise approach for asthma management takes the previous
two features and medication, primarily inhaler use, into
account [2]. Epidemiological assessment of asthma should
also focus on data from the above-mentioned asthma features
closely linked to diagnosis and management.
In 2010, we conducted the First Portuguese National
Asthma Survey (INAsma) [15]. In the present paper, we focus
on the results obtained from the INAsma pediatric population.
Specifically, our primary aim was to estimate the prevalence
of asthma-like symptoms and current asthma (CA) in the
Portuguese pediatric population (518 years). Our secondary
aims were to describe the differences in CA prevalence
estimates according to different definitions to allow for
comparisons with other studies and to assess the proportion of
the use of diagnostic tests and inhaled medication among
children with CA.
Materials and methods
Study design and participants
The INAsma was a population-based, nationwide, cross-
sectional survey applied by telephone interview in Portugal in
2010. The study methodology has been previously described
[15,16]. The INAsma target population was the Portuguese
general population, and the available population included
citizens of all ages living in households with a landline
telephone. A cluster sampling design was used to obtain a
representative sample of the population (detailed in the
Supplementary file). Briefly, all municipalities were used as
natural strata, and a sample of households was then selected
with a probability proportional to the municipality population
as estimated in the 2001 National Census. Households were
randomly selected from the 2010 residential White Pages
telephone directory. Four different lists of telephone numbers
were randomly selected for each municipality to allow for
substitution of nonresidential telephone numbers. In total,
24 412 telephone numbers were retrieved. One participant
(the last person to have had a birthday) was randomly selected
from each household. In this study, we considered all included
individuals aged 518 years (henceforth referred to as
‘‘children’’ for simplification).
This study was reviewed and approved by the Ethics
Committee of Centro Hospitalar de Sa˜o Joa˜o, Porto, Portugal.
Informed consent was obtained from the parent(s) or legal
guardian(s) of the children included in this study. We
followed the STROBE statement for reporting observational
studies [17].
Instruments and data collection
The instrument for data collection was the Portuguese version
of the questionnaire used in the GA2LEN survey, which
includes the European Community Respiratory Health Survey
questions on asthma symptoms [18]. Several questions were
added regarding socio-educational variables, medications, and
diagnostic test use for asthma. Data were collected by
computer-assisted telephone interviews from March to May
2010. Selected participants directly answered the question-
naire. However, in accordance with Portuguese legislation,
when the selected individual was younger than 15 years old,
the respondent was the usual and most knowledgeable
caregiver. To minimize potential bias in data collection,
several quality-assurance measures were followed
(Supplementary file) [15].
Variables
Asthma definition variables were defined based on previous
studies [3,5]. The outcomes were defined as follows: Lifetime
asthma (LA): positive answer to ‘‘Have you ever had
asthma?’’; CA: LA plus at least one of the following four
features: (1) wheezing, (2) waking with breathlessness,
(3) having an asthma attack in the last 12 months, or
(4) taking asthma medication at the time of the interview;
Nocturnal symptoms: at least one of the three symptoms in the
last 12 months: waking with breathlessness, waking with
chest tightness, or waking with coughing; Asthma-like
symptoms: at least one of the three symptoms in the last 12
months: wheezing, nocturnal symptoms, or asthma attacks
(wheezing was further described as wheezing with breath-
lessness or wheezing without a cold); PFT: positive answer to
‘‘Have you ever undergone any test to assess your lung
function?’’; Skin prick tests: positive answer to ‘‘Have you
ever undergone any skin test to assess your allergies?’’; Blood
allergy tests: positive answer to ‘‘Have you ever undergone
any blood test to assess your allergies?’’; Any asthma
medication at present: positive answer to ‘‘Are you currently
taking medication (inhaled, nebulized, or oral) for asthma/
breathlessness?’’; Inhaled therapy in the last 12 months:
positive answer to ‘‘In the last 12 months, did you take any
inhaled medication for asthma/breathlessness?’’ Further char-
acterization of inhaled treatment was based on auto-reported
medication: Allergic rhinitis: Positive answer to ‘‘Do you
have any nasal allergies, including hay fever?’’; Atopic
dermatitis/eczema: Positive answer to ‘‘Have you ever had
eczema or skin allergy?’’; Food allergy: Positive answer to
‘‘Have you been diagnosed with food allergy by a doctor?’’;
and Environmental tobacco smoke: Positive answer to ‘‘Does
anyone smoke inside your home?’’. Municipality was classi-
fied as urban if the residence was located in a municipality
with at least one city (cities must have at least 8000 citizens),
according to Portuguese legislation.
Sample size and statistical analysis
The study sample size was calculated for the total Portuguese
population and took into account the two phases of the
INAsma project [15]. Thus, for the general all-age population,
we estimated an a priori asthma prevalence of 6% and a
proportion of controlled asthma of 20%. Assuming a 20% loss
to follow-up, at least 665 patients with asthma were required.
Within these premises, and assuming a margin of error of
0.65%, our study required a sample of at least 6000 persons
from the general Portuguese population willing to participate
in the first phase of the INAsma. The inclusion of 716
children allowed us to estimate CA prevalence with an error
margin of 0.02 and a 95% confidence level.
The sample estimates were weighted according to the 2001
National Census aiming for generalization to the target
population [19]. A sequential simple random sampling
method without replacement was used to select a random
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sample of households with a landline telephone within each
stratum (municipality) and then one random eligible house-
hold resident. Two types of weights were used: (1) prestrati-
fication weights to adjust for the sampling design and (2)
poststratification weights to adjust for the true sex and age
distribution of the target population, thus partially correcting
for nonresponse and noncoverage bias.
Statistical analyses were weighted for the Portuguese
pediatric population and performed using the complex
samples tool of SPSS version 21 (SPSS IBM, New York,
NY, USA), with the exception of the participants’ character-
istics description, which was performed without weighting
procedures. Categorical variables were described using abso-
lute and relative frequencies with 95% confidence intervals
(95% CIs); comparisons were performed with Pearson’s
chi-squared test. Univariate logistic regression models for
outcomes were developed using independent variables as
risk/predictive factors. Multivariate logistic regression models
were developed to adjust for possible confounders. Results of
multivariate logistic regression models were presented as
odds ratios (ORs) with 95% CIs. A p value of50.05 was
considered statistically significant.
Results
Participants
The corrected response rate of the INAsma was 50%. Of the
6003 participants in the INAsma survey, 716 (11.9%) were
children. A flowchart of all participants is shown in Figure
S1. One-fifth (21.4%) of the children were younger than
6 years of age, and 39% were 13–17 years old; most (80.6%)
were from urban areas. The children’s characteristics are
summarized in Table 1.
Prevalence of asthma-like symptoms
The prevalence of asthma-like symptoms among Portuguese
children was 39.4% (95% CI, 35.7–43.3) (Table 2). Asthma-
like symptoms were highest in children aged56 years (47.9%;
95% CI, 40.0–56.0) and lowest in those aged 13–17 years
(31.8%; 95% CI, 26.3–37.8; p¼ 0.005) (Table S1). Waking
during the night with cough was the most prevalent symptom
(30.9%; 95% CI, 27.5–34.5), followed by wheezing (19.1%;
95% CI, 16.4–22.1).
The prevalence of nocturnal symptoms was higher in
children aged56 years (39.8%; 95% CI, 32.1–48.1) than in
those aged 13–17 years (OR: 0.61; 95% CI, 0.40–0.94),
although the prevalence was not significantly different
from that of children aged 6–12 years (OR: 0.84; 95% CI:
0.55–1.28). The prevalence of wheezing was highest in
children aged56 years (31.0%; 95% CI: 24.4–38.5) and sig-
nificantly decreased with age (OR: 0.46; 95% CI: 0.30–0.70
in the 6- to 12-year-old age group; and OR: 0.24; 95% CI:
0.15–0.40 in the 13- to 17-year-old age group) (Figure 1).
Among children who reported wheezing in the last 12 months,
the symptoms of wheezing without a cold and wheezing with
breathlessness were higher in children aged 6–12 years than in
those aged56 years (p50.001) (Figure 2).
The presence of rhinitis and eczema was associated with a
higher prevalence of having any asthma-like symptom (OR:
3.67; 95% CI: 2.52–5.39 for rhinitis; and OR: 2.11; 95% CI:
1.51–2.94 for eczema). Supplementary information on
asthma-like symptoms is presented in Tables S1 and S2.
Asthma prevalence
The prevalence of LAwas 11.2% (95% CI: 9.1–13.7), and that
of CA was 8.4% (95% CI: 6.6–10.7). No statistically
significant differences were found in the prevalence of CA
according to region or other sociodemographic variables
(Table 1). A higher risk of CA was found in children with
rhinitis and eczema (OR: 5.20; 95% CI: 3.05–8.85 for rhinitis;
and OR: 4.17; 95% CI: 2.41–7.19 for eczema). Table 3 shows
an overview of different asthma definitions according to the
inclusion of different proxies of asthma prevalence.
Diagnostic tests and medication for asthma
PFT and allergy tests (skin prick tests and/or blood allergy
tests) were performed in 12.6% (95% CI: 10.3–15.2) and
28.3% (95% CI: 24.9–31.9) of children, respectively. About
half of children with CA aged "6 years had undergone PFT
(52.9%; 95% CI: 46.0–59.8), and this prevalence did not
change if they had had an asthma attack in the previous
12 months. Children with CA who lived in rural areas were
less likely to report diagnostic testing than those from urban
areas (OR: 0.06; 95% CI: 0.04–0.09 for PFT; and OR: 0.39;
95% CI: 0.22–0.69 for allergy tests) (Table 4).
Among children with CA, the frequency of any asthma
medication at the time of the interview was 76.4% (95% CI:
64.4–85.3). Inhaled reliever and controller therapy were used
in the previous 12 months by 40.1% (95% CI: 28.5–53.0) and
41.5% (95% CI: 29.6–54.5) of children with CA, respectively
(Table S3). Children who reported using only inhaled reliever
medication in the previous year, without any inhaled
controllers, were more likely to experience an asthma attack
in the same time period (OR: 2.69; 95% CI: 1.24–5.84).
Children with CA from rural areas were less likely to report
using any inhaled therapy in the previous 12 months (OR:
0.20; 95% CI: 0.09–0.43).
Discussion
A high prevalence of asthma-like symptoms was found in the
Portuguese pediatric population (39.4%; 95% CI: 35.7–43.3),
and the prevalence of CA was 8.4% (95% CI: 6.6–10.7). This
study showed that less than half of children with CA had been
on inhaled controller medication in the previous 12 months
and that only 52.9% of those aged "6 years had undergone
PFT.
This study was the first population-based nationwide
epidemiological study aiming to estimate the asthma preva-
lence in Portugal among all municipalities and pediatric ages.
It included a large representative sample of the Portuguese
population, allowing us to estimate the prevalence of asthma-
like symptoms, CA, diagnostic tests, and medication use in
asthmatic children. Nationwide studies on the prevalence of
asthma across the entire pediatric population have only been
previously performed in Germany and the United States
[11–13]; no previous study has reported the prevalence of
asthma-like symptoms across all pediatric ages. A multi-
national study of children aged 1–5 years showed that
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approximately one-third had wheezing, coughing, or breath-
lessness [20], which is lower than our observation in children
aged56 years (47.9%). However, the time period considered
in that study was only 6 months, while the time period in our
study was 12 months. Two recent Portuguese studies reported
estimates of wheezing in preschoolers (24.5% and 27.5%)
[21,22], similar to our results. Mvula et al. [23] found that
27.3% of children aged 5–18 years had cough at night, apart
from cold or chest infection. Our question did not distinguish
different causes of cough and association to colds; however,
our prevalence among children aged 0–17 years (30.9%) is
similar to that reported by Mvula et al. [23].
The United States National Center for Health Statistics
reported a 5.4% prevalence of asthma attacks among children
aged 0–17 years [24]. The slightly lower prevalence among
Portuguese children (3.7%) may be related to differences in
the definition of asthma attacks in the two populations.
Differences in asthma-like symptom patterns in
various age subgroups
The prevalence of wheezing and nocturnal symptoms
decreased with age (Figure 1). However, after the age of
5 years, most children with wheezing exhibited wheezing
without a cold and wheezing with breathlessness
(Figure 2). These results suggest that age influences
asthma-like symptom patterns. These findings are in
agreement with previous studies suggesting that wheezing
Table 1. Participants’ characteristics in a pediatric sample.
Total participants, n (%) Current asthma % (95% CI) Odds ratioa (95% CI)
All pediatric Population 716 (100.0) 8.4 (6.6–10.7)
Gender
Female 270 (37.7) 6.7 (4.3–10.1) 1.00 (Ref)
Male 446 (62.3) 10.1 (7.5–13.4) 1.59 (0.92–2.75)
Age groups
0–5 years 153 (21.4) 6.5 (3.5–11.6) 1.00 (Ref)
6–12 years 284 (39.7) 9.7 (6.8–13.8) 1.53 (0.73–3.23)
13–17 years 279 (39.0) 8.7 (5.9–12.5) 1.36 (0.64–2.90)
National region
North 284 (39.7) 7.2 (4.6–11.1) 1.00 (Ref)
Centre and Islands 179 (25.0) 9.7 (6.3–14.7) 1.35 (0.67–2.74)
South 253 (35.3) 8.7 (5.7–12.9) 1.21 (0.61–2.38)
Municipality
Urban 577 (80.6) 8.0 (5.9–10.8) 1.00 (Ref)
Rural 139 (19.4) 9.8 (6.6–14.3) 1.12 (0.59–2.11)
ETSb
No 454 (63.4) 8.2 (5.9–11.3) 1.00 (Ref)
Yes 262 (36.6) 8.8 (6.1–12.6) 1.06 (0.61–1.84)
Allergic rhinitis
No 558 (77.9) 5.0 (3.4–7.4) 1.00 (Ref)
Yes 158 (22.1) 22.3 (16.6–29.2) 5.15 (3.02–8.78)*
Eczema
No 517 (72.2) 5.0 (3.4–7.4) 1.00 (Ref)
Yes 199 (27.8) 18.3 (13.6–24.2) 4.08 (2.35–7.08)*
Food allergy
No 676 (94.4) 8.3 (6.4–10.8) 1.00 (Ref)
Yes 40 (5.6) 9.6 (5.4–16.4) 0.94 (0.45–1.95)
Weighted proportion and odds ratio (95% confidence intervals) of current asthma according to sociodemographic and clinical variables.
aAdjusted odds ratio for gender, age, region, municipality, and ETS.
bEnvironmental tobacco smoke.
*Statistically significant.
Table 2. Weighted prevalence of asthma-like symptoms in the previous 12 months in the Portuguese pediatric population.
Current asthma
Total population % (95% CI) Yes % (n¼ 66) No % (n¼ 750)
Any symptoma 39.4 (35.7–43.3) 91.4 (82.4–96.1) 34.7 (30.9–38.6)
Wheezing 19.1 (16.4–22.1) 76.5 (65.4–84.9) 13.8 (11.4–16.6)
Wheeze w/o cold 8.2 (6.5–10.4) 49.2 (37.2–61.3) 4.5 (3.1–6.3)
Nocturnal symptoms 34.7 (31.1–38.5) 79.2 (68.0–87.3) 30.7 (27.0–34.6)
Waking with breathlessness 5.0 (3.6–7.1) 24.7 (16.1–35.9) 3.2 (2.0–5.3)
Waking with chest tightness 6.7 (5.1–8.8) 27.4 (17.8–39.6) 4.8 (3.4–6.8)
Waking with cough 30.9 (27.5–34.5) 68.7 (56.6–78.7) 27.4 (24.0–31.2)
Asthma attack 3.7 (2.6–5.4) 44.4 (32.6–56.9) 0.0 (0.0–0.0)
aWheezing or waking with breathlessness or waking with chest tightness or waking with cough or asthma attacks.
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in younger children is more closely related to immature
airways and viral respiratory illnesses [25], whereas older
children tend to exhibit wheezing even without respiratory
infections.
Asthma prevalence
There is no consensus on the epidemiologic definition of CA,
which leads to hardly comparable differences in reported
prevalence estimates, depending on the definition used [3,14].
Therefore, we presented estimates using different combin-
ations of asthma proxies (Table 3). The definition we chose
includes the less frequent nocturnal symptom, waking
with breathlessness; the term asthma attack to improve
specificity; and asthma medication, because children with
asthma may not experience symptoms when controlled with
medication, and medication is a known valid proxy for asthma
prevalence [26,27]. By using definitions of prevalence used in
different studies, our prevalence estimates varied from 6.3%
(LA plus wheezing in the last year) and 9.1% (LA plus any
asthma-like symptom in the last year or CA medication).
These differences highlight the importance of setting
standardized definitions to allow for comparisons between
studies.
Figure 2. Weighted prevalence of wheezing with breathlessness and wheezing without a cold in the Portuguese pediatric population. *p50.001,
zp¼ 0.03. Prevalence of wheezing in all Portuguese children: 31.0% in 0- to 5-year age group (OR: 1.00); 17.3% in 6- to 12-year age group (OR: 0.46;
95% CI: 0.30–0.72); 9.9% in 13- to 17-year age group (OR: 0.25; 95% CI: 0.15–0.41). Prevalence of wheezing with breathlessness in all Portuguese
children: 13.6% in 0- to 5-year age group; 12.8% in 6- to 12-year age group; 5.7% in 13- to 17-year age group. Prevalence of wheezing without a cold in
all Portuguese children: 9.9% in 0- to 5-year age group; 9.5% in 6- to 12-year age group; 5.1% in 13- to 17-year age group. Prevalence of wheezing with
breathlessness among all children who wheezed: 43.7% in 0- to 5-year age group (OR: 1.00); 74.4% in 6- to 12-year age group (OR: 3.73; 95% CI:
1.79–7.78); 57.0% in 13- to 17-year age group (OR: 1.71; 95% CI: 0.83–3.50). Prevalence of wheezing without a cold among all children who wheezed:
31.9% in 0- to 5-year age group (OR: 1.00); 55.2% in 6- to 12-year age group (OR: 2.64; 95% CI: 1.27–5.48); 51.7% in 13- to 17-year age group (OR:
2.28; 95% CI: 0.96–5.43).
Figure 1. Weighted prevalence of asthma-like
symptoms within the previous 12 months,
according to age group (%, 95% CI). Symbols
represent prevalence of: " nocturnal symp-
toms (waking with breathlessness or waking
with chest tightness or waking with cough);
g wheezing; m asthma attack. *Difference
between age groups with p50.001;
zDifference between age groups with
p50.001.
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Our estimate of LA is based on the same question of
ISAAC. The estimate in the 6- to 12-year-old age group
(12.3%) was higher than that in the 6- to 7-year-old age group
in the Portuguese ISAAC survey (9.8%) [6], while our
estimate for the 13- to 17-year-old age group (13.9%) was
similar to that in the 13- to 14-year-old age group in the
ISAAC survey (13.8%). In preschoolers, two recent
Portuguese studies had also reported estimates of physician
asthma diagnosis similar to ours: 4.6% in both studies [21,22].
Schmitz et al. [11] reported a 4.7% prevalence of a doctor
diagnose LA in the Germany population of 0- to 17-year-old
using data from the 2003–2006 German Health Interview and
Examination Survey for Children and Adolescents (KiGGS).
This prevalence was much lower than ours and is in
agreement with the estimated prevalence of LA among
German children reported in the ISAAC, which was also
much lower than that in Portugal (in Germany, 4.3% in 6- to
7-year-old children and 7.5% in 13- to 14-year-old children)
[5]. Data from the 2010 United States National Health
Interview Survey for children aged 518 years reported an
estimated doctor diagnosed LA prevalence of 13.6% and CA
prevalence of 9.5% [12,13], which are similar to our
estimations.
Asthma symptoms other than wheezing
In children, epidemiological asthma definitions and clinical
asthma phenotypes are primarily based upon wheezing [28].
However, Skytt et al. [29], based on data from the
Copenhagen Prospective Study on Asthma in Childhood,
Table 4. Weighted proportions (95% confidence interval) of pulmonary function tests, allergy tests (skin or blood), and inhaled medication use in
Portuguese children with current asthma.
PFTa ever % (95% CI)
Allergy testsb
ever % (95% CI)
Inhaled medsc in the last
12 months % (95% CI)
All 45.7 (33.8–58.1) 79.9 (67.9–88.2) 67.6 (58.4–75.7)
Gender
Female 36.9 (26.0–49.3) 87.0 (67.5–95.5) 74.9 (70.7–79.3)
Male 51.4 (41.3–61.4) 75.3 (70.2–79.8) 62.9 (49.1–74.9)
Age groups
0–5 years old 21.9 (13.5–33.6) 48.4 (27.1–70.3) 72.1 (38.7–91.4)
6–12 years old 46.4 (40.2–52.7) 97.1 (96.8–97.5) 72.5 (64.8–79.1)
13–17 years old 61.5 (47.4–73.9) 79.4 (69.0–87.0) 58.1 (47.4–68.1)
National region
North 44.0 (29.6–59.4) 93.3 (82.4–97.7) 57.9 (36.5–76.8)
Centre and Islands 38.6 (29.5–48.5) 75.6 (75.2–75.9) 69.8 (69.3–70.2)
South 53.9 (41.0–66.2) 71.3 (56.2–82.7) 74.7 (61.2–84.7)
Municipality
Urban 57.6 (46.9–67.7) 83.9 (74.8–90.1) 76.4 (63.4–85.9)
Rural 7.3 (7.2–7.3) 67.0 (66.6–67.5) 39.2 (29.5–49.9)
Allergic rhinitis
No 43.8 (33.8–54.4) 71.4 (59.5–81.0) 67.6 (51.8–80.1)
Yes 47.4 (38.9–56.1) 87.7 (84.0–90.7) 67.7 (59.5–74.9)
Food allergy
No 46.2 (38.4–54.2) 78.6 (72.0–84.0) 67.6 (57.8–76.1)
Yes 37.6 (37.6–37.6) 100.0 (n/a) 67.8 (67.8–67.8)
aPFT, pulmonary function tests. bAllergy tests: blood and/or skin tests. cInhaled medications: inhaled medication use. n/a: not applicable.
Bold values are statistically significant differences between row subgroups.
Table 3. Weighted Asthma prevalence in the Portuguese pediatric population, using different asthma proxies.
Population % (95% CI)
Total weighted
population (2,066,953)
Lifetime asthma 11.2 (9.1–13.7) 230,886
Current asthma (with symptoms in the previous 12 months)
Wheezing w/o cold 8.2 (6.5–10.4) 169,991
Lifetime asthma+wheezing 6.4 (4.8–8.6) 132,848
Lifetime asthma+wheezing OR waking with breathlessness 7.0 (5.3–9.1) 143,958
Lifetime asthma+wheezing OR asthma attack OR waking
with breathlessness
7.2 (5.5–9.4) 149,199
Lifetime asthma+wheezing OR waking with breathlessness
OR waking chest tightness OR waking cough
8.3 (6.5–10.6) 171,829
Lifetime asthma+wheezing OR asthma attack OR waking
with breathlessness OR current asthma medicationa
8.4 (6.6–10.7) 173,681
Lifetime asthma+wheezing OR asthma attack OR waking
with breathlessness/chest tightness/cough
8.4 (6.6–10.7) 173,963
Lifetime asthma+wheezing OR asthma attack OR current
asthma medication OR waking with breathlessness/chest tightness/cough
9.1 (7.2–11.5) 188,819
aDefinition used as current asthma.
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addressed the lack of validity of wheezing for asthma
diagnosis in children aged 0–3 years. They argued for a
global description of asthma symptoms to reduce the risk of
misclassification of asthma in children. Wheezing-based
asthma definitions are also limited by differences in the
concept and perception of wheezing. Fernandes et al. [30]
reported a lack of perception of the term ‘‘wheezing’’ among
Portuguese parents and health professionals. To account for
this problem, we used several synonyms of wheezing in
Portuguese in wheezing-related questions. Additionally, the
presence of wheezing was not mandatory in our definition
of CA.
We suggest that questionnaires directed at children and
adolescents should include different measures to comprehen-
sively assess asthma characteristics (previous diagnosis,
several symptoms, and medication), thus aiming to obtain
precise estimates of asthma prevalence, especially in younger
children. In any case, standardization of epidemiologic
asthma definitions and their clinical validation are needed [3].
Diagnostic tests and medication for asthma
In spite of the recommendations to perform spirometry as part
of asthma management [2], only about half of the Portuguese
children with CA aged !6 years had undergone PFT.
Similarly, fewer than half of Portuguese children with CA
had used inhaled controller medications within the previous
12 months, even considering a CA definition based on several
symptoms occurring in the last 12 months, like the one used
in our study. Moreover, those who only used reliever inhaled
medication in the previous year, without any controller
inhalers, were twice as likely to have experienced an asthma
attack in the same time period.
No differences in the prevalence of asthma or asthma-like
symptoms were found between urban and rural municipa-
lities; however, children living in rural areas were much less
likely to have undergone PFT or allergy tests or used inhaled
medication. In agreement with our data, a Greek study with
school-aged children also showed that the prevalence of
asthma diagnosis was the same between rural and urban areas
despite findings on the narrowing of small airways in urban
environments [31]. Disparities in health care for rural-
dwelling patients with asthma have been reported, indicating
that those with asthma who live in rural areas receive
substandard care for asthma; however, there are limited direct
data on these findings [32]. Taken together, our results and
those of previous studies on diagnostic tests and medication
use may be related to differences in health-care access and
may suggest substandard asthma care in Portuguese children,
especially in less urbanized areas.
Limitations
This study has several limitations. The survey was designed
for the overall Portuguese population; however, the questions
included in the questionnaire and the definitions used are
similar to others used in international and Portuguese
pediatric studies [33–35]. The use of the 2001 National
Census for sampling could not account for the reduction in the
number of births that occurred in the last decade; however, it
was the most recently available data at the time of data
collection. Also, the study’s pediatric sample follows the
characteristics of the Portuguese pediatric population charac-
teristics [19]. The use of landline telephones excludes
households without residential telephones; nevertheless, it
allowed us to guarantee a stratified cluster sample by region.
Answers were given by the main caregiver for participants
515 years old and by the adolescent when the participant was
!15 years old. This may limit comparisons between these age
groups; however, changes of parent-reported to auto-reported
outcomes are recommended between school age and adoles-
cence [23], and other studies on asthma prevalence in
pediatric ages had similar methodology [11]. Finally, we
could not obtain a clinical confirmation of the diagnosis;
therefore, participants’ misclassification can be expected, as
in any similar survey.
Conclusion
Asthma-like symptoms were present in more than one-third of
Portuguese children, and the prevalence of CAwas 8.4%. Age
influenced asthma-like symptoms patterns, and asthma
prevalence varied according to different definitions.
Therefore, using composite measures and reporting different
operational estimates is advisable. Fewer than half of the
children with CA had used inhaled controller medications in
the previous year, and those who used inhaled relievers alone
had experienced twice more asthma attacks. PFT were
underused among asthmatic children. Also, the findings on
low inhaled controller medication and PFT use were more
prevalent in children living in rural areas.
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LETTERS
High prevalence of
hospitalisation for asthma in
a population-based paediatric
sample
The asthma prevalence and burden are
high among children. However, available
data for asthma hospitalisation in children
have been mainly reported as annual rates
of asthma hospitalisations.1 The propor-
tion of children with asthma that are hos-
pitalised because of asthma during their
lifetime is still unknown.
INASMA was a cross-sectional, popula-
tion-based, all-age, nationwide telephone
survey conducted in 2010 to estimate
asthma prevalence and control in Portugal.
Details on INASMA methods are described
elsewhere.2 We report the proportion of
lifetime hospitalisation (LH) for asthma in
Portuguese children and adolescents aged
6–17 years (hereafter referred to as ‘chil-
dren’). INASMA included 563 participants
in this age group, representative of the
Portuguese paediatric population.3 This
sample size allowed us to estimate the
prevalence of LH with a margin of error of
0.1, considering a 95% conﬁdence level.
LH was deﬁned as a positive answer to
‘Have you ever been hospitalised for
asthma (inpatient admission >24 h)?’
Lifetime asthma was deﬁned as a positive
answer to ‘Have you ever had asthma?’
Current asthma was deﬁned as lifetime
asthma plus, at least, one of the following
in the previous 12 months: wheezing,
waking with breathlessness, asthma attack,
or currently taking asthma medication.
The prevalence of LH for asthma in
Portuguese children was 3.9% (95% CI
2.6 to 5.7). In children with lifetime
asthma, this prevalence was 29.7% (95%
CI 23.6 to 36.7) (table 1). Children with
current asthma had a higher prevalence of
hospitalisations (36.5%; 95% CI 28.8 to
44.9) than children with a history of life-
time asthma but without current asthma
(prevalence 13.4%; 95% CI 11.5 to 15.6)
(OR 3.70; 95% CI 2.64 to 5.20). The
presence of any asthma-like symptom in
the previous 12 months increased the pro-
portion of LH (OR 1.85; 95% CI 1.16 to
2.95). Female children had more hospitali-
sations than male children (OR 1.97; 95%
CI 1.22 to 3.18). No differences in the
prevalence of LH were observed with
socioeconomic status or in children with
rhinitis, sinusitis, or food or drug allergies.
In the present study, a high number of
hospitalisations for asthma were
observed, with more than 55 000
Portuguese children aged 6–17 years hos-
pitalised for asthma during their lifetime.
Moreover, of the children with current
asthma, more than one-third had been
hospitalised for asthma. Our study is
limited by the lack of diagnosis/LH con-
ﬁrmation by a physician, as in other
epidemiological studies. We excluded
from the analysis participants aged
0–5 years to avoid misclassiﬁcation of
hospital admissions for bronchiolitis and/
or viral-induced wheezing. To our knowl-
edge, only one other study reported the
prevalence of LH in children4; however,
it only included children aged 6–7 years
from one Italian city, and the proportion
of children with asthma who had LH was
not reported. More studies with compar-
able data from other countries and set-
tings are needed. Our results should
contribute to improve knowledge on
asthma-related hospitalisations in chil-
dren, leading to the development of
healthcare programmes aiming to reduce
their frequency.
For the ﬁrst time, the proportion of LH
for asthma was reported for a national
population-based paediatric sample. In
Portugal, about one-third of children with
Table 1 Proportion and OR (95% CI) for lifetime hospitalisation (LH) for asthma in
Portuguese children aged 6–17 years with lifetime asthma
LH % (95% CI) OR for LH (95%CI)
Overall 29.7 (23.6 to 36.7)
Sex
Male 24.1 (18.0 to 31.5) 1.00 (Ref)
Female 38.5 (28.8 to 49.2) 1.97 (1.22 to 3.18)
Age groups
6–12 years old 33.0 (24.2 to 43.1) 1.00 (Ref)
13–17 years old 26.4 (19.0 to 35.5) 0.73 (0.40 to 1.34)
Regions
North 26.1 (20.0 to 33.2) 1.00 (Ref)
Centre and Islands 46.8 (33.8 to 60.3) 2.10 (1.31 to 4.76)
South 14.5 (6.2 to 30.2) 0.48 (0.18 to 1.31)
Municipality
Urban 27.3 (19.1 to 37.4) 1.00 (Ref)
Rural 35.9 (35.9 to 35.9) 1.49 (0.94 to 2.37)
Socioeconomic status*
Low 34.1 (25.3 to 44.3) 1.00 (Ref)
Medium 19.7 (11.3 to 32.1) 0.47 (0.19 to 1.19)
High 23.5 (3.4 to 73.1) 0.59 (0.06 to 5.47)
ETS†
No 34.4 (24.5 to 45.7) 1.00 (Ref)
Yes 24.0 (17.9 to 31.3) 0.60 (0.31 to 1.17)
‘Wheezing’
No 18.8 (15.2 to 23.0) 1.00 (Ref)
Yes 41.1 (32.7 to 50.1) 3.03 (2.15 to 4.26)
‘Nocturnal symptoms’‡
No 21.8 (11.8 to 36.7) 1.00 (Ref)
Yes 34.6 (27.6 to 42.4) 1.90 (0.85 to 4.25)
‘Asthma attack’
No 23.4 (17.0 to 31.3) 1.00 (Ref)
Yes 43.5 (33.0 to 54.5) 2.52 (1.46 to 4.34)
‘Asthma-like symptoms’§
No 21.2 (15.4 to 28.5) 1.00 (Ref)
Yes 33.2 (25.9 to 41.5) 1.85 (1.16 to 2.95)
‘Current asthma’
No 13.4 (11.5 to 15.6) 1.00 (Ref)
Yes 36.5 (28.8 to 44.9) 3.70 (2.64 to 5.20)
Bold values are statistically significant.
*Socioeconomic status was categorised based on occupation and school education of the person who contributed most
to the household income.
†Environmental tobacco smoke.
‡‘Nocturnal symptoms’ in the last 12 months: waking with breathlessness or waking with cough or waking with chest
tightness.
§‘Asthma-like symptoms’ in the last 12 months: wheezing or nocturnal symptoms or asthma attacks.
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Prolonged school
non-attendance in adolescence:
a practical approach
Hawkrigg and Payne provide a very helpful
medically focused approach to the manage-
ment of prolonged school non-attendance
in adolescence.1 Their emphasis on a
multiagency systemic approach and on
rehabilitation is particularly welcome. I
would suggest that consideration of poten-
tial child protection issues is equally
important in these cases. There are at least
four situations in which this may arise, all
of which I have come across in my own
practice:
1. The young person who is experiencing
maltreatment in the home and the non-
attendance is a reaction to this. This
may arise particularly with ongoing
emotional or sexual abuse, but also in
situations of physical abuse or domestic
violence in the home. In these situa-
tions, the young person may develop
physical or emotional symptoms which
may keep them from attending school,
may develop mental health problems as
a consequence of the maltreatment, or
may deliberately avoid school because
of the emotional distress they are
experiencing, or to avoid the maltreat-
ment being discovered.
2. The young person who is kept from
attending school by the parents or
carers. This may arise when the young
person is acting as a young carer, for
example for a parent with physical or
mental health needs, or addiction; as
part of a wider pattern of neglect of
the young person’s needs; or as a
more deliberate denial by the parent
of the young person’s educational
needs (a form of deprivational abuse).
3. Where the young person is experien-
cing or reporting symptoms as a con-
sequence of disordered family beliefs
about health and illness. This may
occur along a spectrum from over-
reaction to or exaggeration of minor
illness, through to more extreme
forms of fabricated or induced illness.
In these situations, the primary
responsibility for the illness behaviour
lies with the parent or carer, but often
these beliefs and behaviour patterns
are picked up by the young person.
4. Where the young person is a victim of
sexual exploitation.
In all of these situations, the maltreat-
ment underlying or contributing to the
young person’s non-attendance may not
be immediately apparent. The
management in such situations should be
as recommended by Hawkrigg and Payne,
but unless these possibilities are pro-
actively considered, it is unlikely that the
maltreatment will be identiﬁed, the young
person is likely to continue to suffer
harm, and it is unlikely that the non-
attendance will be resolved. I would
suggest that in each situation of school
non-attendance the question of whether
the young person may be experiencing
maltreatment is speciﬁcally asked in the
multiagency forum, and where possible
maltreatment is identiﬁed, that this is
thoroughly investigated by the relevant
authorities.
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Response to ‘In adolescence,
extreme prematurity is
associated with signiﬁcant
changes in the
microvasculature, elevated
blood pressure and increased
carotid intima-media thickness’
We have read with great interest the com-
mendable article by Lee et al,1 who have
demonstrated that adolescents who have
been born extremely preterm show an
increase in their systemic blood pressure
and carotid intima-media thickness, as
well as a decrease in forearm vessel
reactivity during arterial occlusion.
The authors have suggested that this
condition might predispose to future vas-
cular adverse events in adulthood.
As pioneer in this ﬁeld,2 3 our research
group had already demonstrated a similar
508 Arch Dis Child May 2015 Vol 100 No 5
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EDITOR’S CHOICE
The Editor recommends this issue’s articles to the reader
Time to symptom improvement using elimination diets in non-IgE-mediated gastrointestinal
food allergies
The prevalence of food allergy in the pediatric population has increased in recent decades, and it is recognized as a
major public health concern. The most common allergens are cow’s milk, soya, egg, and wheat. The clinical
presentation of the non-IgE-mediated food allergy is characterized by heterogeneous gastrointestinal symptom
manifestations and lack of conclusive tests, with the final diagnosis mainly based on the improvement of symptoms
after initiation of exclusion diet.
The majority of the available studies regarding this subject focus on the management options. However, there is
paucity of data on time to symptom improvement using elimination diets in these cases, with the recommended
length for a diagnostic exclusion diet being based on experts opinion and varying from 2 to 12 weeks.
In this study, Lozinsky et al. (1) investigated 131 children with suspected diagnosis of non-IgE-mediated food
allergy on elimination diet, assessing the time required for symptom improvement with a questionnaire that
evaluated the nine most common gastrointestinal symptoms in this disease. The authors showed significant
improvement of the symptoms after 4 weeks of elimination diet in more than 98% of the studied children, which
highlights the fact that this might be the minimum length necessary to evaluate response. The study also shows that
although patients presented with significant symptom improvements, it was clear that some symptoms responded
only partially and some did not improve at all. While rectal bleeding improved in 70% of the children, diarrhea,
food aversion, and pain fully improved in only 30%. Therefore, clinicians dealing with food allergy should not
expect full remission of symptoms with elimination diet in all of the cases, so perhaps the term ‘Not IgE’, rather than
non-IgE-mediated allergy, could be used.
Diagnostic accuracy of patch test in children with food allergy
The most common triggers of food allergy are hen’s egg and cow’s milk in childhood. Much research has been
conducted to find practical methods for diagnosing these allergies. In this context, several studies have investigated
atopy patch tests (APT) as a diagnostic tool for food allergies. However, results have not been consistent, both for
IgE- and non-IgE-mediated food allergy.
Sozmen et al. (2) analyzed data from 243 children with a suspicion of egg or cow’s milk allergy. All children
underwent APT, skin prick test (SPT), and oral food challenge (OFC). The study population included both IgE- and
non-IgE-mediated food-allergic children. The authors found that a quarter of the group reacted in food challenge
and 23% (56) of children had positive APT. Sensitivity, specificity, negative predictive value, and positive predictive
value for both egg and cow’s milk allergy were all low for APT. There was no significant difference between children
with positive APT results and those with negative APT results in age, gender, positive OFC outcome, and symptoms
occurring during OFC. APT did not have an additional value to improve diagnostic accuracy of SPT.
The authors concluded that OFC remains the primary mean for identifying children with food allergy. APT is
not necessary in daily clinical practice and could not predict the results of OFC. The authors also reviewed the
studies in the last 10 years regarding the diagnostic role of APT in diagnosing of food allergy and compared the
results and methods of these studies with their findings.
Asthma control in children is associated with nasal symptoms, obesity, and health insurance: a
nationwide survey
Asthma control has been associated with several factors, such as modifiable medical conditions or social
characteristics. Also, children with uncontrolled asthma are more likely to use medication and healthcare services
for asthma. Health insurance status may play an important role in modeling healthcare access in asthmatic children.
In Europe, there are different healthcare systems and financing modalities among and within countries, but no study
has evaluated the influence of the children’s health insurance status on asthma outcomes.
Ferreira-Magalh~aes et al. (3) published the results of a nationwide study that assessed asthma control in children
and adolescents (0–18 years of age) randomized from the general population. In this study, half of children did not
have their asthma controlled. Having substantial nasal symptoms, being obese, and not having health insurance
were the significant determinants of lack of asthma control in children. Moreover, the presence of substantial nasal
symptoms and the absence of health insurance were also associated with higher unscheduled medical visits for
asthma.
Rhinitis is a known risk factor for uncontrolled asthma, but this study also showed that the presence of a higher
number of different nasal symptoms (runny nose, stuffy nose, itchy nose, or sneeze) was associated with a higher
prevalence of lack of asthma control.
Children without health insurance were at greater risk of poor asthma outcomes such as uncontrolled asthma
and higher use of unscheduled medical attendance. In the mixed Portuguese healthcare system, this may point to the
importance of parents’ options in choosing the site of medical asthma care for their children.
This population-based study shows that lack of asthma control is high in these children. It also brings important
new evidence on determinants of asthma control, not only regarding the classical modifiable factors, such as nasal
symptoms and obesity, but also regarding the influence of health insurance status and healthcare access.
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Abstract
Background: This study aimed to estimate the prevalence of asthma control and
determinants of poor control in the Portuguese pediatric population (<18 years);
secondarily, we described asthma-related healthcare services and medication use.
Methods: Data of 98 children with current asthma, from the second phase of a
nationwide population-based telephone survey (INAsma study), were analyzed.
Asthma control definition was based on GINA criteria, grouping partially controlled
and uncontrolled asthma as ‘not-controlled asthma’ (NCA). We used multivariate
logistic regression to study factors associated with NCA and with unscheduled medical
visits for asthma.
Results: About half of the children had NCA (49%, 95% CI 39–59%). In the
multivariate model, risk factors for NCA were as follows: substantial nasal symptoms
(aOR 6.80), overweight/obesity (aOR 3.44), and not having health insurance (aOR
3.78). All the children with NCA had nasal symptoms, and the lack of asthma control
was also associated with the increasing number of nasal symptoms (p < 0.001). In the
previous year, 90% (95% CI 84–96%) of children with current asthma had healthcare
visits and 67% (95% CI 58–77%) used medication for asthma. The risk of
unscheduled medical visits was higher in children with nasal symptoms (aOR 3.63)
and in those without health insurance (aOR 2.79), and lower in adolescents (aOR 0.19).
Conclusions: Half of the children with asthma were poorly controlled. Nasal
symptoms and obesity are important determinants of asthma control. Children
without health insurance are at greater risk of poor asthma outcomes; this association
is reported for the first time in a European country.
The main goal of asthma management is to achieve disease
control (1). In children, the proportion of poor asthma control
varies widely, from 15% to 90%, depending on the age groups
included, countries, settings, and control definition (2–8).
Children with uncontrolled asthma need to use more asthma
medication and are more likely to use healthcare services for
asthma, especially unscheduled medical visits (9, 10). Several
factors have been associated with lack of asthma control in
children, such as rhinitis (11), eczema (4), obesity (12), lower
socioeconomic status (13), or parents’ impaired perception of
asthma control (7).
Health insurance status plays an important role in healthcare
access, namely in asthmatic children: uninsured children are
more likely to have restrictedmedical care and impaired access to
healthcare services (14, 15). Data on the 2007–2009US recession
has shown that children that experienced a gap on health
insurance coverage had poorer asthma control (16). In Europe,
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there are different healthcare systems and financing modalities
amongandwithin countries, but no study evaluated the influence
of the children’s health insurance status on asthma outcomes.
Improving knowledge on asthma control, including its
prevalence and related factors, is needed to assess the extent
of the asthma-related burden and to inform policymakers,
aiming to achieve better results in health.
In 2010, we conducted the first Portuguese National Asthma
Survey (INAsma), a two-phase nationwide study aiming to
estimate asthma prevalence and control (17). In the present
paper, we report data from children and adolescents included
in the second phase of the study. Our aims were to estimate the
prevalence of asthma control and determinants of poor control
in the Portuguese pediatric population (<18 years). Secondary
aims were to describe asthma-related healthcare services and
medication use.
Methods
Study design and participants
INAsma was a nationwide survey from the general population
applied by telephone interview to individuals living in Portugal
in 2010. The study methodology has been previously described
(17). Briefly, to obtain a representative sample of the general
population a two-stage cluster and stratified sampling design
was performed, using municipality as stratum and randomly
selecting participants from households. When the selected
individual had <15 years old, the respondent was the usual and
most knowledgeable caregiver. Methodological details are
described in supplementary file.
Overall, 716 children completed the first phase of the
INAsma study (Fig. 1); all the participants identified as having
current asthma were eligible for participation in the second
phase. Additional asthmatics identified in the participants’
households were also contacted. The flowchart (Fig. 1) sum-
marizes the children included in INAsma study.
This study was approved by the Ethics Committee of Centro
Hospitalar de S~ao Jo~ao, Porto, Portugal. Oral informed consent
was obtained from parent(s) or legal guardian(s). We followed
the STROBE statement for reporting observational studies (18).
Instruments and data collection
The instrument for data collection in the second phase of
INAsma was based on the Portuguese version of the GA2LEN
survey questionnaire (19); it also included the Control of
Allergic Rhinitis and Asthma Test (CARAT) (20) and ques-
tions on socio-educational factors and use of healthcare
resources. Trained interviewers performed data collection
between June and October 2010, using computer-assisted
telephone interview. To minimize potential bias in data
collection, the same quality-assurance measures used in the
first phase were followed (supplementary file).
Figure 1 Participants’ flowchart.
1Current asthma – Lifetime
asthma + (wheezing OR asthma
attack OR awakening with
breathlessness OR current asthma
medication).
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Variables and outcomes definition
Current asthma was defined as children with ‘lifetime asthma’
plus at least one of the following: wheezing, awakening with
breathlessness or having an asthma attack in the previous
12 months, or taking asthma medication at the time of the
interview.
Nasal symptoms were classified as ‘mild/absent’ or ‘sub-
stantial’ based on the daily frequency of 4 isolated symptoms –
runny nose, stuffy nose, itchy nose, or sneeze in the previous
4 weeks. Each symptom was scored as: 0, if present ‘almost
every day’; 1, if ‘≥2 days a week’; 2, if ‘1 or 2 days a week’; or 3,
if ‘never’. When the sum of all symptoms was >7, nasal
symptoms were classified as ‘mild/absent; when ≤7, they were
considered ‘substantial’.
Overweight/obesity was defined as a z-score >1 for body
mass index (BMI), using WHO Growth reference 2007
macros (21).
Having health insurance was defined as a positive answer to
‘Do you/your child have/has any healthcare insurance?’.
Asthma control definition was based on GINA criteria for
asthma symptom control (1): ‘Well-controlled asthma’ (WCA)
corresponds to ‘well controlled’ from GINA guidelines; and
partially controlled and uncontrolled were grouped as ‘not-
controlled asthma’ (NCA). Unscheduled medical visits for
asthma was defined as having at least one emergency depart-
ment and/or any unscheduled medical attendance because of
asthma worsening/exacerbation in the previous 12 months.
Additional definitions are available in supplementary
material.
Table 1 Participants characteristics – n(%). There are not statistical
differences between diagnostic groups. Statistically significant
differences in asthma control are presented in bold
Current
asthma
(n = 98) (%)
Asthma Control (%)
Well
Controlled
(n = 48)
Not controlled
(n = 46)
Gender
Female 33 (33) 14 (45) 17 (55)
Male 65 (66) 34 (54) 29 (46)
Age groups
0–5 years old 18 (18) 11 (65) 6 (35)
6–12 years old 46 (47) 22 (50) 22 (50)
13–17 years old 34 (35) 15 (46) 18 (55)
Region
North 46 (47) 21 (49) 22 (51)
Centre/Islands 22 (22) 9 (41) 13 (59)
South 30 (30.6) 18 (62) 11 (38)
Urbanity†
Rural 24 (25) 10 (44) 13 (57)
Urban 74 (76) 38 (54) 33 (47)
SES‡
High 15 (15) 11 (73) 4 (27)*
Medium 33 (34) 18 (60) 12 (40)*
Low 50 (51) 19 (39) 30 (61)*
Health insurance
Yes 47 (50) 30 (68) 14 (32)**
No 47 (50) 17 (36) 30 (64)**
Body mass index
Thinness 3 (3) 1 (33) 2 (67)
Normal 57 (60) 33 (62) 20 (38)***
Overweight/Obesity 35 (37) 11 (31) 24 (69)***
ETS§
Yes 40 (41) 23 (59) 16 (41)
No 58 (59) 25 (46) 30 (55)
†Urbanity was classified as urban if residence was located in
municipalities with at least one city (cities must have at least 8000
citizens) according to Portuguese law.
‡Socioeconomic Status, categorized based on family income,
occupation, and school education of the person who contributes
more for the household income.
§Environmental Tobacco Smoke.
*p = 0.03. **p = 0.002. ***p = 0.005.
Table 2 Rhinitis diagnosis ever and nasal symptoms in the previous
4 weeks, in children with current asthma, % (95% CI); and level of
asthma control within children with rhinitis diagnosis ever and nasal
symptoms in the previous 4 weeks, % (95% CI)
Current asthma
children, %
Asthma control, %
p
Well
controlled
Not
controlled
Doctor diagnosis of rhinitis
No 55 (45–65) 49 (33–65) 51 (35–68) 0.42
Yes 45 (35–55) 53 (40–66) 47 (34–60)
Any nasal symptom*
No 11 (5–17) 100 (n/a) 0 (n/a) 0.001
Yes 89 (83–95) 45 (34–55) 55 (45–66)
Itchy nose
No 34 (25–42) 77 (63–92) 23 (8–37) <0.001
Yes 66 (57–75) 38 (26–50) 62 (50–74)
Sneeze
No 33 (23–42) 67 (50–84) 33 (16–50) 0.04
Yes 67 (58–77) 44 (32–56) 56 (44–69)
Runny nose
No 56 (46–66) 64 (52–77) 36 (23–48) 0.004
Yes 44 (34–54) 33 (19–48) 67 (52–82)
Stuffy nose
No 48 (38–58) 73 (60–86) 27 (14–41) <0.001
Yes 52 (42–62) 31 (18–44) 69 (57–82)
Number of nasal symptoms
0 11 (5–17) 100 (n/a) 0 (n.a.) <0.001
1 10 (4–15) 100 (n/a) 0 (n.a.)
2 37 (27–46) 50 (33–67) 50 (33–69)
3 24 (16–33) 32 (12–51) 68 (49–88)
4 19 (11–27) 22 (3–41) 78 (59–97)
Bold values show statistical significant differences of asthma control
in children, according to the presence of different nasal symptoms.
n/a, not applicable.
*“Any nasal symptom”: runny nose or stuffy nose or itchy nose or
sneeze.
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Study sample size and statistical analysis
The sample size was calculated considering the two phases of the
INAsma study (17). The proportion of not-controlled asthma
was estimatedwith amargin of error of 0.098, considering a 95%
confidence level (95% CI). Statistical analyses were performed
using SPSS version 22 (SPSS IBM, New York, NY, USA).
Categorical variables were described using frequencies and
compared with Pearson’s chi-squared test. We usedmultivariate
logistic regression analysis to evaluate which variables were
associated with (1) NCA and with (2) asthma-related unsched-
uled medical visits. For each outcome, we used a data-driven
backward approach, with a priori inclusion of predictive
variables with p-value <0.20 in univariate analysis. The two
final multivariate models included the statistically significant
variables. Results from the logistic regressions were presented as
adjusted odds ratio (aOR) with 95% CI. A p-value <0.05 was
considered statistically significant. Hosmer–Lemeshow test and
percentage of correctly predicted cases were used to assess
goodness of fit for logistic regression models.
Results
The participant’s characteristics are summarized in Table 1.
About half of the children with current asthma had NCA
(49%, 95% CI 39–59%; Table 1). Nasal symptoms in the
previous 4 weeks were present in 89% (95% CI 83–95%) of
children with current asthma (Table 2). Nevertheless, pre-
vious medical diagnosis of rhinitis was made in only 45%
(95% CI 35–55%) of children with current asthma. All
asthma-like and nasal symptoms were more frequent in
children with NCA (p < 0.001; Fig. 2 and Table S1), when
compared with WCA. In children with a parent/self-report
of good asthma control, only 52% fulfilled the criteria for
WCA.
Determinants of poor asthma control
Control of asthma was significantly worse in children with
substantial nasal symptoms, overweight/obesity, lower socio-
economic status, and unscheduled medical attendance for
asthma, or in those without health insurance coverage, in
univariate analysis (Table 3).
Children with any nasal symptom had significantly more
NCA (p = 0.001; Table 2). Moreover, as the number of nasal
symptoms increased, the proportion of children with NCA also
increased (Fig. 3): none of the children with 0 or 1 nasal
symptom had NCA, while 50% of those with 2 symptoms,
68% of those with 3 symptoms and 78% of those with 4
different nasal symptoms had NCA.
In the final multivariate model, the risk factors for NCA
were as follows: having substantial nasal symptoms (aOR 6.80,
95% CI 2.34–19.80), overweight/obesity (aOR 3.60, 95% CI
1.46–10.13), and not having health insurance (aOR 3.78, 95%
CI 1.36–10.92).
Healthcare visits and medication use by children with current
asthma
In the previous 12 months, 90% (95% CI 84–96%) of children
with current asthma had at least one asthma-related visit to
healthcare services (Table S2): 86% (95% CI 79–93%) had
scheduled medical visits, 39% (95% CI 29–48%) had emer-
gency room visits, and 25% (95% CI 16–33%) had at least one
unscheduled medical visit to a doctor. All the preschoolers had
asthma-related healthcare visits (scheduled or unscheduled) in
the last year, compared with 94% (95% CI 86–100%) of school
age children and 79% (95% CI 66–93%) of adolescents
(p = 0.04). The determinants of unscheduled medical visits, in
the multivariate model, were substantial nasal symptoms (aOR
3.63, 95% CI 1.39–9.51), not having health insurance (aOR
Figure 2 Prevalence of isolated nasal symptoms in asthmatic children, stratified by asthma control (prevalence and 95% CI). Full line –
controlled asthma; Dotted line – not-controlled asthma.
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2.79, 95% CI 1.08–7.21) and age 13–17 (aOR 0.19, 95% CI
0.05–0.78; Table 3).
In children with current asthma, 67% (95% CI 58–77%)
used asthma medication in the previous 4 weeks (Table S3):
controller medication was used by 58% (95% CI 48–68%) and
reliever medication by 31% (95% CI 22–40%). Children with
NCA had a non-significant higher frequency of any medication
use (76%, 95% CI 64–88%) when compared with those with
WCA (58%, 95% CI 44–72%); no statistically significant
differences were seen in the use of controller or reliever
medication. Over-the-counter medications (e.g.: antihistamines
and cough medication) were used more frequently by children
with NCA (p < 0.02; Table S3). School-aged children used
more asthma medication (p = 0.03), comparing with pre-
schoolers and adolescents (Table S2).
Discussion
In this nationwide study from the general population, only half
of children with asthma were controlled. Determinants for not-
Table 3 Crude and adjusted odds ratio for not-controlled asthma and unscheduled medical visits
Not-controlled asthma Unscheduled visits
Crude odds
ratio (95% CI)
Adjusted odds
ratio (95% CI)
Crude odds
ratio (95% CI)
Adjusted odds
ratio (95% CI)
Gender
Female 1.00 (ref) n.i. 1.00 (ref) n.i
Male 0.70 (0.30–1.67) 1.54 (0.66–3.61)
Age
0–5 years old 1.00 (ref) n.i. 1.00 (ref) 1.00 (ref)
6–12 years old 1.83 (0.58–5.83) 1.16 (0.38–3.53) 0.72 (0.21–2.43)
13–17 years old 2.20 (0.66–7.36) 0.37 (0.11–1.24) 0.19 (0.05–0.78)
Body mass index
Normal 1.00 (ref) 1.00 (ref) 1.00 (ref) n.i.
Overweight/Obese 3.60 (1.46–8.89) 3.44 (1.17–10.13) 0.74 (0.32–1.73)
Nasal symptoms
Absent/mild 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Substantial 4.42 (1.85–10.56) 6.80 (2.34–19.80) 2.82 (1.22–6.53) 3.63 (1.39–9.51)
Urbanity†
Rural 1.00 (ref) n.i. 1.00 (ref) n.i.
Urban 0.67 (0.26–1.72) 0.66 (0.26–1.67)
SES‡
High 1.00 (ref) n.i. 1.00 (ref) n.i.
Medium 1.83 (0.47–7.13) 2.08 (0.54–8.01)
Low 4.34 (1.21–15.63) 2.71 (0.75–9.80)
Health insurance
Yes 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
No 3.78 (1.59–9.02) 3.85 (1.36–10.92) 2.10 (0.92–4.81) 2.79 (1.08–7.21)
Local of asthma care
Public 1.00 (ref) n.i. 1.00 (ref) n.i.
Private 0.71 (0.31–1.60) 0.68 (0.30–1.53)
Scheduled medical visits
Yes 1.00 (ref) n.i. 1.00 (ref) n.i.
No 0.30 (0.08–1.20) 0.30 (0.08–1.17)
Unscheduled medical visits
Yes 1.00 (ref) – –
No 0.44 (0.19–0.99) n.i. – –
Asthma control
Controlled – – 1.00 (ref) n.i.
Not controlled – – 2.29 (1.01–5.28)
Bold values show statistical significant differences. n.i.: not included in the model (non-significant variables).
Asthma control model: Hosmer–Lemeshow test = 0.37 and 75% of correctly predicted cases.
Unscheduled visits model: Hosmer–Lemeshow test = 0.95 and 67% of correctly predicted cases.
†Urbanity was classified as urban if residence was located in municipalities with at least one city (cities must have at least 8000 citizens)
according to Portuguese law.
‡Socioeconomic Status, categorized based on family income, occupation, and school education of the person who contributes more for the
household income.
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controlled asthma were the presence of substantial nasal
symptoms, overweight/obesity, and not having health insur-
ance. The presence of a higher number of nasal symptoms was
associated with poorer asthma control. Moreover, children
with substantial nasal symptoms and without health insurance
needed more unscheduled medical services, while adolescents
needed less.
Strengths and limitations
This was the first study assessing childhood asthma control in
Portugal, and for the first time, we reported the effect of health
insurance coverage on asthma control in a European country.
The participants were randomly recruited from the general
Portuguese population, and overall, our sample followed the
same distribution of our National pediatric population (22).
The sample size may limit the precision of our estimates in
subgroup analysis, but we were able to construct logistic
regression models with good fit for the main outcomes. The use
of a selection strategy based on landline telephone numbers
excluded households without residential telephone; neverthe-
less, it is a widely used method for epidemiological nationwide
surveys, and it was already used in similar studies assessing
asthma control in children (3). Physician assessment cannot be
included in this type of study. Yet, we used an internationally
recommended measure for asthma control – the GINA
guidelines – which are frequently used in epidemiological
studies with similar methodology (23). Also, parents’ recall of
doctor’s diagnosis, for example, rhinitis, may lead to underes-
timation of concomitant diseases.
High frequency of not-controlled asthma
The proportion of Portuguese children with controlled asthma
was similar to that found in USA 6- to 17-year-old children
(46%) (5), in Dutch 6- to 16-year-old children (55%) (7), or in
French preschoolers (42%) (6); however, estimates on the
prevalence of uncontrolled asthma in children are highly variable
(15-90%) depending on the studies (2, 8). In our report, only half
of the children that were considered controlled by their caregiv-
ers had, in fact, controlled asthma.Carroll et al. have shown that
parents usually overestimate asthma control (24). Others
reported a poorer asthma control (7), or medication underuse
among parents that failed to correctly estimate control (3).
The prevalence of nasal symptoms in children with current
asthma (79%) was similar to that found in Dutch asthmatic aged
5–18 (76%) (11). Although the majority of our children with
asthmahadnasal symptoms, less thanhalfof these (45%)reported
a past medical diagnosis of rhinitis. Under-diagnosis and under-
treatmentof rhinitis inasthmatic childrenwasassociatedwith lack
of parental recognition and poorer asthma control (25, 26).
In our study, the increasing number of nasal symptoms was
associated with a decrease in asthma control (Fig. 3). We could
not find previous papers assessing the association of the
number of nasal symptoms with the lack of asthma control in
children; nevertheless, previous studies supported a strong link
between upper and lower airway disease (27, 28).
Worse asthma control in children with obesity, nasal
symptoms, and absence of health insurance
Determinants for not-controlled asthma were the presence of
substantial nasal symptoms, overweight/obesity, and not
having health insurance (Table 3). Rhinitis is a known com-
orbidity associated with poorer asthma control in children,
especially in those with untreated nasal symptoms (11). Our
results are in line with these findings, as substantial nasal
symptoms were associated to a six-fold higher probability of
NCA. Recently published data also showed that increased BMI
was associated to lack of asthma control (2), to a higher use of
inhaled b-agonists or oral corticosteroids (12), and to worst
asthma control in children with higher airway inflammation
(29). In our study, overweight/obesity was associated with a
three-fold higher probability of NCA.
The Portuguese Health System is a mixed universal health-
care system. It is financed by taxes and by health insurances,
both private and public (for state employees), complemented
by out-of-pocket expenses. All Portuguese citizens have access
to medical care services in public primary care and hospital
units. The public care access is primarily based on visits to
primary care physician that can refer to hospital specialities;
Figure 3 Frequency of number of
nasal symptoms in asthmatic
children, according to asthma
control. Full line – well-controlled
asthma; Dotted line – not-controlled
asthma.
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this is limited by the waiting time and referral geographical
areas that prevent the patients from fully choosing the place
where they will be followed. Private practices/hospitals access
is only dependent on patient’s will to attend these institutions;
however, due to significant out-of-pocket expenses, the access
is easier for those with complementary health insurance
coverage. In fact, citizens with healthcare insurance, regardless
of the socioeconomic status, may easily choose the site of
medical care that they perceive as the best, with easier access to
medical specialities and lower waiting time for medical
observations. In what concerns medication, prices are the
same for every Portuguese children, independently of health
insurance status.
In our model, not having health insurance was associated
with a three-fold higher probability of NCA. Also, on
exploratory univariate analysis, the frequency of children with
health insurance coverage followed in private practice/hospital
for their asthma was significantly higher than those followed in
public settings (p < 0.001; Table S4). Taking these results
altogether, we may speculate that these relations between
asthma control and health insurance status may address
differences in types of asthma care that can be influenced by
parents’ options in choosing the site of medical asthma care for
their children (either public or private providers).
Healthcare visits and medication use by children with current
asthma
We showed a trend toward more healthcare visits and
medication use in children with NCA. Previous studies had
already shown the association between healthcare visits and/or
medication with uncontrolled asthma (8, 10). Children with
NCA used more antihistamines and cough medication than
those with WCA; this association of NCA with a higher use of
over-the-counter medication was already observed in asthma
patients (30), and it may point to a worst asthma care plan in
children with NCA.
Unscheduled medical visits for asthma worsening/exacerba-
tion were more frequent in children with substantial nasal
symptoms and without health insurance, and less frequent in
adolescents. This model on urgent medical care, which was also
used as a proxy for poor asthma control, corroborates that
uninsured children, as well as those with substantial nasal
symptoms, were at a higher risk of uncontrolled asthma and
use of urgent medical care.
In conclusion, only half of children with asthma were
controlled in this nationwide study. Determinants for not-
controlled asthma were the presence of substantial nasal
symptoms, overweight/obesity, and not having healthcare
insurance. Our results support the importance of modifiable
factors, namely nasal symptoms and obesity, as determinants
of asthma control in children. Healthcare insurance status
was related to asthma control; in our healthcare system, this
association may be related to parents’ options in choosing
the site of medical asthma care for their children. More
studies are needed to understand the effect on asthma
control of the access to different types of asthma care
services and of being able to choose where the child is cared
for asthma.
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Ferreira-Magalhães M, Amaral R, Pereira AM, Sá-Sousa A, Azevedo I, Azevedo, LF, 24 
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Abstract 26 
Background: This study aimed to estimate the cost of asthma in Portuguese children; 27 
furthermore, we studied the factors associated with cost of asthma and the costs per level 28 
of asthma control. 29 
Methods: A nationwide, population- and prevalence-based cost-of-illness study with a 30 
societal perspective was conducted. We measured direct and indirect costs using a 31 
bottom-up approach and a human capital method, respectively, for 208 children (<18 32 
years), from two national repositories. Generalised linear modelling for analysis of asthma 33 
costs’ determinants and sensitivity analysis to assess uncertainty were performed. 34 
Results: The mean annualised asthma cost per child was €929.35 (95%CI, 809.65–35 
1,061.11): €698.65 (95%CI, 600.88–798.27) for direct costs, and €230.70 (95%CI, 36 
197.36–263.81) for indirect costs. Extrapolations for the Portuguese children amounted to 37 
€161,410,007.61 (95%CI, 140,620,769.55–184,293,968.55) for total costs. Direct costs 38 
represent 75.2% with the costliest domain (51.1% of total costs) being the healthcare 39 
service use: 20.7% for scheduled medical visits and 30.4% for acute asthma care – non-40 
scheduled medical visits (7.9%, €12,766,203.20), emergency department visits (11.7%, 41 
€18,932,464.80) and hospitalisations (10.8%, €17,406,946.00). 42 
Children with partly controlled and uncontrolled asthma had higher mean costs per year 43 
(adjusted coefficients: 1.46 [95%CI, 1.12-1.90] and 2.25 [95%CI, 1.56-3.24], respectively). 44 
Conclusions: Costs of childhood asthma are high (0.9% of the healthcare expenditures in 45 
Portugal). Direct costs represented 3/4 of total costs, mainly related to the use of 46 
healthcare services for acute asthma care. Policies and interventions to improve asthma 47 
Page 2 of 41
Scholarone, Inc. Support (434) 964 4100
Pediatric Allergy and Immunology
198 | Burden of childhood asthma in Portugal 
 
  
For Peer Review
 
control and reduce acute use of healthcare services have the potential to reduce asthma 48 
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Introduction 59 
Health economic studies are important to support decision-makers in defining health 60 
priorities (1). (2,3). In light of the increasing healthcare costs and the consequent threat to 61 
the sustainability of healthcare systems, focus should be put in assess the impact of 62 
chronic diseases, aiming to reduce their burden (4). 63 
As one of the most common chronic diseases in childhood, asthma should have reliable 64 
economic data available. In childhood asthma, important direct costs (diagnostic tests, 65 
medications, medical visits, hospitalisations or emergency admissions) and indirect costs 66 
(mainly caregivers’ loss of work days and transportation to healthcare services) are 67 
relevant and can be high, especially in severe disease (5). In 2002, Druss et al have 68 
quoted asthma as the 13th most expensive medical condition in USA (6). In 2011, Barnett 69 
and Nurmagambetov used a regression-based method to estimate $56 billions of 70 
incremental costs in all-age asthmatic USA population, with a mean value of $3,259 per 71 
person/year (7). In the same year, Bravo et al estimated the cost of asthma in children 72 
younger than 15 years old, in Spain, to be €532 million, (€1,149 person/year) (5). In the 73 
same study, the costs within each category of asthma severity ranged from €403 for the 74 
mildest to €5,930 for the most severe (costs person/year). Even though other asthma 75 
economic studies have been  conducted, there are few population based and 76 
comprehensive pediatric cost-of-illness studies (8). 77 
This study aimed to estimate the cost of childhood asthma in Portugal. Secondary aims 78 
were: 1) to describe direct and indirect costs, 2) to determine factors associated with costs, 79 
and 3) to assess costs according to the level of asthma control.  80 
Page 4 of 41
Scholarone, Inc. Support (434) 964 4100
Pediatric Allergy and Immunology
200 | Burden of childhood asthma in Portugal 
 
  
For Peer Review
 
Methods 81 
Study design and setting 82 
The Cost of Childhood Asthma in Portugal (CASCA project) was a Portuguese, 83 
nationwide, population- and prevalence-based, cost-of-illness study with a societal 84 
perspective. This project was reviewed and approved by the Ethics Committee of Centro 85 
Hospitalar de São João, Porto, Portugal. Informed consent was obtained from parent(s) or 86 
legal guardian(s). 87 
Participants and data collection 88 
Data from participants of two studies (INAsma and CED2013) was analysed. INAsma was 89 
a nationwide survey, from the general population, applied by telephone interview to 90 
individuals living in Portugal, in 2010 (9,10). CED2013 was a population-based survey 91 
applied to children attending primary public schools in a Portuguese city (Guimarães), in 92 
2013. Questionnaires were similar in the both studies, however, data on diagnostic tests 93 
use and immunotherapy were only available in the CED2013 study. When the selected 94 
participant was younger than 15 years old, the respondent was the usual and most 95 
knowledgeable caregiver. For the CASCA project we included 208 children with current 96 
asthma (CA): 98 (0- to 17-years old) from the INAsma Study and 110 (5- to 12-years old) 97 
from the CED2013 Study (Fig. S1). Participants and data collection are further described 98 
in supplementary material. 99 
Data collection of prices of healthcare services, diagnostic tests, medication, holding 100 
chambers, absenteeism, transportation and subsidies were performed in different sources 101 
and databases as described below and in supplementary material.  102 
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Cost estimation methods 103 
Direct healthcare costs of childhood asthma were estimated using a bottom-up approach 104 
(person-based). The cost domains included in direct costs were: 1) healthcare services 105 
(scheduled medical visits, non-scheduled medical visits, emergency department visits and 106 
hospitalisations); 2) diagnostic tests (blood workouts, skin prick tests, spirometries and 107 
chest x-ray); and 3) treatment (asthma-specific medication, other asthma-related 108 
medication and medical devices). Databases and reports from Portuguese Central 109 
Administration of Health System (ACSS) (11), Ministry of Health (12) and National 110 
Authority of Medicines and Health Products (INFARMED) (13) were used to achieve 111 
unitary costs. A mean usage scenario for each medication was achieved by consensus, in 112 
accordance with international guidelines (14), in case of parent/self-reported use of the 113 
corresponding medication. 114 
Indirect costs of childhood asthma were estimated using the human capital method. The 115 
cost domains included in indirect costs were: 1) absenteeism; 2) transportation and 3) 116 
subsidies because of asthma. Databases and reports from National Statistics Institute 117 
(INE) (15) and Ministry of Social Security (16,17) were used to achieve unitary costs. 118 
Each cost item was calculated for each participant by multiplying the parent/self-reported 119 
amount of resources used by the unitary costs of the resources. The total cost was then 120 
calculated for each participant by adding direct and indirect costs. Mean cost per patient 121 
was achieved by the sum of the total cost of each participant, dividing for the total number 122 
of asthmatic children in our sample. Costs were indexed to 2010 Portuguese prices in 123 
euros. Cost estimation methods are further described in supplementary material. 124 
Definitions 125 
CA was defined as children that ‘ever had asthma’ plus at least one of the following: 126 
wheezing, awakening with breathlessness or having an asthma attack in the previous 12 127 
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months, or taking asthma medication at the time of the interview. Asthma control was 128 
defined according to GINA (14), and categorized into ‘controlled’, ‘partially controlled’ and 129 
‘uncontrolled’. Definitions for other variables are described in supplementary material. 130 
Statistical analysis 131 
Statistical analysis was performed using SPSS version 23 (SPSS IBM, New York, NY, 132 
USA). General characteristics of the included participants were described using absolute 133 
and relative frequencies. 134 
Cost variables were all annualised and presented as mean and standard deviation (SD) or 135 
95% confidence interval (95%CI), calculated using bootstrap methods because of their 136 
skewed distributions (18,19). For each cost item and domain, extrapolated estimates for 137 
the Portuguese population were calculated. Extrapolation estimates were based on a 138 
prevalence estimate of CA from the INAsma Study (8.4% [95%CI, 6.6-10.7]), 139 
corresponding to a total weighted population of 173,681 Portuguese children with CA (9). 140 
The factors associated with costs of childhood asthma and, specifically, differences in 141 
levels of asthma control, were assessed using mixed Poisson-gamma models. A p-value 142 
of <0.05 was considered statistically significant. 143 
We additionally used decision analytic modelling to perform univariate and multivariate 144 
deterministic sensitivity analysis, in order to evaluate how the uncertainty would impact the 145 
estimates of national annualised costs of childhood asthma in Portugal. Univariate 146 
deterministic sensitivity analysis was performed with the 95%CI of the proportion estimates 147 
of occurrence of each item in Portuguese population. The multivariate deterministic 148 
sensitivity analysis was set with two case scenarios. The best-/worst-case scenario were 149 
set, respectively, with: the lower/upper limit of the 95%CI of CA prevalence in Portuguese 150 
children; scenario of minimum/maximum use of asthma medications; and the lower/upper 151 
limit of the 95%CI for the proportion of occurrence of each item in Portuguese population. 152 
Page 7 of 41
Scholarone, Inc. Support (434) 964 4100
Pediatric Allergy and Immunology
 Appendices I Paper 4 I Ferreira-Magalhães et al. [submitted] | 203 
 
  
For Peer Review
 
Results 153 
Characteristics of the children included in cost-of-illness analysis are summarized in Table 154 
S3. Estimates of mean annualised costs for each cost domain are presented in Table 1. 155 
The mean annualised total costs per child were €929.35 (95%CI, 809.65–1,061.11), with 156 
€698.65 (95%CI, 600.88–798.27) for direct costs, and €230.70 (95%CI, 197.36–263.81) 157 
for indirect costs. The extrapolations for Portuguese children amount to absolute total 158 
costs of €161,410,007.61 (95%CI, 140,620,769.55–184,293,968.55), with direct costs of 159 
€121,341,498.02 (95%CI, 104,362,186.11–138,645,096.07) and indirect costs of 160 
€40,068,509.59 (95%CI, 34,276,935.33–45,819,027.76). 161 
Direct costs represent 75% and indirect costs 25% of the total costs. The most expensive 162 
domain was healthcare services use (€82,519,684.10; 51% of total costs), specifically 163 
scheduled medical visits (€33,414,070.10; 21% of total costs) and those related to acute 164 
asthma care (€49,105,614.06; 30% of total costs): non-scheduled medical visits 165 
(€12,766,203.20), emergency department visits (€18,932,464.80) and hospitalisations 166 
(€17,406,946.00). 167 
Factors associated with costs of asthma 168 
We observed significant crude associations between total annualised costs of childhood 169 
asthma and nocturnal symptoms, asthma attacks and level of asthma control (Table 2). 170 
However, only asthma attacks and level of asthma control had significant and independent 171 
associations with total annualised costs of childhood asthma in the final multivariate model 172 
adjusted for age. 173 
Children with asthma attacks in the previous 12 months had higher costs than those 174 
without asthma attacks (adjusted exponential model coefficients: 1.57 [95%CI, 1.22-2.02]). 175 
Children with partly controlled asthma and uncontrolled asthma had higher mean costs per 176 
year with adjusted exponential model coefficients of 1.46 [95%CI, 1.12-1.90] and 2.25 177 
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[95%CI, 1.56-3.24], respectively. The mean annualised costs per asthmatic child were 178 
€747.63 in those with controlled asthma, €1,120.50 in partly controlled and 1,758.44 in 179 
uncontrolled (p<0.001) (Fig. 1). Total costs and direct costs, specifically healthcare 180 
services use by acute asthma care and diagnostic tests domains were significantly higher 181 
in children with uncontrolled asthma (Fig. 2). Scheduled medical visits, treatment or 182 
indirect costs were not different between asthma control groups. 183 
Sensitivity analysis 184 
The univariate deterministic sensitivity analysis is presented in supplementary material 185 
(Table S6). The multivariate deterministic sensitivity analysis is presented in Table 3. The 186 
adjusted estimates for the mean of annualised costs per child with asthma in total costs 187 
varied between -35% and +53%, in direct costs between -36 and +63%, and in indirect 188 
costs between -30 and +23%.  189 
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Discussion 190 
We conducted a cost-of-illness analysis on Portuguese childhood asthma, with a 191 
prevalence-based, societal perspective, that allowed a broad economic analysis of the 192 
disease. We adopted a societal perspective, the most comprehensive approach, because 193 
it uses the direct and indirect costs for all members of the society (20). From a societal 194 
perspective, the childhood asthma in Portugal costs over €150 million per year, 195 
corresponding to more than €900 per child with CA. Childhood asthma costs correspond to 196 
0.91% of the Portuguese expenses in health in 2010. These expenditures are undertaken 197 
together by the patients, by the Portuguese state and by health insurance companies, 198 
depending on the type of healthcare services used. Direct costs were 3/4 of the costs, with 199 
the most being related to healthcare services use and specially to acute asthma care. The 200 
most important factors for higher costs were uncontrolled asthma (2.3-fold) and asthma 201 
attacks in the previous 12 months (1.6-fold). 202 
Total, direct and indirect costs of childhood asthma 203 
The cost estimates for childhood asthma in Portugal were slightly lower than the Spanish 204 
estimates in 2008 (€1,149 child/year) (5). Otherwise, USA estimates for 2008 prices of 5- 205 
to 17-years old asthmatics were lower than ours: $791 child/year (direct costs, $401 206 
child/year; indirect costs, $390 child/year) (21). In that study, the authors analysed data 207 
from the 1996 Medical Expenditure Panel Survey and the type of asthma-related 208 
expenditures used in direct costs were not clear. In Turkey, a study performed in 2006, in 209 
pediatric allergy and asthma referral centres, reported medical and non-medical costs of 210 
$1,597 per child/year (medical, $775; non-medical, $821), however, no formal indirect 211 
costs were reported (22). The definition of medical costs was similar to our definition of 212 
direct costs, and the results were also similar (assuming 1.23 exchange rate of dollar to 213 
euro, in 2006). Non-medical costs included transportation (not absenteeism), but were 214 
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mainly driven by non-allergic household measures ($710) like air filters, special vacuum 215 
cleaners or anti-allergic bed covers, that we did not assess in our study, as the current 216 
guidelines do not recommend them (14).  217 
Previously published studies reported proportions of direct costs between 61-88% (8). 218 
Healthcare services use in the context of asthma worsening (non-scheduled medical visits, 219 
emergency and hospitalisations) were, altogether, 30% of the total costs of childhood 220 
asthma in Portugal. Reducing acute asthma care costs, should be one of the major targets 221 
for potential savings. Also, by reducing it other domains (e. g., indirect costs) could also be 222 
lowered. 223 
Indirect costs were one-fourth of the costs in childhood asthma. Other studies showed that 224 
indirect costs can be as high as 50% (8). The lack of assessment of costs related to 225 
presenteeism and lower salaries in Portugal may justify our proportion of indirect costs. 226 
Nevertheless, more than 13 million euros were spent yearly with parental absenteeism 227 
because of childhood asthma. This value can represent a potential higher burden to 228 
society, as loss of parental work can further impact the overall economy. 229 
Determinants of cost variation in childhood asthma 230 
The most important determinants for higher costs were the asthma attacks in the previous 231 
12 months (1.6-fold) and having uncontrolled asthma (2.3-fold). Direct costs were 232 
significantly higher in children with uncontrolled asthma, specifically acute asthma care 233 
and diagnostic test use. Interestingly, there were no significant differences in costs of 234 
scheduled medical visits and treatment for controlled vs. uncontrolled children. 235 
Considering a hypothetic scenario (data not shown) in which all Portuguese children with 236 
asthma were controlled, the savings would be more than 30,000,000 € per year (20% 237 
reduction). As previously reported, children with not controlled asthma had significantly 238 
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more unscheduled medical visits and hospitalisations (10,23); knowing that uncontrolled 239 
asthma is, also, the major determinant for higher costs, effective policies should be 240 
directed to improve asthma control and reduce acute care medical visits. 241 
Future studies should be designed to have multinational cost-of-illness data, aiming to 242 
understand differences between asthma care and to compare outcomes. Quality-of-life 243 
assessment in childhood asthma should also be improved and be part of a burden of 244 
disease analysis. 245 
Strengths and limitations 246 
This was the first Portuguese nationwide, population-based study on costs of childhood 247 
asthma. The cost domains analysed allowed us to create a comprehensive picture of 248 
childhood asthma costs in Portugal, as did the prevalence-based analysis and societal 249 
perspective. We performed a univariate and multivariate deterministic sensitivity analysis, 250 
aiming to understand different variations according to uncertainty. Sensitivity analysis is 251 
crucial to highlight variability, to make comparisons with other data, and is recommended 252 
in economic studies (24,25), but this was the first cost-of-illness study on childhood 253 
asthma to report a sensitivity analysis. 254 
There were some limitations regarding the participants and the reported outcomes used 255 
for cost estimations. Participants were derived from INAsma and CED2013; school-age 256 
children may be overrepresented in our sample, nevertheless, this is the age group with 257 
the higher prevalence of asthma in our country (9). Also, differences in cost estimations 258 
between the two studies were only seen in the domain of ‘Treatment’ and total costs were 259 
not significantly different (Table S4). Data on diagnostic tests use and immunotherapy 260 
were only available in the CED2013 study and then extrapolated for the entire sample. The 261 
assumptions made in the treatment domain may also have masked higher cost differences 262 
between asthma control groups. Specifically, medication costs were based on the reported 263 
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medicines used in the previous year, but we were unable to assess the number of doses 264 
performed by each participant; we used a clinical consensus approach for the number of 265 
doses of controller and reliever medication, based on GINA guidelines and on 266 
conservative estimations of adherence. In transportation, we used an official Portuguese 267 
price by kilometre, however we could not assess how many of the patients used public 268 
transports or ambulances. The absenteeism costs were based on a mean Portuguese 269 
daily income according to the parents’ professional occupation, not with a reported 270 
income; this could possibly underestimate the costs of absenteeism. Also, we couldn’t 271 
assess parent’s presenteeism because of child’s asthma. 272 
In conclusion, childhood asthma in Portugal costs €161,410,007.61 per year, 273 
corresponding to €929.35 per child with CA. The total cost estimate of childhood asthma 274 
corresponds to 0.91% of the Portuguese expenses in health in 2010. Direct costs were 3/4 275 
of total costs, mainly related to acute asthma care (non-scheduled visits, emergency and 276 
hospitalisations). The most important factors determining higher costs were asthma 277 
attacks in the previous 12 months (1.6-fold) and uncontrolled asthma (2.3-fold). A better 278 
asthma control, with a consequent reduction in the acute use of healthcare services, 279 
should be the major target for potential savings in this disease.  280 
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Legends 346 
Table 1 Annualised costs (in euros) of childhood asthma in Portugal: total costs, mean 347 
cost per child with current asthma and percentage of total costs for each domain/variable. 348 
Table 2 Factors associated with annualised total costs of childhood asthma in Portugal. 349 
Table 3 Multivariate deterministic sensitivity analysis – Annualised total costs extrapolated 350 
to total Portuguese children with current asthma and mean costs per patient. 351 
Fig. 1 Mean cost per child with current asthma, per year; mean cost variation according to 352 
the level of asthma control. Mean costs are marked in euros and the lines represent 353 
95%CI. *p<0.001 between groups of asthma control. 354 
Fig. 2 Mean cost per child with current asthma, per year, in each domain. Panel A: total 355 
costs. Panel B: cost variation according to the level of asthma control. *p<0.001 between 356 
groups of asthma control.  357 
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Table 1 358 
 
Total costs in Portuguese 
children* 
(95%CI#) 
Mean cost per 
patient† 
(95%CI#) 
Percentage of 
total costs 
TOTAL COSTS 161,410,007.61            
(142,367,218.84 -181,369,857.87) 
929.35                    
(819.71 - 1,044.27) 
100% 
DIRECT COSTS 121,341,498.02     
(104,319,912.15 -139,851,241.14) 
698.65                    
(600.64 - 805.22) 
75.2% 
     Healthcare services use 82,519,684.10 
(67,027,110.46 – 99,248,305.38) 
475.12 
(385.92 - 571.46) 
51.1% 
         Scheduled medical visits 33,414,070.10 
(29,192,806.15 - 38,204,470.63) 
192.39 
(168.08 - 219.97) 
20.7% 
         Acute asthma care 49,105,614.06 
(35,070,014.88 - 64,089,678.45) 
282.73 
(201.92 - 369.01) 
30.4% 
                 Non-scheduled medical visits 12,766,203.20 
(9,809,363.94 - 15,874,252.35) 
73.50 
(56.48 - 91.40) 
7.9% 
                 Emergency department visits 18,932,464.80 
(13,136,536.12 - 26,300,288.04) 
109.01 
(75.64 - 151.43) 
11.7% 
                 Hospitalisation 17,406,946.00 
(6,189,712.95 – 30,072,795.68) 
100.22 
(35.64 - 173.15) 
10.8% 
     Diagnostic tests 9,128,914.10 
(7,988,735.48 - 10,293,812.35) 
52.56 
(46.00 - 59.27) 
5.7% 
          Blood workout 2,498,121.71 
(2,056,174.62 - 3,027,259.83) 
14.38 
(11.84 - 17.43) 
1.5% 
          Chest x-ray 867,148.15 
(726,594.46 - 1,012,508.13) 
4.99 
(4.18 - 5.83) 
0.5% 
          Pulmonary function tests 4,840,864.14 
(4,047,079.93 - 5,594,160.80) 
27.87 
(23.30 - 32.21) 
3.0% 
          Skin prick tests 922,780.11 
(787,921.22 - 1,060,409.35) 
5.31 
(4.54 - 6.11) 
0.6% 
     Treatment 29,692,899.78 
(26,638,427.58 - 32,734,734.89) 
170.96 
(153.38 - 188.48) 
18.4% 
         Asthma-specific medication 16,005,602.20 
(14,170,511.21 - 16,552,789.28) 
92.16 
(81.59 - 102.71) 
9.9% 
                 Controller medication 14,731,639.10 
(12,945,695.43 - 16,516,489.95) 
84.82 
(74.54 - 95.31) 
9.1% 
                 Reliever medication 1,273,963.08 
(1,122,865.03 - 1,433,510.87) 
7.34 
(6.47 - 8.25) 
0.8% 
         Other asthma medication 10,789,280.82 
(8,948,166.70 - 12,786,638.37) 
62.12 
(51.52 - 73.62) 
6.7% 
                 Immunotherapy 7,403,386.43 
(5,663,424.78 - 9,313,209.42) 
42,63 
(32.61 - 53.62) 
4.6% 
                 Antihistamines 1,792,454.72 
(1,663,308.20 - 1,910,421.53) 
10.32 
(9.58 - 11.00) 
1.1% 
                 Antibiotics 1,491,836.29 
(1,264,692.94 - 1,736,306.33) 
8.59 
(7.28 - 10.00) 
0.9% 
                Flu vaccine 101,603.39 
(n.a.) 
0.59 
(n.a.) 
0.1% 
         Holding chamber 2,898,016.76 
(2,659,281.90 - 3,159,830.54) 
16.69 
(15.31 - 18.19) 
1.8% 
INDIRECT COSTS 40,068,509.59     
(34,117,635.12 - 46,811,024.16) 
230.70                      
(196.44 - 269.52) 
24.8% 
     Parental absenteeism 13,689,797.60 
(10,775,047.66 - 16,906,907.47) 
78.82 
(62.04 - 97.34) 
8.5% 
     Transportation 3,931,536.64 
(3,397,478.25 - 4,553,290.57) 
22.64 
(19.56 - 26.22) 
2.4% 
     Subsidies 22,447.175.39 
(17,551,402.93 - 27,735,327.31) 
129.24 
(101.06 - 159.69) 
13.9% 
Each cost item was calculated for each participant by multiplying the parent/self-reported amount of resources used by the unitary costs 359 
of the resources. Costs were indexed to 2010 Portuguese prices in euros. 360 
*Total costs were extrapolated to total Portuguese children with current asthma (n=173,681)(9);#Bootstrapped 95%CI; n.a,not applicable 361 
†Mean cost per patient: sum of the total cost of each participant, dividing for the total number of asthmatic children in our sample. 362 
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Table 2 363 
 Mean cost (SD) 
Factors associated with childhood 
asthma costs 
Crude association 
(95%CI) 
Adjusted association* 
(95%CI) 
Gender    
     Female 999.44  (1,155.01)           1.00            (ref) n.i. 
     Male 888.99     (806.34) 0.89  (0.67-1.18) n.i. 
Age groups   
       0- 5 years old 1,035.91  (1,146.11)            1.00           (ref)        1.00             (ref) 
       6-12 years old 969.84     (974.54) 0.94 (0.60-1.46)   0.86  (0.59 -1.26) 
     13-17 years old 681.33     (618.04) 0.66 (0.39-1.14)   0.64  (0.40-1.03) 
Caregiver education  
     No education 1,190.65  (1,311.41)           1.00            (ref) n.i. 
     0-4 years (basic 1st cycle) 1,011.55  (1,151.59) 0.85  (0.49-1.47) n.i. 
     5-9 years (basic 2nd and 3rd cycle)) 1,010.83  (1,136.31) 0.85  (0.51-1.42) n.i. 
     10-12 years (secondary) 669.32     (442.65) 0.56  (0.32-1.01) n.i. 
     >12 years (higher) 840.07     (477.72) 0.71  (0.41-1.21) n.i. 
Mensal income of caregiver  
     < 650.00 € 1,064.76  (1,187.16)           1.00            (ref) n.i. 
     650.00 – 749.99 € 1,009.69     (909.77) 0.95  (0.67-1.35) n.i. 
     750.00 – 1,199.99€ 839.60     (972.68) 0.79  (0.52-1.21) n.i. 
     >= 1,200.00 € 755.10     (550.96) 0.71  (0.50-1.02) n.i. 
Wheezing  
     No 776.19     (746.83)          1.00             (ref) n.i. 
     Yes 964.25     (985.50) 1.24   (0.84-1.83) n.i. 
Nocturnal symptoms  
     No 685.41     (588.66)          1.00             (ref) n.i. 
     Yes 1,014.00  (1,034.80) 1.48  (1.07-2.05) n.i. 
Asthma attacks  
     No 677.58     (713.02)          1.00             (ref)       1.00              (ref) 
     Yes 1,136.82  (1,058.60) 1.68  (1.27-2.22) 1.57  (1.22-2.02) 
Asthma control  
     Controlled 747.63     (562.79)          1.00             (ref)       1.00              (ref) 
     Partly controlled 1,120.50  (1,135.96) 1.50  (1.14-1.98) 1.46  (1.12-1.90) 
     Uncontrolled 1,758.44  (1,795.65)           2.35  (1.60-3.47)  2.25  (1.56-3.24) 
Bold values show statistical significant differences. n.i.: not included in the model (non-significant variables) 364 
*Adjusted coefficients were calculated using multivariate mixed Poisson-gamma (Tweedie distribution family) generalised linear models. 365 
Goodness-of-fit statistics for the multivariate regression model: scaled deviance (D = 2,919.3; df = 181); scaled Pearson chi-square (v2 366 
= 181.0; df = 181); AIC = 5,111.3; consistent AIC = 5,136.7   367 
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Table 3 368 
 Costs in Portuguese childhood asthma 
Multivariate sensitivity analysis 
Best-case scenario* Worst-case scenario# 
TOTAL COSTS 161,410,007.61     
(929.35) 
79,585,960.00    
(606.99) 
308,018,952.55    
(1,424.38) 
DIRECT COSTS 121,341,498.02     
(698.65) 
58,535,047.13    
(446.44) 
246,538,052.49     
(1,140.07) 
     Healthcare services use 82,519,684.10 
(475.12) 
42,595,571.35 
(324.87) 
138,329,936.99 
(639.68) 
         Scheduled medical visits 33,414,070.10 
(192.39) 
23,171,710.16 
(176.73) 
44,989,758.82 
(208.05) 
         Acute asthma care 49,105,614.00 
(282.73) 
19,423,861.19 
(148.14) 
93,340,178.17 
(431.63) 
                 Non-scheduled medical visits 12,766,203.20 
(73.50) 
6,167,963.51 
(47.04) 
20,981,450.09 
(97.02) 
                 Emergency department visits 18,932,464.80 
(109.01) 
10,627,732.56 
(81.06) 
29,012,394.70 
(134.16) 
                 Hospitalisation 17,406,946.00 
(100.22) 
2,628,165.12 
(20.04) 
43,346,333.38 
(200.45) 
     Diagnostic tests 9,128,914.10 
(52.56) 
5,000,033.78 
(38.13) 
14,486,032.35 
(66.99) 
          Blood workout 2,498,121.71 
(14.38) 
1,305,608.05 
(9.96) 
4,067,419.36 
(18.81) 
          Chest x-ray 867,148.15 
(4.99) 
458,238.33 
(3.49) 
1,403,577.64 
(6.49) 
          Pulmonary function tests 4,840,864.14 
(27.87) 
2,626,641.61 
(20.03) 
7,722,475.88 
(35.71) 
          Skin prick tests 922,780.11 
(5.31) 
609,545.80 
(4.65) 
1,292,559.47 
(5.98) 
     Treatment 29,692,899.78 
(170.96) 
10,939,442.00 
(83.43) 
93,722,083.15 
(433.40) 
         Asthma-specific medication 16,005,602.20 
(92.16) 
3,225,956.01 
(24.60) 
67,162,295.84 
(310.58) 
                 Controller medication 14,731,639.10 
(84.82) 
2,883,526.64 
(21.99) 
63,387,483.49 
(293.12) 
                 Reliever medication 1,273,963.08 
(7.34) 
342,429.37 
(2.61) 
3,774,812.35 
(17.46) 
         Other asthma medication 10,789,280.82 
(62.12) 
5,819,598.60 
(44.39) 
22,412,953.76 
(103.64) 
                 Immunotherapy 7,403,386.43 
(42.63) 
4,017,060.24 
(30.64) 
16,754,942.43 
(77.48) 
                 Antihistamines 1,792,454.72 
(10.32) 
1,127,631.03 
(8.60) 
2,603,722.95 
(12.04) 
                 Antibiotics 1,491,836.29 
(8.59) 
636,556.20 
(4.85) 
2,826,579.23 
(13.07) 
                Flu vaccine 101,603.39 
(0.59) 
38,351.14 
(0.29) 
227,709.14 
(1.05) 
         Holding chamber 2,898,016.76 
(16.69) 
1,893,887.38 
(14.44) 
4,146,833.55 
(19.18) 
INDIRECT COSTS 40,068,509.59        
(230.70) 
21,050,912.88     
(160.55) 
61,480,900.06     
(284.31) 
     Parental absenteeism 13,689,797.60 
(78.82) 
8,312,678.55 
(63.40) 
20,379,882.34 
(94.24) 
     Transportation 3,931,536.64 
(22.64) 
2,770,123.76 
(21.13) 
5,221,446.58 
(24.15) 
     Subsidies 22,447,175.39 
(129.24) 
9,968,110.57 
(76.03) 
41,101,017.72 
(190.06) 
*Best-case scenario was set with: the lower limit of the 95%CI of CA prevalence in Portuguese children; scenario of minimum use of 369 
asthma medications; and the lower limit of the 95%CI for the proportion of occurrence of each variable in Portuguese population. 370 
#Worst-case scenario was set with: the upper limit of the 95%CI of CA prevalence in Portuguese children; scenario of maximum use of 371 
asthma medications; and the upper limit of the 95%CI for the proportion of occurrence of each variable in Portuguese population. 372 
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Fig. 1 Mean cost per child with current asthma, per year; mean cost variation according to the level of 
asthma control. Mean costs are marked in euros and the lines represent 95%CI. *p<0.001 between groups 
of asthma control.  
 
147x200mm (72 x 72 DPI)  
 
 
Page 22 of 41
Scholarone, Inc. Support (434) 964 4100
Pediatric Allergy and Immunology
218 | Burden of childhood asthma in Portugal 
 
 
For Peer Review
  
 
 
Fig. 2 Mean cost per child with current asthma, per year, in each domain. Panel A: total costs. Panel B: cost 
variation according to the level of asthma control. *p<0.001 between groups of asthma control.  
 
352x238mm (72 x 72 DPI)  
 
 
Page 23 of 41
Scholarone, Inc. Support (434) 964 4100
Pediatric Allergy and Immunology
   
 
 
 
